<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1602221728
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZYKADIA 150 mg capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CERITINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23120.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS Pharma Stein AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS Pharma Stein AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XE28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What </strong><strong>Zykadia</strong><strong> is</strong></p><p>Zykadia is a cancer medicine that contains the active substance ceritinib. It is used to treat adults with advanced stages of a form of lung cancer called non‑small cell lung cancer (NSCLC). Zykadia is only given to patients whose disease is due to a defect in a gene called ALK (anaplastic lymphoma kinase).</p><p>&nbsp;</p><p><strong>How </strong><strong>Zykadia</strong><strong> works</strong></p><p>In patients with ALK defects, an abnormal protein is produced that stimulates the growth of the cancer cells. Zykadia blocks the action of this abnormal protein and thus slows down the growth and spread of NSCLC.</p><p>&nbsp;</p><p>If you have any questions about how Zykadia works or why this medicine has been prescribed for you, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.Do not take </strong><strong>Zykadia</strong><strong>:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to ceritinib or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&nbsp;</p><p><strong>b.Take special care with </strong><strong>Zykadia</strong></p><p>Talk to your doctor or pharmacist before taking Zykadia:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have problems with your liver.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have problems with your lungs or problems breathing.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have problems with your heart, including reduced heart rate, or if the results of an electrocardiogram (ECG) have shown that you have an abnormality of the electrical activity of your heart known as &ldquo;prolonged QT interval&rdquo;.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes (high level of sugar in your blood).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have problems with your pancreas.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are currently taking steroids.</p><p>&nbsp;</p><p>Tell your doctor or pharmacist immediately if you get any of the following signs or symptoms during treatment with Zykadia:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness, itchy skin, yellowing of your skin or the whites of your eyes, nausea (feeling sick) or vomiting, decreased appetite, pain on the right side of your abdomen (belly), dark or brown urine, bleeding or bruising more easily than normal. These may be signs or symptoms of liver problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; new or worsening cough with or without mucus, fever, chest pain, trouble breathing or shortness of breath. These may be symptoms of lung problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain or discomfort, changes in your heartbeat (fast or slow), light‑headedness, fainting, dizziness, blue discoloration of your lips, shortness of breath, swelling of your lower limbs or skin. These may be signs or symptoms of heart problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe diarrhoea, nausea or vomiting. These are symptoms of digestive problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; excessive thirst or increased frequency of urination. These may be symptoms of a high level of sugar in the blood.</p><p>Your doctor may need to adjust your treatment or stop Zykadia temporarily or permanently.</p><p>&nbsp;</p><p><strong>Blood tests during treatment with </strong><strong>Zykadia</strong></p><p>Your doctor should perform blood tests before you start treatment, every 2&nbsp;weeks during the first three months of treatment and monthly therafter. The purpose of these tests is to check your liver function. Your doctor should also perform blood tests to check the functioning of your pancreas and the level of sugar in your blood before you start treatment with Zykadia and regularly during treatment.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>The use of Zykadia in children and adolescents up to 18&nbsp;years of age is not recommended.</p><p>&nbsp;</p><p><strong>c.Taking other medicines and herbal or dietary supplements</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription such as vitamins or herbal supplements, because they might interact with Zykadia. It is particularly important that you mention any of the following medicines.</p><p>&nbsp;</p><p>Medicines which may increase the risk of side effects with Zykadia:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat AIDS/HIV (e.g. ritonavir, saquinavir).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat infections. These include medicines that treat fungal infections (antifungals such as ketoconazole, itraconazole, voriconazole, posaconazole) and medicines that treat certain types of bacterial infection (antibiotics such as telithromycin).</p><p>&nbsp;</p><p>The following medicines may reduce the effectiveness of Zykadia:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s Wort, a herbal medicine used to treat depression.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to stop seizures or fits (anti‑epileptics such as phenytoin, carbamazepine, or phenobarbital).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat tuberculosis (e.g. rifampicin, rifabutin).</p><p>&nbsp;</p><p>Zykadia may increase the side effects associated with the following medicines:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat irregular heartbeat or other heart problems (e.g. amiodarone, disopyramide, procainamide, quinidine, sotalol, dofetilide, ibutilide and digoxin).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat stomach problems (e.g. cisapride).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat mental health problems (e.g. haloperidol, droperidol, pimozide).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat depression (e.g. nefazodone).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; midazolam, a medicine used to treat acute seizures or as a sedative before or during surgery or medical procedures.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; warfarin and dabigatran, medicines used to prevent blood clots.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diclofenac, a medicine used to treat joint pain and inflammation.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alfentanil and fentanyl, medicines used to treat severe pain.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciclosporin, sirolimus and tacrolimus, medicines used in organ transplantation to prevent transplant organ rejection.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dihydroergotamine and ergotamine, medicines used to treat migraine.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; domperidone, a medicine used to treat nausea and vomiting.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; moxifloxacin and clarithromycin, medicines used to treat bacterial infections.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; methadone, a medicine used to treat pain and for the treatment of opioid dependence.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chloroquine and halofantrine, medicines used to treat malaria.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; topotecan, a medicine used to treat certain types of cancer.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; colchicine, a medicine used to treat gout.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pravastatine and rosuvastatine, medicines used to reduce cholesterol levels.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sulfasalazine, a medicine used to treat inflammatory bowel disease or rheumatoid arthritis.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist if you are not sure whether your medicine is one of the medicines listed above.</p><p>&nbsp;</p><p>These medicines should be used with care or may need to be avoided during your treatment with Zykadia. If you are taking any of these, your doctor might need to prescribe an alternative medicine for you.</p><p>&nbsp;</p><p>You should also tell your doctor if you are already taking Zykadia and you are prescribed a new medicine that you have not already taken at the same time as Zykadia.</p><p>&nbsp;</p><p><strong>Oral contraceptives</strong></p><p>If you take Zykadia whilst using oral contraceptives, the oral contraceptives may become ineffective.</p><p>&nbsp;</p><p><strong>d.Taking Zykadia</strong><strong> with food and drink</strong></p><p>You should not eat grapefruit or drink grapefruit juice during treatment. It may make the amount of Zykadia in your blood increase to a harmful level.</p><p>&nbsp;</p><p><strong>e.Pregnancy and breast‑feeding</strong></p><p>You must use a highly effective method of birth control during treatment with Zykadia and for 3&nbsp;months after stopping treatment. Talk to your doctor about the birth control methods that may be right for you.</p><p>&nbsp;</p><p>Zykadia is not recommended during pregnancy unless the potential benefit outweighs the potential risk to the baby. If you are pregnant, think you might be pregnant or plan to become pregnant, ask your doctor for advice before taking this medicine. Your doctor will discuss with you the potential risks of taking Zykadia during pregnancy.</p><p>&nbsp;</p><p>Zykadia should not be used during breast‑feeding. You and your doctor will decide together whether you should breast‑feed or take Zykadia. You should not do both.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>You should take special care when driving and using machines when taking Zykadia as you may experience visual disturbances or tiredness.</p><p>&nbsp;</p><p><strong>Zykadia contains Sodium</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per capsule, that is to say essentially &ldquo;sodium-free&rdquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How to take </strong><strong>Zykadia</strong></p><p>&nbsp;</p><p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>&nbsp;</p><p>Zykadia is an anti-cancer medical product. Treatment with Zykadia should be initiated and supervised by a physician experienced in the use of anti-cancer medicinal products. See section &nbsp;&nbsp;&nbsp;&nbsp; 5 How to store Zykadia</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p>The recommended dose is 450&nbsp;mg (three capsules) taken once daily with food, although your doctor could modify this recommendation if needed. Your doctor will tell you exactly how many capsules you need to take. Do not change the dose without talking to your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take Zykadia once a day at about the same time each day with food (for example a snack or a full meal). If you cannot eat food while taking Zykadia, talk to your doctor.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the capsules whole with water. Do not chew or crush them.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you vomit after you swallow the Zykadia capsules, do not take any more capsules until your next scheduled dose.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>How long to take </strong><strong>Zykadia</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Continue taking Zykadia for as long as your doctor tells you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This is a long‑term treatment, possibly lasting for months. Your doctor will monitor your condition to see that the treatment is having the desired effect.</p><p>&nbsp;</p><p>If you have questions about how long to take Zykadia, talk to your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>a.&nbsp;&nbsp;&nbsp; </strong><strong>If you take more Zykadia than you should</strong></p><p>If you accidentally take too many capsules, or if someone else accidentally takes your medicine, contact a doctor or hospital for advice immediately. Medical treatment may be necessary.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp;&nbsp; </strong><strong>If you forget to take Zykadia</strong></p><p>What to do if you forget to take a dose depends on how long it is until your next dose.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your next dose is in 12&nbsp;hours or more, take the missed capsules as soon as you remember. Then take the next capsules at the usual time.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your next dose is in less than 12&nbsp;hours, skip the missed capsules. Then take the next capsules at the usual time.</p><p>Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>c.&nbsp;&nbsp;&nbsp; </strong><strong>If you stop taking Zykadia</strong></p><p>Do not stop taking this medicine before talking to your doctor. If you have any further questions on the use of this medicine, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>STOP taking </strong><strong>Zykadia</strong><strong> and seek medical help immediately if you experience any of the following</strong>, which may be signs of an allergic reaction:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in breathing or swallowing</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the face, lips, tongue or throat</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe itching of the skin, with a red rash or raised bumps</p><p>&nbsp;</p><p><strong>Some side effects could be serious</strong></p><p>If you experience any of the following side effects, tell your doctor or pharmacist immediately:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain or discomfort, changes in your heartbeat (fast or slow), light‑headedness, fainting, dizziness, blue discoloration of your lips, shortness of breath, swelling of your lower limbs or skin (potential signs or symptoms of heart problems)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; New or worsening cough with or without mucus, fever, chest pain, trouble breathing or shortness of breath (potential signs of lung problems)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tiredness, itchy skin, yellowing of your skin or the whites of your eyes, nausea (feeling sick) or vomiting, decreased appetite, pain on the right side of your abdomen (belly), dark or brown urine, bleeding or bruising more easily than normal (potential signs or symptoms of liver problems)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe diarrhoea, nausea or vomiting</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive thirst, increased frequency of urination (symptoms of high level of glucose in the blood)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe upper stomach pain (sign of inflammation of the pancreas, also known as pancreatitis)</p><p>&nbsp;</p><p><strong>Other possible side effects</strong></p><p>Other side effects are listed below. If these side effects become severe, please tell your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>Very common</strong> (may affect more than 1 in 10&nbsp;people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tiredness (fatigue and asthenia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal results of blood tests to check liver function (high levels of enzymes called alanine aminotransferase and/or aspartate aminotransferase and/or gamma glutamyltransferase and/or blood alkaline phosphatase, high levels of bilirubin)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased appetite</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight decreased</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal results of blood tests to check kidney function (high level of creatinine)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heartburn (potential sign of a disorder of the digestive tract)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in the number of red blood cells, known as anaemia</p><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1 in 10&nbsp;people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vision problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low level of phosphate in the blood (this would be detected during blood tests)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High level of enzymes called lipase and/or amylase in the blood (this would be detected during blood tests)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Significantly decreased urine flow (potential sign of a kidney problem)</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How to store Zykadia</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not store above 30&ordm;C.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine if you notice any damage to the packaging or if there are any signs of tampering.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>Handling:</p><p>Zykadia is an anti-cancer medical product. In healthcare settings, use designated area for medication storage and restrict access to only authorized personal.</p><p>Disposal:</p><p>Any unused medicinal product or waste material should be disposed in accordance with local requirements. Wash hands thoroughly with water after disposal of any unused medicinal product or waste material, for further instructions on disposal, ask your pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance of Zykadia is ceritinib. Each hard capsule contains 150&nbsp;mg of ceritinib.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Capsule contents: silica, colloidal anhydrous, hydroxypropylcellulose, low-substituted, sodium starch glycolate (type A), magnesium stearate, cellulose, microcrystalline.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Capsule shell: gelatin, indigotine (E132) and titanium dioxide (E171).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Printing ink: Shellac (bleached, de‑waxed) glaze 45%, iron oxide black (E172), propylene glycol and ammonium hydroxide 28%.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	Zykadia hard capsules have a white opaque body and blue opaque cap, with “LDK 150MG” imprinted on the cap and “NVR” on the body. They contain white to almost white powder.
	
	The capsules are provided in blisters and are available in packs containing 150 (3 packs of 50) capsules. Not all pack sizes may be marketed in your country.
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 04/2021 by EMA.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ما هوعقار زيكاديا</p><p dir="RTL">زيكاديا هو دواء لعلاج السرطان يحتوي على المادة الفعالة سيريتينيب. وهو يُستخدم لعلاج البالغين المصابين بمراحل متقدمة من أحد أنواع سرطان الرئة ويُدعى سرطان الرئة ذو الخلايا غير الصغيرة. يُعطى عقار زيكاديا فقط للمرضى ممن كان المرض لديهم ناجمًا عن خلل في أحد الجينات يُدعى كيناز الورم اللمفاوي الكشمي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ما هي دواعي استعماله ؟ وما هي آلية عمله</p><p dir="RTL">ينتج لدى المرضى المصابين بخلل في كيناز الورم اللمفاوي الكشمي بروتين غير طبيعي يحفز من نمو الخلايا السرطانية. يعيق عقار زيكاديا من تأثير هذا البروتين غير الطبيعي وبالتَّالي يبطئ من نمو سرطان الرئة ذي الخلايا غير الصغيرة وانتشاره.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة حول كيفية عمل عقار زيكاديا أو لماذا تم وصف هذا الدواء لك، فاستشر طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ.موانع استعمال عقار </strong><strong>زيكاديا</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه سيريتينيب أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء</p><p dir="RTL">(المدرجة في قسم: 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ب.الاحتياطات عند استعمال </strong><strong>زيكاديا</strong><strong>:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل تناول عقار زيكاديا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالرئتين أو مشاكل بالتَّنفس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالقلب، من ضمنها انخفاض معدل ضربات القلب أو إذا أظهرت نتائج مخطط كهربية القلب (رسم القلب) أنك مصاب باضطراب بالنَّشاط الكهربائي للقلب يُعرف بـ&quot;إطالة فترة QT&quot;.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض السُّكَّرِي (ارتفاع مستوى السكر لديك بالدَّم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالبنكرياس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول حاليًا الستيرويدات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي الخاص بك على الفور إذا أُصبت بأي من العلامات أو الأعراض التَّالية أثناء العلاج بعقار زيكاديا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب، حكة بالجلد، تحول لون جلدك أو بياض عينيك إلى اللون الأصفر، غثيان (شعور بالإعياء) أو قيء، انخفاض الشهية، ألم في الجانب الأيمن من البطن، بول داكن أو بني اللون، الإصابة بنزيف أو كدمات بشكل أسهل من المعتاد. قد تُشير هذه العلامات أو الأعراض إلى وجود مشاكل بالكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة جديدة أو متفاقمة من السعال المصحوب أو غير المصحوب ببلغم، حمى، ألم في الصدر، صعوبة بالتَّنفس أو ضيق التَّنفس. قد تُشير هذه الأعراض إلى وجود مشاكل بالرئتين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو ضيق بالصدر، تغيرات بضربات القلب لديك (تسارعها أو تباطؤها)، شعور بدوار بالرَّأس، إغماء، دوخة، تحول لون شفتيك إلى اللون الأزرق، ضيق التَّنفس، تورم بالأطراف السفلية أو الجلد. قد تُشير هذه العلامات أو الأعراض إلى وجود مشاكل بالقلب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال شديد، غثيان أو قيء. تُشير هذه الأعراض إلى وجود مشاكل بالجهاز الهضمي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عطش شديد أو زيادة معدل تكرار التبوُّل. قد تُشير هذه الأعراض إلى ارتفاع مستوى السكر بالدَّم.</p><p dir="RTL">قد يحتاج طبيبك إلى ضبط علاجك أو وقف عقار زيكاديا بشكل مؤقت أو دائم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إجراء اختبارات الدَّم أثناء العلاج بعقار </strong><strong>زيكاديا</strong></p><p dir="RTL">ينبغي على طبيبك إجراء اختبارات بالدَّم قبل أن تبدأ العلاج، كل أسبوعين خلال الثلاثة أشهر الأولى من العلاج وبصفة شهرية بعد ذلك. الغرض من هذه الاختبارات هو فحص وظائف الكبد لديك. كما ينبغي على طبيبك إجراء اختبارات بالدَّم لفحص وظائف البنكرياس لديك ومستوى السكر لديك بالدَّم قبل أن تبدأ العلاج بعقار زيكاديا وبشكل منتظم أثناء العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يُوصى باستخدام عقار زيكاديا في الأطفال والمراهقين حتى 18 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج. التداخلات الدوائية من أخذ </strong><strong>زيكاديا</strong><strong> مع أي أدوية أخرى</strong> <strong>أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول، قد تناولت مؤخرًا &nbsp;أو قد تتناول أيَّة أدوية أخرى، بما في ذلك الأدوية التي حصلت عليها دون وصفة طبية مثل: الفيتامينات أو المكملات العشبية؛ لأنها قد تتداخل مع عقار زيكاديا. يُعد من المهم بشكل خاص أن تذكر أيًّا من الأدوية الآتية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأدوية التي قد تزيد من خطر حدوث الآثار الجانبية مع استخدام عقار زيكاديا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستَخدَم لعلاج متلازمة نقص المناعة المكتسبة (الإيدز)/ فيروس نقص المناعة البشرية (على سبيل المثال: ريتونافير وساكوينافير).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستَخدَم لعلاج العدوى. ويشمل ذلك الأدوية التي تُستَخدَم لعلاج العدوى الفطرية (مضادات الفطريات مثل: كيتوكونازول، إتراكونازول، فوريكونازول، پوساکونازول) والأدوية التي تُستَخدَم لعلاج أنواع محددة من العدوى البكتيرية (المضادات الحيوية مثل تيليثروميسين).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تقلل الأدوية التَّالية من فعّالية عقار زيكاديا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جونز، دواء عشبي يُستخدم لعلاج الاكتئاب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستَخدَم لوقف النوبات التَّشنجية أو التَّشنجات (مضادات الصَّرع مثل: فينيتوين، كَرْبامازِيبين أو فينوباربيتال).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستخدم لعلاج مرض السل (على سبيل المثال: ريفامبيسين، ريفابوتين).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يزيد عقار زيكاديا من حدوث الآثار الجانبية المصاحبة لاستخدام الأدوية التَّالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستَخدَم لعلاج عدم انتظام ضربات القلب أو مشاكل القلب الأخرى (على سبيل المثال: أميودارون، ديسوبيراميد، بروكايناميد، كينيدين، سوتالول، دوفتيليد، إبيوتيليد وديجوكسِين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستَخدَم لعلاج مشاكل المعدة (على سبيل المثال: سيسابريد).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستَخدَم لعلاج مشاكل الصحة النفسية (على سبيل المثال: هالُوبِيرِيدُول، دُروبِيرِيدُول، بيموزيد).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تُستخدم لعلاج الاكتئاب (على سبيل المثال: نيفازودون).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميدازولام، أحد الأدوية التي تُستَخدَم لعلاج النوبات التَّشنجية الحادة أو كمهدئ قبل أو أثناء الخضوع لعملية جراحية أو الإجراءات الطبية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وارفارين ودابيجاتران، أدوية تُستَخدَم للوقاية من جلطات الدَّم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديكلوفيناك، أحد الأدوية التي تُستَخدَم لعلاج آلام المفاصل والالتهابات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألفينتانيل وفينتانيل، أدوية تُستَخدَم لعلاج الآلام الشَّديدة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين، سيروليموس وتاكروليموس، أدوية تُستخدم في عمليات زرع الأعضاء لمنع رفض العضو المزروع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثنائي هيدرو إرجوتامين و إرجوتامين، الأدوية التي تُستَخدَم لعلاج الصداع النصفي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دومبيريدون، أحد الأدوية التي تُستَخدَم لعلاج الغثيان والقيء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موكسيفلوكساسين وكلاريثروميسين، أدوية تُستخدَم لعلاج العدوى البكتيرية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثادون، أحد الأدوية التي تُستَخدَم لعلاج الألم ولعلاج الاعتماد على المواد الأفيونية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلوروكين وهالوفانترين، أدوية تُستَخدَم لعلاج الملاريا.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توبوتيكان، أحد الأدوية التي تُستَخدَم لعلاج أنواع محددة من السرطان.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كُولْشيسين، أحد الأدوية التي تُستَخدَم لعلاج مرض النقرس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; برافاستاتين وروزيوفاستاتين، أدوية تُستَخدَم لخفض مستويات الكوليسترول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سالفاسالازين، أحد الأدوية التي تُستَخدَم لعلاج مرض الأمعاء الالتهابي أو التهاب المفاصل الروماتويدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشر طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا مما إذا كان دواؤك واحدًا من الأدوية المدرجة أعلاه أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي استخدام هذه الأدوية بحذر أو قد يستلزم الأمر تجنُّبها أثناء علاجك بعقار زيكاديا. إذا كنت تتناول أيًّا من تلك الأدوية، فقد يحتاج طبيبك إلى وصف دواء بديل لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أيضًا أن تخبر طبيبك إذا كنت تتناول بالفعل عقار زيكاديا وإذا وُصف لك دواء جديد لم تتناوله بالفعل بالتَّزامن مع عقار زيكاديا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>وسائل منع الحمل الفموية</strong></p><p dir="RTL">إذا كنتِ تتناولين عقار زيكاديا أثناء استخدام وسائل منع الحمل الفموية، قد تصبح وسائل منع الحمل الفموية غير فعالة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>د.تناول عقار </strong><strong>زيكاديا</strong><strong> مع الطعام و الشراب:</strong></p><p dir="RTL">ينبغي عليك أَلَّا تتناول الجريب فروت أو تشرب عصير الجريب فروت أثناء العلاج. فقد يزيد من كمية عقار زيكاديا لديك في الدَّم ليصل إلى مستوى ضار.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هـ. الحمل والرضاعة </strong></p><p dir="RTL">ينبغي عليكِ استخدام وسيلة فعالة للغاية لمنع الحمل أثناء العلاج بعقار زيكاديا ولمدة 3 أشهر بعد وقف العلاج. تحدَّثي إلى طبيبكِ حول وسائل منع الحمل التي قد تكون مناسبة لكِ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُوصى باستخدام عقار زيكاديا أثناء الحمل إِلَّا إذا كانت الفوائد المحتملة تفوق المخاطر المحتملة على الطفل. استشيري طبيبكِ إذا كنت حاملًا أو تظنين أنكِ قد تكونين حاملًا أو تعتزمين الحمل قبل تناول هذا الدواء. سيناقش معكِ طبيبكِ المخاطر المُحتملة التي تنتج عن تناوُل عقار زيكاديا أثناء الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يجب استخدام عقار زيكاديا أثناء ممارسة الرضاعة الطبيعية. ستقررين أنت وطبيبك معًا ما إذا كان عليكِ ممارسة الرضاعة الطبيعيَّة أو تناول عقار زيكاديا. وينبغي عليك عدم القيام بهما معًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>و. </strong><strong>.تأثير عقار </strong><strong>زيكاديا</strong><strong> على القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تتوخى حذرًا خاصًّا عند ممارسة القيادة واستخدام الآلات أثناء تناول عقار زيكاديا؛ لأنك قد تصاب باضطرابات بصرية أو تعب.</p><p dir="RTL">&nbsp;</p><p><strong>يحتوي زيكاديا على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 ملغ) لكل كبسولة ، وهذا يعني بشكل أساسي &quot;خال من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>طريقة</strong><strong> </strong><strong>استخدام عقار زيكاديا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تناول دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. يُرجى مراجعة طبيبك إذا لم تكن متأكدًا من كيفية التَّناول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">زيكاديا مستحضر طبي مضاد للسرطان. يجب البدء بالعلاج بزيكاديا والإشراف عليه من قبل طبيب ذو خبرة في استخدام المستحضرات الطبية المضادة للسرطان. أنظر القسم 5 كيفية تخزين زيكاديا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما كمية زيكاديا</strong><strong> التي يجب استخدامها؟</strong></p><p dir="RTL">تبلغ الجرعة المُوصى بها 450 مجم (ثلاث كبسولات) يتم تناولها مرَّة واحدة يوميًّا مع الطعام، بالرَّغم من ذلك، يمكن لطبيبك تعديل هذه التَّوصية إذا لزم الأمر. سيخبرك طبيبك بالضبط بعدد الكبسولات التي تحتاج إلى تناولها. لا تغير الجرعة دون التَّحدث إلى طبيبك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول عقار زيكاديا مرة واحدة يوميًّا في الوقت نفسه تقريبًا كل يوم مع الطعام (على سبيل المثال: مع وجبة خفيفة أو وجبة كاملة). إذا كنت لا تستطيع تناول الطعام أثناء تناول عقار زيكاديا، فتحدَّث إلى طبيبك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع الكبسولات كاملة مع الماء. لا تقم بمضغها أو طحنها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تقيأت بعد ابتلاع كبسولات عقار زيكاديا، فلا تتناول أي كبسولات إضافية حتى يحين موعد جرعتك التَّالية المقررة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما المدة اللازمة لتناول عقار </strong><strong>زيكاديا؟</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استمر في تناوُل عقار زيكاديا طالما أخبرك طبيبك بذلك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هذا العلاج طويل الأمد، ومن المحتمل أن يستمر لأشهر. سيقوم طبيبك بمراقبة حالتك؛ للتَّحقق من أنَّ العلاج يحقق التَّأثير المرغوب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أسئلة حول طول المدة اللازمة لتناول عقار زيكاديا، فيُرجى التَّحدث إلى طبيبك أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الجرعة الزائدة من عقار </strong><strong>زيكاديا</strong></p><p dir="RTL">إذا تناولت كمية كبيرة جدًّا من الكبسولات عن طريق الخطأ أو إذا تناول شخص آخر دواءك عن طريق الخطأ، فاتصل بطبيبك أو المستشفى لطلب المشورة فورًا. قد يكون العلاج الطبي ضروريًّا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>نسيان تناول جرعة من عقار </strong><strong>زيكاديا</strong></p><p dir="RTL">ما يجب عليك فعله إذا نسيت تناول إحدى الجرعات يعتمد على كم تبقى من الوقت حتى موعد جرعتك التَّالية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان موعد جرعتك التَّالية في غضون 12 ساعة أو أكثر، فتناول الكبسولات التي نسيتها بمجرد أن تتذكر. ثم تناول الكبسولات التَّالية في الموعد المعتاد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان موعد جرعتك التَّالية خلال أقل من 12 ساعة، فتجاوز الكبسولات التي نسيتها. ثم تناول الكبسولات التَّالية في الموعد المعتاد.</p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض جرعة تم نسيانها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج. التوقف عن تناول </strong><strong>زيكاديا</strong></p><p dir="RTL">يجب أَلَّا تتوقف عن تناوُل هذا الدَّواء قبل التَّحدث إلى طبيبك. إذا كانت لديك أية أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توقف عن تناول عقار </strong><strong>زيكاديا واطلب مساعدة طبية على الفور إذا أُصبت بأي من الآتي، </strong>والتي قد تكون علامات تُشير إلى الإصابة بأحد تفاعلات الحساسية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التَّنفس أو البلع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم الوجه، الشفتين، اللسان أو الحَلْق.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة شديدة بالجلد مصحوبة بطفح جلدي أحمر اللون أو ظهور نتوءات بارزة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بعض الآثار الجانبية قد تكون خطيرة</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي الخاص بك فورًا إذا كنت تواجه أيًّا من الآثار الجانبية التَّالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألمًا أو ضيقًا بالصدر، تغيرات بضربات القلب لديك (تسارعها أو تباطؤها)، شعورًا بدوار بالرَّأس، إغماء، دوخة، تحول لون شفتيك إلى اللون الأزرق، ضيق التَّنفس، تورمًا بالأطراف السفلية أو الجلد (علامات أو أعراض محتملة لوجود مشاكل بالقلب).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة جديدة أو متفاقمة من السعال المصحوب أو غير المصحوب ببلغم، حمى، ألمًا في الصدر، صعوبة بالتَّنفس أو ضيق التَّنفس (علامات محتملة لوجود مشاكل بالرئة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعبًا، حكة بالجلد، تحول لون بشرتك وبياض عينيك إلى اللون الأصفر، الغثيان (شعورًا بالإعياء) أو قيئًا، انخفاض الشهية، ألمًا في الجانب الأيمن من البطن، بولًا داكنًا أو بني اللون، الإصابة بنزيف أو كدمات بشكل أسهل من المعتاد (علامات أو أعراض محتملة لوجود مشاكل بالكبد).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهالًا شديدًا، الغثيان أو القيء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عطشًا شديدًا أو زيادة معدل تكرار التبوُّل (علامات تُشير إلى ارتفاع مستوى الجلوكوز في الدَّم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألمًا شديدًا بأعلى المعدة (علامة تُشير إلى التهاب البنكرياس).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية المحتملة الأخرى</strong></p><p dir="RTL">تم إدراج الآثار الجانبية الأخرى أدناه. إذا أصبحت هذه الآثار الجانبية شديدة، يُرجى إخبار طبيبك أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًّا </strong>(قد تُؤثر على أكثر من 1 من بين كل 10&nbsp;أشخاص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب (إرهاق ووهن).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية لاختبارات الدَّم التي أُجريت لفحص وظائف الكبد (ارتفاع مستويات إنزيمات تُدعى ناقلة الأمين الألانينية و/ أو ناقِلَة الأَمينِ الأسبارتية و/ أو ناقلة الجاما جلوتاميل و/ أو الفوُسْفاتيز القَلَوِي بالدَّم، ارتفاع مستويات البيليروبين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشهية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الوزن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية لاختبارات الدَّم التي أُجريت لفحص وظائف الكُلى (ارتفاع مستوى الكرياتينين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحموضة (حُرْقَةُ الفُؤاد) (علامة محتملة لوجود اضطراب بالجهاز الهضمي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدَّم الحمراء ويُعرف بفقر الدَّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة </strong>(قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالرؤية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الفوسفات في الدَّم (سيتم الكشف عن ذلك أثناء الخضوع لاختبارات الدَّم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى إنزيمات تُدعى الليباز و/ أو الأميلاز في الدَّم (سيتم الكشف عن ذلك أثناء الخضوع لاختبارات الدَّم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تدفق البول بشكل ملحوظ (علامة محتملة لوجود مشكلة بالكُلى).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى طبيبك أو الصيدلي الخاص بك.ويشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة. من خلال إبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير معلومات إضافية حول أمان استخدام هذا الدَّواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية والشريط بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يُخزَّن في درجة حرارة تتعدى 30 درجة مئوية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدَّواء إذا لاحظت وجود أي تلف بالعبوة أو إذا كانت هناك أي علامات للعبث.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. ستُساعد هذه الإجراءات في الحفاظ على البيئة.</p><p dir="RTL">التعامل مع زيكاديا:</p><p dir="RTL">&nbsp;</p><p dir="RTL">زيكاديا مستحضر طبي مضاد للسرطان. في أماكن الرعاية الصحية، استخدم منطقة مخصصة لتخزين الأدوية وتقييد الوصول إليها على الأشخاص المصرح لهم فقط.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعَّالة في عقار زيكاديا هي سيريتينيب. تحتوي كل كبسولة صلبة على 150 مجم من سيريتينيب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; محتويات الكبسولة: سيليكا غروية لا مائية، هيدروكسي بروبيل السليلوز، منخفض الاستبدال، جليكولات نشا الصوديوم (نوع أ)، ستيرات الماغنسيوم وسليلوز، دقيق التَّبلور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غلاف الكبسولة: جيلاتين، إنديجوتين (E132)، ثاني أكسيد التيتانيوم (E171).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حبر الطباعة: شيلاك (صَمْغُ اللَّك) (مُبيض، خال من الشمع)، صقال 45٪، أوكسيد الحديد الأسود (E172)، جليكول البروبيلين وهيدروكسيد الأمونيوم 28٪.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ما هو الشكل الصيدلاني </strong><strong>زيكاديا</strong><strong> ووصفه وحجم عبوته</strong></p><p dir="RTL" style="text-align:right">لدى الكبسولات الصلبة لعقارزيكاديا جسم أبيض غير شفاف وغطاء أزرق غير شفاف، مع وجود كلمة &ldquo;LDK 150MG&rdquo; محفورة على الغطاء و&ldquo;NVR&rdquo; على الجسم. وتحتوي على مسحوق ذي لون مائل إلى الأبيض.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">تتوافر الكبسولات في شرائط وتكون متاحة في عبوات تحتوي على 150 ( 3 عبوات بها 50) كبسولة. قد لا يتم تسويق جميع أحجام العبوات في دولتك.</p><p style="text-align:right">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التَّسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             تم اعتماد هذه النَّشرة من قبل منظمة الأدوية الأوروبية في   4/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zykadia 150 mg hard capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each hard capsule contains 150 mg ceritinib.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule.

Capsule with white opaque body and blue opaque cap, with “LDK 150MG” imprinted on the cap and “NVR” on the body, containing white to almost white powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zykadia as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).</p><p>&nbsp;</p><p>Zykadia as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC) previously treated with crizotinib.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Zykadia should be initiated and supervised by a physician experienced in the use of anti‑cancer medicinal products.</p><p>&nbsp;</p><p><u>ALK testing</u></p><p>&nbsp;</p><p>An accurate and validated ALK assay is necessary for the selection of ALK‑positive NSCLC patients (see section&nbsp;5.1).</p><p>&nbsp;</p><p>ALK‑positive NSCLC status should be established prior to initiation of Zykadia therapy. Assessment for ALK‑positive NSCLC should be performed by laboratories with demonstrated proficiency in the specific technology being utilised.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>The recommended dose of Zykadia is 450&nbsp;mg taken orally once daily with food at the same time each day.</p><p>&nbsp;</p><p>The maximum recommended dose with food is 450&nbsp;mg taken orally once daily. Treatment should continue as long as clinical benefit is observed.</p><p>&nbsp;</p><p>If a dose is missed, the patient should make up that dose, unless the next dose is due within 12&nbsp;hours.</p><p>&nbsp;</p><p>If vomiting occurs during the course of treatment, the patient should not take an additional dose, but should continue with the next scheduled dose.</p><p>&nbsp;</p><p>Zykadia should be discontinued in patients unable to tolerate 150&nbsp;mg daily taken with food.</p><p>&nbsp;</p><p><em><u>Dose adjustment due to adverse reactions</u></em></p><p>Temporary dose interruption and/or dose reduction of Zykadia may be required based on individual safety and tolerability. If dose reduction is required due to an adverse drug reaction (ADR) not listed in Table&nbsp;1, then this should be achieved by decrements of 150&nbsp;mg daily. Early identification and management of ADRs with standard supportive care measures should be considered.</p><p>&nbsp;</p><p>In patients treated with Zykadia 450&nbsp;mg with food, 24.1% of patients had an adverse event that required at least one dose reduction and 55.6% of patients had an adverse event that required at least one dose interruption. The median time to first dose reduction due to any reason was 9.7&nbsp;weeks.</p><p>&nbsp;</p><p>Table&nbsp;1 summarises recommendations for dose interruption, reduction or discontinuation of Zykadia in the management of selected ADRs.</p><p>&nbsp;</p><p><strong>Table&nbsp;</strong><!--[if supportFields]><span
style='mso-bookmark:_Toc372495322'></span><span style='mso-element:field-begin'></span><span
style='mso-bookmark:_Toc372495322'><b style='mso-bidi-font-weight:normal'><span
style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-US'><span
style='mso-spacerun:yes'>  </span>SEQ Table \s 1 \* ARABIC<span
style='mso-spacerun:yes'>  </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b></span><![endif]--><strong>1</strong><!--[if supportFields]><span style='mso-bookmark:_Toc372495322'></span><span
style='mso-element:field-end'></span><![endif]--><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Zykadia</strong><strong> dose adjustment and management recommendations for ADRs</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Criteria</strong></p></td><td style="vertical-align:top"><p><strong>Zykadia</strong><strong> </strong><strong>dosing</strong></p></td></tr><tr><td style="vertical-align:top"><p>Severe or intolerable nausea, vomiting or diarrhoea despite optimal anti‑emetic or anti‑diarrhoeal therapy</p></td><td style="vertical-align:top"><p>Withhold Zykadia until improved, then reinitiate Zykadia with dose reduced by 150&nbsp;mg.</p></td></tr><tr><td style="vertical-align:top"><p>Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevation &gt;5&nbsp;times upper limit of normal (ULN) with concurrent total bilirubin &le;2&nbsp;times ULN</p></td><td style="vertical-align:top"><p>Withhold Zykadia until recovery to baseline ALT/AST levels or to &le;3&nbsp;times ULN, then reinitiate with dose reduced by 150&nbsp;mg.</p></td></tr><tr><td style="vertical-align:top"><p>ALT or AST elevation &gt;3&nbsp;times ULN with concurrent total bilirubin elevation &gt;2&nbsp;times ULN (in the absence of cholestasis or haemolysis)</p></td><td style="vertical-align:top"><p>Permanently discontinue Zykadia.</p></td></tr><tr><td style="vertical-align:top"><p>Any grade treatment‑related interstitial lung disease (ILD)/pneumonitis</p></td><td style="vertical-align:top"><p>Permanently discontinue Zykadia.</p></td></tr><tr><td style="vertical-align:top"><p>QT corrected for heart rate&nbsp;(QTc) &gt;500&nbsp;msec on at least 2&nbsp;separate electrocardiograms (ECGs)</p></td><td style="vertical-align:top"><p>Withhold Zykadia until recovery to baseline or to a QTc &le;480&nbsp;msec, check and if necessary correct electrolytes, then reinitiate with dose reduced by 150&nbsp;mg.</p></td></tr><tr><td style="vertical-align:top"><p>QTc &gt;500&nbsp;msec or &gt;60&nbsp;msec change from baseline and torsade de pointes or polymorphic ventricular tachycardia or signs/symptoms of serious arrhythmia</p></td><td style="vertical-align:top"><p>Permanently discontinue Zykadia.</p></td></tr><tr><td style="vertical-align:top"><p>Bradycardia<sup>a</sup> (symptomatic, may be severe and medically significant, medical intervention indicated)</p></td><td style="vertical-align:top"><p>Withhold Zykadia until recovery to asymptomatic (grade &le;1) bradycardia or to a heart rate of 60&nbsp;beats per minute (bpm) or above.</p><p>Evaluate concomitant medicinal products known to cause bradycardia, as well as anti‑hypertensive medicinal products.</p><p>If a contributing concomitant medicinal product is identified and discontinued, or its dose is adjusted, reinitiate Zykadia at the previous dose upon recovery to asymptomatic bradycardia or to a heart rate of 60&nbsp;bpm or above.</p><p>If no contributing concomitant medicinal product is identified, or if contributing concomitant medicinal products are not discontinued or dose modified, reinitiate Zykadia with dose reduced by 150&nbsp;mg upon recovery to asymptomatic bradycardia or to a heart rate of 60&nbsp;bpm or above.</p></td></tr><tr><td style="vertical-align:top"><p>Bradycardia<sup>a</sup> (life‑threatening consequences, urgent intervention indicated)</p></td><td style="vertical-align:top"><p>Permanently discontinue Zykadia if no contributing concomitant medicinal product is identified.</p><p>If a contributing concomitant medicinal product is identified and discontinued, or its dose is adjusted, reinitiate Zykadia with dose reduced by 150&nbsp;mg upon recovery to asymptomatic bradycardia or to a heart rate of 60&nbsp;bpm or above, with frequent monitoring<sup>b</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>Persistent hyperglycaemia greater than 250&nbsp;mg/dl despite optimal anti‑hyperglycaemic therapy</p></td><td style="vertical-align:top"><p>Withhold Zykadia until hyperglycaemia is adequately controlled, then reinitiate Zykadia with dose reduced by 150&nbsp;mg.</p><p>If adequate glucose control cannot be achieved with optimal medical management, permanently discontinue Zykadia.</p></td></tr><tr><td style="vertical-align:top"><p>Lipase or amylase elevation grade&nbsp;&ge;3</p></td><td style="vertical-align:top"><p>Withhold Zykadia until lipase or amylase returns to grade&nbsp;&le;1, then reinitiate with dose reduced by 150&nbsp;mg.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart rate less than 60&nbsp;beats per minutes (bpm)</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue in the event of recurrence</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Strong CYP3A inhibitors</em></p><p>Concomitant use of strong CYP3A inhibitors should be avoided (see section&nbsp;4.5). If concomitant use of a strong CYP3A inhibitor is unavoidable, the dose of Zykadia should be reduced by approximately one third (dose not clinically verified), rounded to the nearest multiple of the 150&nbsp;mg dosage strength. Patients should be carefully monitored for safety.</p><p>&nbsp;</p><p>If long‑term concomitant treatment with a strong CYP3A inhibitor is necessary and the patient tolerates the reduced dose well, the dose may be increased again with careful monitoring for safety, to avoid potential under‑treatment.</p><p>&nbsp;</p><p>After discontinuation of a strong CYP3A inhibitor, resume at the dose that was taken prior to initiating the strong CYP3A inhibitor.</p><p>&nbsp;</p><p><em>CYP3A substrates</em></p><p>When ceritinib is co-administered with other medicinal products, the Summary of Product Characteristics (SmPC) for the other product must be consulted for the recommendations regarding co-administration with CYP3A4 inhibitors.</p><p>&nbsp;</p><p>Co-administration of ceritinib with substrates primarily metabolised by CYP3A or CYP3A substrates known to have narrow therapeutic indices (e.g. alfuzosin, amiodarone, cisapride, ciclosporin, dihydroergotamine, ergotamine, fentanyl, pimozide, quetiapine, quinidine, lovastatin, simvastatin, sildenafil, midazolam, triazolam, tacrolimus, alfentanil and sirolimus) should be avoided and alternative medicinal products that are less sensitive to CYP3A4 inhibition should be used if possible. If unavoidable, dose reduction for co-administered medicinal products that are CYP3A substrates with narrow therapeutic indices should be considered.</p><p><em>&nbsp;</em></p><p><em><u>Special populations</u></em></p><p><em><u>&nbsp;</u></em></p><p><em>Renal impairment</em></p><p>A dedicated pharmacokinetic study in patients with renal impairment has not been conducted. However, based on available data, ceritinib elimination via the kidney is negligible. Therefore, no dose adjustment is necessary in patients with mild to moderate renal impairment. Caution should be used in patients with severe renal impairment, as there is no experience with ceritinib in this population (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Based on available data, ceritinib is eliminated primarily via the liver. Particular caution should be exercised when treating patients with severe hepatic impairment and the dose should be reduced by approximately one third, rounded to the nearest multiple of the 150&nbsp;mg dosage strength (see sections&nbsp;4.4 and 5.2). No dose adjustment is necessary in patients with mild or moderate hepatic impairment.</p><p>&nbsp;</p><p><em>Elderly (&ge;65&nbsp;years)</em></p><p>The limited data on the safety and efficacy of ceritinib in patients aged 65&nbsp;years and older do not suggest that a dose adjustment is required in elderly patients (see section&nbsp;5.2). There are no available data on patients over 85&nbsp;years of age.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of ceritinib in children and adolescents aged up to 18&nbsp;years have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p><em>Zykadia is an anti-cancer medical product. Treatment with Zykadia should be initiated and supervised by a physician experienced in the use of anti-cancer medicinal products.</em><em> </em></p><p><em>&nbsp;</em></p><p>Zykadia is for oral use. The capsules should be administered orally once daily with food at the same time every day. It is important that Zykadia is taken with food to reach the appropriate exposure. Food can range from a light to a full meal (see section&nbsp;5.2). The capsules should be swallowed whole with water and should not be chewed or crushed. For more details refer to section 6.6 Special precautions for handling and disposal.</p><p>For patients who develop a concurrent medical condition and are unable to take Zykadia with food please refer to section&nbsp;4.5.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hepatotoxicity</u></p><p>&nbsp;</p><p>Cases of hepatotoxicity occurred in 1.1% of patients receiving ceritinib in clinical studies. Increases to grade&nbsp;3 or 4 ALT elevations were observed in 25% of patients. The majority of cases were manageable with dose interruption and/or dose reduction. Few events required discontinuation of treatment.</p><p>&nbsp;</p><p>Patients should be monitored with liver laboratory tests (including ALT, AST and total bilirubin) prior to the start of treatment, every 2&nbsp;weeks during the first three months of treatment and monthly thereafter. In patients who develop transaminase elevations, more frequent monitoring of liver transaminases and total bilirubin should be carried out as clinically indicated (see sections&nbsp;4.2 and 4.8). Particular caution should be exercised when treating patients with severe hepatic impairment, and the dose should be adjusted (see section 4.2). Limited experience in these patients showed a worsening of the underlying condition (hepatic encephalopathy) in 2 out of 10 patients exposed to 750 mg single doses of ceritinib under fasted conditions (see sections 4.2, 4.8 and 5.2). Other factors apart from study treatment could have impacted on observed events of hepatic encephalopathy, however, the relation between study treatment and events cannot be fully ruled out. No dose adjustment is necessary in patients with mild or moderate hepatic impairment (see section 4.2).</p><p>&nbsp;</p><p><u>Interstitial lung disease/Pneumonitis</u></p><p>&nbsp;</p><p>Severe, life‑threatening or fatal ILD/pneumonitis have been observed in patients treated with ceritinib in clinical studies. Most of these severe/life-threatening cases improved or resolved with interruption of treatment.</p><p>&nbsp;</p><p>Patients should be monitored for pulmonary symptoms indicative of ILD/pneumonitis. Other potential causes of ILD/pneumonitis should be excluded, and Zykadia permanently discontinued in patients diagnosed with any grade treatment‑related ILD/pneumonitis (see sections&nbsp;4.2 and 4.8).</p><p>&nbsp;</p><p><u>QT interval prolongation</u></p><p>&nbsp;</p><p>QTc prolongation has been observed in clinical studies in patients treated with ceritinib (see sections&nbsp;4.8 and 5.2), which may lead to an increased risk for ventricular tachyarrhythmias (e.g. torsade de pointes) or sudden death.</p><p>&nbsp;</p><p>Use of Zykadia in patients with congenital long QT syndrome should be avoided. The benefits and potential risks of ceritinib should be considered before beginning therapy in patients who have pre‑existing bradycardia (heart rate less than 60&nbsp;beats per minute [bpm]), patients who have a history of or predisposition for QTc prolongation, patients who are taking anti‑arrhythmics or other medicinal products that are known to prolong the QT interval and patients with relevant pre‑existing cardiac disease and/or electrolyte disturbances. Periodic monitoring with ECGs and periodic monitoring of electrolytes (e.g. potassium) is recommended in these patients. In the event of vomiting, diarrhoea, dehydration or impaired renal function, correct electrolytes as clinically indicated. Zykadia should be permanently discontinued in patients who develop QTc &gt;500&nbsp;msec or &gt;60&nbsp;msec change from baseline and torsade de pointes or polymorphic ventricular tachycardia or signs/symptoms of serious arrhythmia. Zykadia should be withheld in patients who develop QTc &gt;500&nbsp;msec on at least two separate ECGs until recovery to baseline or a QTc &le;480&nbsp;msec, then reinitiated with dose reduced by 150&nbsp;mg (see sections&nbsp;4.2, 4.8 and 5.2).</p><p>&nbsp;</p><p><u>Bradycardia</u></p><p>&nbsp;</p><p>Asymptomatic cases of bradycardia (heart rate less than 60&nbsp;bpm) have been observed in 21 out of 925&nbsp;(2.3%)&nbsp;patients treated with ceritinib in clinical studies.</p><p>&nbsp;</p><p>Use of Zykadia in combination with other agents known to cause bradycardia (e.g. beta blockers, non‑dihydropyridine calcium channel blockers, clonidine and digoxin) should be avoided as far as possible. Heart rate and blood pressure should be monitored regularly. In cases of symptomatic bradycardia that is not life‑threatening, Zykadia should be withheld until recovery to asymptomatic bradycardia or to a heart rate of 60&nbsp;bpm or above, the use of concomitant medicinal products should be evaluated and the Zykadia dose adjusted if necessary. In the event of life‑threatening bradycardia Zykadia should be permanently discontinued if no contributing concomitant medicinal product is identified; however, if associated with a concomitant medicinal product known to cause bradycardia or hypotension, Zykadia should be withheld until recovery to asymptomatic bradycardia or to a heart rate of 60&nbsp;bpm or above. If the concomitant medicinal product can be adjusted or discontinued, Zykadia should be reinitiated with dose reduced by 150&nbsp;mg on recovery to asymptomatic bradycardia or to a heart rate of 60&nbsp;bpm or above, with frequent monitoring (see sections&nbsp;4.2 and 4.8).</p><p>&nbsp;</p><p><u>Gastrointestinal adverse reactions</u></p><p>&nbsp;</p><p>Diarrhoea, nausea, or vomiting occurred in 74.2% of 89&nbsp;patients treated with Zykadia at the recommended dose of 450&nbsp;mg taken with food in a dose optimisation study and were mainly grade&nbsp;1 (52.8%) and grade&nbsp;2 (22.2%) events. Two patients (1.9%) experienced one grade&nbsp;3 event each (diarrhoea and vomiting respectively). Nine patients (8.3%) required study drug interruption due to diarrhoea, nausea or vomiting. One patient (0.9%) required dose adjustment due to vomiting. In the same study, the incidence and severity of gastrointestinal adverse drug reactions were higher for patients treated with Zykadia 750&nbsp;mg fasted (diarrhoea 80.0%, nausea 60.0%, vomiting 65.5%; 17.3% reported a grade&nbsp;3 event) compared to 450&nbsp;mg with food (diarrhoea 59.3%, nausea 42.6%, vomiting 38.0%; 1.9% reported a grade&nbsp;3 event).</p><p>&nbsp;</p><p>&nbsp;</p><p>In the 450&nbsp;mg with food and 750&nbsp;mg fasted arms of this dose optimisation study, no patients required</p><p>discontinuation of Zykadia due to diarrhoea, nausea or vomiting (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Patients should be monitored and managed using standards of care, including anti‑diarrhoeals, anti‑emetics or fluid replacement, as clinically indicated. Dose interruption and dose reduction should be employed as necessary (see sections 4.2 and 4.8). If vomiting occurs during the course of treatment, the patient should not take an additional dose, but should continue with the next scheduled dose.</p><p>&nbsp;</p><p><u>Hyperglycaemia</u></p><p>&nbsp;</p><p>Cases of hyperglycaemia (all grades) have been reported in less than 10% of patients treated with ceritinib in clinical studies; grade 3‑4 hyperglycaemia was reported in 5.4% of patients. The risk of hyperglycaemia was higher in patients with diabetes mellitus and/or concurrent steroid use.</p><p>&nbsp;</p><p>Patients should be monitored for fasting plasma glucose prior to the start of Zykadia treatment and periodically thereafter as clinically indicated. Anti‑hyperglycaemic medicinal products should be initiated or optimised as indicated (see sections&nbsp;4.2 and 4.8).</p><p>&nbsp;</p><p><u>Lipase and/or amylase elevations</u></p><p>&nbsp;</p><p>Elevations of lipase and/or amylase have occurred in patients treated with ceritinib in clinical studies. Patients should be monitored for lipase and amylase elevations prior to the start of Zykadia treatment and periodically thereafter as clinically indicated (see sections&nbsp;4.2 and 4.8). Cases of pancreatitis have been reported in patients treated with ceritinib (see section&nbsp;4.8).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Sodium content</u></p><p><u>&nbsp;</u></p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per capsule, that is to say essentially &ldquo;sodium-free&rdquo;.</p><p><u>&nbsp;</u></p><p><u>Pancreatitis</u></p><p>Pancreatitis occurred in patients receiving ZYKADIA. Pancreatitis, including one fatality, occurred in less than 1% of patients receiving ZYKADIA in clinical studies. CTCAE Grade 3 or 4 amylase increased occurred in 3.1% of patients receiving ZYKADIA across a pool of 7 clinical studies, while CTCAE Grade 3 or 4 lipase increased occurred in 3.5% of patients. Monitor lipase and amylase prior to the start of ZYKADIA treatment and periodically thereafter as clinically indicated. Based on the severity of the laboratory abnormalities, withhold ZYKADIA with resumption at a reduced dose (see sections 4.2, 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Agents that may increase ceritinib plasma concentrations</u></p><p><em>&nbsp;</em></p><p><em><u>Strong CYP3A inhibitors</u></em></p><p>In healthy subjects, co‑administration of a single 450&nbsp;mg fasted ceritinib dose with ketoconazole (200&nbsp;mg twice daily for 14&nbsp;days), a strong CYP3A/P‑gp inhibitor, resulted in 2.9‑fold and 1.2‑fold increase in ceritinib AUC<sub>inf</sub> and C<sub>max</sub>, respectively, compared to when ceritinib was given alone. The steady‑state AUC of ceritinib at reduced doses after co‑administration with ketoconazole 200&nbsp;mg twice daily for 14&nbsp;days was predicted by simulations to be similar to the steady‑state AUC of ceritinib alone. Concomitant use of strong CYP3A inhibitors should be avoided during treatment with Zykadia. If it is not possible to avoid concomitant use with strong CYP3A inhibitors (including, but not limited to, ritonavir, saquinavir, telithromycin, ketoconazole, itraconazole, voriconazole, posaconazole and nefazodone), the dose of Zykadia should be reduced by approximately one third, rounded to the nearest multiple of the 150&nbsp;mg dosage strength. After discontinuation of a strong CYP3A inhibitor, Zykadia should be resumed at the dose that was taken prior to initiating the strong CYP3A inhibitor.</p><p><em>&nbsp;</em></p><p><em><u>P-gp inhibitors</u></em></p><p>Based on <em>in vitro</em> data, ceritinib is a substrate of the efflux transporter P‑glycoprotein (P‑gp). If ceritinib is administered with medicinal products that inhibit P‑gp, an increase in ceritinib concentration is likely. Caution should be exercised with concomitant use of P‑gp inhibitors and ADRs carefully monitored.</p><p>&nbsp;</p><p><u>Agents that may decrease ceritinib plasma concentrations</u></p><p>&nbsp;</p><p><em><u>Strong CYP3A and P-gp inducers</u></em></p><p>In healthy subjects, co‑administration of a single 750&nbsp;mg fasted ceritinib dose with rifampicin (600&nbsp;mg daily for 14&nbsp;days), a strong CYP3A/P‑gp inducer, resulted in 70% and 44% decreases in ceritinib AUC<sub>inf</sub> and C<sub>max</sub>, respectively, compared to when ceritinib was given alone. Co‑administration of ceritinib with strong CYP3A/P‑gp inducers decreases ceritinib plasma concentrations. Concomitant use of strong CYP3A inducers should be avoided; this includes, but is not limited to, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampicin and St. John&rsquo;s Wort (<em>Hypericum perforatum</em>). Caution should be exercised with concomitant use of P‑gp inducers.</p><p>&nbsp;</p><p><em><u>Agents that affect gastric pH</u></em></p><p>Ceritinib demonstrates pH-dependent solubility and becomes poorly soluble as pH increases <em>in vitro</em>. Acid reducing agents (e.g., proton pump inhibitors, H<sub>2</sub>-receptor antagonists, antacids) can alter the solubility of ceritinib and reduce its bioavailability. Co‑administration of a single 750&nbsp;mg fasted ceritinib dose with a proton pump inhibitor (esomeprazole) 40&nbsp;mg daily for 6&nbsp;days in healthy, fasting subjects decreased ceritinib AUC by 76% and C<sub>max</sub> by 79%. The drug-drug interaction study was designed to observe the impact of proton pump inhibitor in the worst scenario, but in clinical use the impact of proton pump inhibitor on ceritinib exposure appears to be less pronounced. A dedicated study to evaluate the effect of gastric acid‑reducing agents on the bioavailability of ceritinib under steady state has not been conducted. Caution is advised with concomitant use of proton pump inhibitors, as exposure of ceritinib may be reduced. There is no data with concomitant use of H<sub>2</sub> blockers or antacids. However, the risk for a clinically relevant decrease in bioavailability of ceritinib is possibly lower with concomitant use of H<sub>2</sub> blockers if they are administered 10&nbsp;hours before or 2&nbsp;hours after the ceritinib dose, and with antacids if they are administered 2&nbsp;hours before or 2&nbsp;hours after the ceritinib dose.</p><p>&nbsp;</p><p><u>Agents whose plasma concentration may be altered by ceritinib</u></p><p>&nbsp;</p><p><em><u>CYP3A and CYP2C9 substrates</u></em></p><p>Based on <em>in vitro</em> data, ceritinib competitively inhibits the metabolism of a CYP3A substrate, midazolam, and a CYP2C9 substrate, diclofenac. Time‑dependent inhibition of CYP3A was also observed.</p><p>&nbsp;</p><p>Ceritinib has been classified in vivo as a strong CYP3A4 inhibitor and has the potential to interact with medicinal products that are metabolised by CYP3A, which may lead to increased serum concentrations of the other product. Co-administration of a single dose of midazolam (a sensitive CYP3A substrate) following 3&nbsp;weeks of ceritinib dosing in patients (750&nbsp;mg daily fasted) increased the midazolam AUC<sub>inf</sub> (90% CI) by 5.4‑fold (4.6, 6.3) compared to midazolam alone.Co‑administration of ceritinib with substrates primarily metabolised by CYP3A or CYP3A substrates known to have narrow therapeutic indices (e.g. alfuzosin, amiodarone, cisapride, ciclosporin, dihydroergotamine,ergotamine, fentanyl, pimozide, quetiapine, quinidine, lovastatin, simvastatin, sildenafil, midazolam, triazolam, tacrolimus, alfentanil and sirolimus) should be avoided and alternative medicinal products that are less sensitive to CYP3A4 inhibition should be used if possible. If unavoidable, dose reduction for co-administered medicinal products that are CYP3A substrates with narrow therapeutic indices should be considered.</p><p>Ceritinib has been classified <em>in vivo</em> as a weak CYP2C9 inhibitor. Co-administration of a single dose of warfarin (a CYP2C9 substrate) following 3&nbsp;weeks of ceritinib dosing in patients (750&nbsp;mg daily fasted) increased the S-warfarin AUC<sub>inf </sub>(90% CI) by 54% (36%, 75%) compared to warfarin alone. Co-administration of ceritinib with substrates primarily metabolised by CYP2C9 or CYP2C9 substrates known to have narrow therapeutic indices (e.g. phenytoin and warfarin) should be avoided.</p><p>If unavoidable, dose reduction for co-administered medicinal products that are CYP2C9 substrates with narrow therapeutic indices should be considered. Increasing the frequency of international normalised ratio (INR) monitoring may be considered if co-administration with warfarin is unavoidable.</p><p>&nbsp;</p><p><em><u>CYP2A6 and CYP2E1 substrates</u></em></p><p>Based on <em>in vitro</em> data, ceritinib also inhibits CYP2A6 and CYP2E1 at clinically relevant concentrations. Therefore, ceritinib may have the potential to increase plasma concentrations of co‑administered medicinal products that are predominantly metabolised by these enzymes. Caution should be exercised with concomitant use of CYP2A6 and CYP2E1 substrates and ADRs carefully monitored.</p><p>&nbsp;</p><p>A risk for induction of other PXR regulated enzymes apart from CYP3A4 cannot be completely excluded. The effectiveness of concomitant administration of oral contraceptives may be reduced.</p><p>&nbsp;</p><p><u>Agents that are substrates of transporters</u></p><p>&nbsp;</p><p>Based on <em>in vitro</em> data, ceritinib does not inhibit apical efflux transporter MRP2, hepatic uptake transporters OATP1B1 or OATP1B3, renal organic anion uptake transporters OAT1 and OAT3, or the organic cation uptake transporters OCT1 or OCT2 at clinically relevant concentrations. Therefore, clinical drug‑drug interactions as a result of ceritinib‑mediated inhibition of substrates for these transporters are unlikely to occur. Based on <em>in vitro</em> data, ceritinib is predicted to inhibit intestinal P‑gp and BCRP at clinically relevant concentrations. Therefore, ceritinib may have the potential to increase plasma concentrations of co‑administered medicinal products transported by these proteins. Caution should be exercised with concomitant use of BCRP substrates (e.g. rosuvastatin, topotecan, sulfasalazine) and P‑gp substrates (digoxin, dabigatran, colchicine, pravastatin) and ADRs carefully monitored.</p><p>&nbsp;</p><p><u>Pharmacodynamic interactions</u></p><p>&nbsp;</p><p>In clinical studies, QT prolongation was observed with ceritinib. Therefore, ceritinib should be used with caution in patients who have or may develop prolongation of the QT interval, including those patients taking anti‑arrhythmic medicinal products such as class&nbsp;I (e.g. quinidine, procainamide, disopyramide) or class&nbsp;III (e.g. amiodarone, sotalol, dofetilide, ibutilide) anti‑arrhythmics or other medicinal products that may lead to QT prolongation such as domperidone, droperidol, chloroquine, halofantrine, clarithromycin, haloperidol, methadone, cisapride and moxifloxacin. Monitoring of the QT interval is indicated in the event of combinations of such medicinal products (see sections&nbsp;4.2 and 4.4).</p><p>&nbsp;</p><p><u>Food/drink interactions</u></p><p>&nbsp;</p><p>Zykadia should be taken with food. The bioavailability of ceritinib is increased in the presence of food.</p><p>&nbsp;</p><p>For patients who develop a concurrent medical condition and are unable to take Zykadia with food, Zykadia can be taken on an empty stomach as the alternate continued treatment regimen, in which no food should be eaten for at least two hours before and one hour after the dose. Patients should not alternate between fasted and fed dosing. Dose must be adjusted properly, i.e for patients treated with 450&nbsp;mg or 300&nbsp;mg with food, the dose should be increased to 750&nbsp;mg or 450&nbsp;mg taken on an empty stomach, respectively (see section&nbsp;5.2) and for patients treated with 150&nbsp;mg with food treatment should be discontinued. For subsequent dose adjustment and management recommendations for ADRs, please follow table&nbsp;1 (see section&nbsp;4.2). The maximum allowable dose under fasted condition is 750&nbsp;mg (see section&nbsp;5.2).</p><p>&nbsp;</p><p>Patients should be instructed to avoid grapefruit and grapefruit juice as they may inhibit CYP3A in the gut wall and may increase the bioavailability of ceritinib.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception</u></p><p>&nbsp;</p><p>Women of childbearing potential should be advised to use a highly effective method of contraception while taking Zykadia and for up to 3&nbsp;months after discontinuing treatment (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no or limited amount of data from the use of ceritinib in pregnant women.</p><p>&nbsp;</p><p>Animal studies are insufficient with respect to reproductive toxicity (see section&nbsp;5.3).</p><p>&nbsp;</p><p>Zykadia should not be used during pregnancy unless the clinical condition of the woman requires treatment with ceritinib.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>&nbsp;</p><p>It is unknown whether ceritinib/metabolites are excreted in human milk. A risk to the newborn/infant cannot be excluded.</p><p>&nbsp;</p><p>A decision must be made whether to discontinue breast‑feeding or discontinue/abstain from Zykadia therapy taking into account the benefit of breast‑feeding for the child and the benefit of therapy for the woman (see section&nbsp;5.3).</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>The potential for Zykadia to cause infertility in male and female patients is unknown (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zykadia has minor influence on the ability to drive or use machines. Caution should be exercised when driving or using machines during treatment as patients may experience fatigue or vision disorders.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>Adverse drug reactions (ADRs) described below reflect exposure to Zykadia 750&nbsp;mg once daily fasted in 925&nbsp;patients with ALK‑positive advanced NSCLC across a pool of seven clinical studies including two randomised, active-controlled, phase&nbsp;3 studies (studies A2301 and A2303).</p><p>&nbsp;</p><p>The median duration of exposure to Zykadia 750&nbsp;mg fasted was 44.9&nbsp;weeks (range: 0.1 to 200.1&nbsp;weeks).</p><p>&nbsp;</p><p>ADRs with an incidence of &ge;10% in patients treated with Zykadia 750&nbsp;mg fasted were diarrhoea, nausea, vomiting, fatigue, liver laboratory test abnormalities, abdominal pain, decreased appetite, weight decreased, constipation, blood creatinine increased, rash, anaemia and oesophageal disorder.</p><p>&nbsp;</p><p>Grade&nbsp;3‑4 ADRs with an incidence of &ge;5% in patients treated with Zykadia 750&nbsp;mg fasted were liver laboratory test abnormalities, fatigue, vomiting, hyperglycaemia, nausea and diarrhoea.</p><p>&nbsp;</p><p>In the dose optimisation study A2112 (ASCEND-8) in both previously treated and untreated patients with ALK-positive advanced NSCLC, the overall safety profile of Zykadia at the recommended dose of 450&nbsp;mg with food (N=89) was consistent with Zykadia 750&nbsp;mg fasted (N=90), except for a reduction in gastrointestinal adverse drug reactions, while achieving comparable steady-state exposure (see section&nbsp;5.1 and subsection &lsquo;Gastrointestinal adverse reactions&rsquo; below).</p><p>&nbsp;</p><p><u>Tabulated list of ADRs</u></p><p>&nbsp;</p><p>Table&nbsp;2 shows the frequency category of ADRs reported for Zykadia in patients treated at a dose of 750&nbsp;mg fasted (N=925) in seven clinical studies. The frequency of selected gastrointestinal ADRs (diarrhoea, nausea and vomiting) are based on patients treated with a dose of 450&nbsp;mg once-daily with food (N=108).</p><p>&nbsp;</p><p>ADRs are listed according to MedDRA system organ class. Within each system organ class, the ADRs are ranked by frequency, with the most frequent reactions first. In addition, the corresponding frequency category using the following convention (CIOMS III) is also provided for each ADR: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); and not known (cannot be estimated from the available data).</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Table&nbsp;2 ADRs in patients treated with Zykadia</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:661px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p><p><strong>Preferred term</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Zykadia</strong></p><p><strong>N=925</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Blood and lymphatic system disorders</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Anaemia</p></td><td colspan="3"><p>15.2</p></td><td><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Neutropenia</p></td><td colspan="3"><p>4.4</p></td><td><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Thrombocytopenia</p></td><td colspan="3"><p>1.9</p></td><td><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Metabolism and nutrition disorders</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Decreased appetite</p></td><td colspan="3" style="vertical-align:top"><p>39.5</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Hyperglycaemia</p></td><td colspan="3" style="vertical-align:top"><p>9.4</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Hypophosphataemia</p></td><td colspan="3" style="vertical-align:top"><p>5.3</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Eye disorders</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Vision disorder<sup>a</sup></p></td><td colspan="3" style="vertical-align:top"><p>7.0</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Cardiac disorders</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Pericarditis<sup>b</sup></p></td><td colspan="3" style="vertical-align:top"><p>5.8</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Bradycardia<sup>c</sup></p></td><td colspan="3" style="vertical-align:top"><p>2.3</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Pneumonitis<sup>d</sup></p></td><td colspan="3" style="vertical-align:top"><p>2.1</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Cough</p></td><td colspan="3" style="vertical-align:top"><p>23.4</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Gastrointestinal disorders</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Diarrhoea<sup>e</sup></p></td><td colspan="3" style="vertical-align:top"><p>59.3</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Nausea<sup>e</sup></p></td><td colspan="3" style="vertical-align:top"><p>42.6</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Vomiting<sup>e</sup></p></td><td colspan="3" style="vertical-align:top"><p>38.0</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Abdominal pain<sup>f</sup></p></td><td colspan="3" style="vertical-align:top"><p>46.1</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Constipation</p></td><td colspan="3" style="vertical-align:top"><p>24.0</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Oesophageal disorder<sup>g</sup></p></td><td colspan="3" style="vertical-align:top"><p>14.1</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Pancreatitis</p></td><td colspan="3" style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Hepatobiliary disorders</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Abnormal liver function tests<sup>h</sup></p></td><td colspan="3" style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Hepatotoxicity<sup>i</sup></p></td><td colspan="3" style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Rash<sup>j</sup></p></td><td colspan="3" style="vertical-align:top"><p>19.6</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Pruritus</p></td><td colspan="3" style="vertical-align:top"><p>7.8</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Nervous system disorders</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>20.6</p></td><td colspan="3" style="vertical-align:top"><p>Very common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>12.4</p></td><td colspan="3" style="vertical-align:top"><p>Very common</p></td></tr><tr><td colspan="5"><p><strong>Renal and urinary disorders</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Renal failure<sup>k</sup></p></td><td colspan="3" style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Renal impairment<sup>l</sup></p></td><td colspan="3" style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>General disorders and administration site conditions</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Fatigue<sup>m</sup></p></td><td colspan="3" style="vertical-align:top"><p>48.4</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Investigations</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Liver laboratory test abnormalities<sup>n</sup></p></td><td colspan="3" style="vertical-align:top"><p>60.5</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Weight decreased</p></td><td colspan="3" style="vertical-align:top"><p>27.6</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Blood creatinine increased</p></td><td colspan="3" style="vertical-align:top"><p>22.1</p></td><td style="vertical-align:top"><p>Very common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Electrocardiogram QT prolonged</p></td><td colspan="3" style="vertical-align:top"><p>9.7</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Lipase increased</p></td><td colspan="3" style="vertical-align:top"><p>4.8</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Amylase increased</p></td><td colspan="3" style="vertical-align:top"><p>7.0</p></td><td style="vertical-align:top"><p>Common</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p>Includes cases reported within the clustered terms:</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vision disorder (vision impairment, vision blurred, photopsia, vitreous floaters, visual acuity reduced, accommodation disorder, presbyopia)</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pericarditis (pericardial effusion, pericarditis)</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bradycardia (bradycardia, sinus bradycardia)</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonitis (interstitial lung disease, pneumonitis)</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The frequency of these selected gastrointestinal ADRs (diarrhoea, nausea and vomiting) is based on patients treated with the recommended dose of ceritinib 450&nbsp;mg with food (N=89) in the study A2112 (ASCEND-8) (see subsection &lsquo;Gastrointestinal adverse reactions&rsquo; below)</p><p><sup>f</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain (abdominal pain, abdominal pain upper, abdominal discomfort, epigastric discomfort)</p><p><sup>g</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oesophageal disorder (dyspepsia, gastro‑oesophageal reflux disease, dysphagia)</p><p><sup>h</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal liver function test (hepatic function abnormal, hyperbilirubinaemia)</p><p><sup>i</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatotoxicity (drug‑induced liver injury, hepatitis cholestatic, hepatocellular injury, hepatotoxicity)</p><p><sup>j</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash (rash, dermatitis acneiform, rash maculopapular)</p><p><sup>k</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal failure (acute renal injury, renal failure)</p><p><sup>l</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal impairment (azotaemia, renal impairment)</p><p><sup>m</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue (fatigue, asthenia)</p><p><sup>n</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver laboratory test abnormalities (alanine aminotransferase increased, aspartate aminotransferase increased, gamma‑glutamyltransferase increased, blood bilirubin increased, transaminases increased, hepatic enzyme increased, liver function test abnormal, liver function test increased, blood alkaline phosphatase increased)</p></td><td><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><u>Elderly (&ge;65&nbsp;years)</u></p><p>&nbsp;</p><p>Across seven clinical studies, 168 out of 925&nbsp;patients (18.2%) treated with Zykadia were aged 65&nbsp;years or older. The safety profile in patients aged 65&nbsp;years or older was similar to that in patients less than 65&nbsp;years of age (see section&nbsp;4.2). There are no safety data in patients older than 85&nbsp;years of age.</p><p>&nbsp;</p><p><u>Hepatotoxicity</u></p><p>&nbsp;</p><p>Concurrent elevations of ALT or AST greater than 3&times; ULN and total bilirubin greater than 2&times; ULN without elevated alkaline phosphatase have been observed in less than 1% of patients in clinical studies with ceritinib. Increases to grade&nbsp;3 or 4 ALT elevations were observed in 25% of patients receiving ceritinib. Hepatotoxicity events were managed with dose interruptions or reductions in 40.6% of patients. 1% of patients required permanent discontinuation of treatment in clinical studies with ceritinib (see sections&nbsp;4.2 and 4.4).</p><p>&nbsp;</p><p>Liver laboratory tests including ALT, AST and total bilirubin should be performed prior to the start of treatment, every 2&nbsp;weeks during the first three months of treatment and monthly thereafter, with more frequent testing for grade&nbsp;2, 3 or 4 elevations. Patients should be monitored for liver laboratory test abnormalities and managed as recommended in sections&nbsp;4.2 and 4.4.</p><p>&nbsp;</p><p><u>Gastrointestinal </u><u>adverse reactions</u></p><p>&nbsp;</p><p>Nausea, diarrhoea and vomiting were among the most commonly reported gastrointestinal events. In the dose optimisation study A2112 (ASCEND-8) in both previously treated and untreated patients with ALK-positive advanced NSCLC at the recommended dose of ceritinib 450&nbsp;mg taken with food (N=108), adverse events of diarrhoea, nausea and vomiting were mainly grade&nbsp;1 (52.8%) and grade&nbsp;2 (22.2%).Grade&nbsp;3 event of diarrhoea and vomiting were each reported in two different patients (1.9%). Gastrointestinal events were managed primarily with concomitant medicinal products including anti‑emetic/anti‑diarrhoeal medicinal products. Nine patients (8.3%) &nbsp;required study drug interruption due to diarrhoea,nausea or vomiting. One patient (0.9%) required dose adjustment. In the 450&nbsp;mg with food and 750&nbsp;mg fasted arms, No patients had diarrhoea, nausea, or vomiting that required discontinuation of study drug. In the same study the incidence and severity of gastrointestinal adverse drug reactions were reduced for patients treated with Zykadia 450&nbsp;mg with food (diarrhoea 59.3%, nausea 42.6%, vomiting 38%; 1.9% reported a grade&nbsp;3 event) compared to 750&nbsp;mg fasted (diarrhoea 80%, nausea 60%, vomiting 65.5%; 17.3% reported a grade&nbsp;3 event). Patients should be managed as recommended in sections&nbsp;4.2 and 4.4.</p><p>&nbsp;</p><p><u>QT interval prolongation</u></p><p>&nbsp;</p><p>QTc prolongation has been observed in patients treated with ceritinib. Across the seven clinical studies, 9.7% of patients treated with ceritinib had events of QT prolongation (any grade), including grade&nbsp;3 or 4 events in 2.1% of patients. These events required dose reduction or interruption in 2.1% of patients and led to discontinuation in 0.2% of patients.</p><p>&nbsp;</p><p>Treatment with ceritinib is not recommended in patients who have congenital long QT syndrome or who are taking medicinal products known to prolong the QTc interval (see sections&nbsp;4.4 and 4.5). Particular care should be exercised when administering ceritinib to patients with an increased risk of experiencing torsade de pointes during treatment with a QTc‑prolonging medicinal product.</p><p>&nbsp;</p><p>Patients should be monitored for QT prolongation and managed as recommended in sections&nbsp;4.2 and 4.4.</p><p>&nbsp;</p><p><u>Bradycardia</u></p><p>&nbsp;</p><p>Across the seven clinical studies, bradycardia and/or sinus bradycardia (heart rate less than 60&nbsp;bpm) events (all grade&nbsp;1) were reported in 2.3% of patients. These events required dose reduction or interruption in 0.2% of patients. None of these events led to discontinuation of ceritinib treatment. The use of concomitant medicinal products associated with bradycardia should be carefully evaluated. Patients who develop symptomatic bradycardia should be managed as recommended in sections&nbsp;4.2 and 4.4.</p><p>&nbsp;</p><p><u>Interstitial lung disease/Pneumonitis</u></p><p>&nbsp;</p><p>Severe, life‑threatening, or fatal interstitial lung disease (ILD)/pneumonitis have been observed in patients treated with ceritinib. Across the seven clinical studies, any grade ILD/pneumonitis has been reported in 2.1% of patients treated with ceritinib, and grade&nbsp;3 or 4 events have been reported in 1.2% of patients. These events required dose reduction or interruption in 1.1% of patients and led to discontinuation in 0.9% of patients.<em> </em>Patients with pulmonary symptoms indicative of ILD/pneumonitis should be monitored. Other potential causes of ILD/pneumonitis should be excluded (see sections&nbsp;4.2 and 4.4).</p><p>&nbsp;</p><p><u>Hyperglycaemia</u></p><p>&nbsp;</p><p>Hyperglycaemia (all grades) was reported in 9.4% of patients treated with ceritinib across the seven clinical studies; grade&nbsp;3 or 4 events were reported in 5.4% of patients. These events required dose reduction or interruption in 1.4% of patients and led to discontinuation in 0.1% of patients. The risk of hyperglycaemia was higher in patients with diabetes mellitus and/or concurrent steroid use. Monitoring of fasting serum glucose is required prior to the start of ceritinib treatment and periodically thereafter as clinically indicated. Administration of anti‑hyperglycaemic medicinal products should be initiated or optimised as indicated (see sections&nbsp;4.2 and 4.4).</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions</p><p>&nbsp;</p><p><strong>--<em>To reports any side effect(s): </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia: </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>O Toll Free Number: 8001240078<br />O Phone: +966112658100<br />O Fax: +966112658107<br />O Email: adverse.events@novartis.com</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong><em>Other GCC States: </em></strong></p><p>- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no reported experience with overdose in humans. General supportive measures should be initiated in all cases of overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antineoplasic and immunomodulating agents, ATC code: L01XE28.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Ceritinib is an orally highly selective and potent ALK inhibitor. Ceritinib inhibits autophosphorylation of ALK, ALK‑mediated phosphorylation of downstream signalling proteins and proliferation of ALK‑dependent cancer cells both <em>in vitro</em> and <em>in vivo</em>.</p><p>&nbsp;</p><p>ALK translocation determines expression of the resulting fusion protein and consequent aberrant ALK signaling in NSCLC. In the majority of NSCLC cases, EML4 is the translocation partner for ALK; this generates an EML4‑ALK fusion protein containing the protein kinase domain of ALK fused to the N‑terminal part of EML4. Ceritinib was demonstrated to be effective against EML4‑ALK activity in a NSCLC cell line (H2228), resulting in inhibition of cell proliferation <em>in vitro</em> and regression of tumours in H2228‑derived xenografts in mouse and rat.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em><u>Previously untreated ALK‑positive advanced NSCLC - randomised phase&nbsp;3 Study A2301 (ASCEND-4)</u></em></p><p>The efficacy and safety of Zykadia for the treatment of advanced ALK-positive NSCLC patients who have not received previous systemic treatment anti-cancer therapy (including ALK inhibitor) with the exception of neo-adjuvant or adjuvant therapy, was demonstrated in a global multicentre, randomised, open-label phase&nbsp;3 Study A2301.</p><p>&nbsp;</p><p>A total of 376&nbsp;patients were randomised in a 1:1 ratio (stratified by WHO performance status, prior adjuvant/neoadjuvant chemotherapy and presence/absence of brain metastasis at screening) to receive either ceritinib (750&nbsp;mg daily, fasted) or chemotherapy (based on investigator&rsquo;s choice - pemetrexed [500&nbsp;mg/m<sup>2</sup>] plus cisplatin [75&nbsp;mg/m<sup>2</sup>] or carboplatin [AUC 5-6], administered every 21&nbsp;days). Patients who completed 4&nbsp;cycles of chemotherapy (induction) without progressive disease subsequently received pemetrexed (500&nbsp;mg/m<sup>2</sup>) as single-agent maintenance therapy every 21&nbsp;days. One hundred and eighty-nine (189) patients were randomised to ceritinib and one hundred eighty-seven (187) were randomised to chemotherapy.</p><p>&nbsp;</p><p>The median age was 54&nbsp;years (range: 22 to 81&nbsp;years); 78.5% of patients were younger than 65&nbsp;years. A total of 57.4% of patients were female. 53.7% of the study population was Caucasian, 42.0% Asian, 1.6% Black and 2.6% other races The majority of patients had adenocarcinoma (96.5%) and had either never smoked or were former smokers (92.0%). The Eastern Cooperative Oncology Group (ECOG) performance status was 0/1/2 in 37.0%/56.4%/6.4% of patients, and 32.2% had brain metastasis at baseline. 59.5% of patients with brain metastasis at baseline received no prior radiotherapy to the brain. Patients with symptomatic CNS (central nervous system) metastases who were neurologically unstable or had required increasing doses of steroids within the 2&nbsp;weeks prior to screening to manage CNS symptoms, were excluded from the study.</p><p>&nbsp;</p><p>Patients were allowed to continue the assigned study treatment beyond initial progression in case of continued clinical benefit as per the investigator&#39;s opinion. Patients randomised to the chemotherapy arm could cross‑over to receive ceritinib upon RECIST-defined disease progression confirmed by blinded independent review committee (BIRC). One hundred and five (105) patients out of the 145&nbsp;patients (72.4%) that discontinued treatment in the chemotherapy arm received subsequent ALK inhibitor as first antineoplastic therapy. Of these patients 81 received ceritinib.</p><p>&nbsp;</p><p>The median duration of follow-up was 19.7&nbsp;months (from randomisation to cut-off date).</p><p>&nbsp;</p><p>The study met its primary objective demonstrating a statistically significant improvement in progression free survival (PFS) by BIRC (see Table&nbsp;3 and Figure&nbsp;1). The PFS benefit of ceritinib was consistent by investigator assessment and across various subgroups including age, gender, race, smoking class, ECOG performance status and disease burden.</p><p>&nbsp;</p><p>The overall survival (OS) data was not mature with 107&nbsp;deaths representing approximately 42.3% of the required events for the final OS analysis.</p><p>&nbsp;</p><p>Efficacy data from Study A2301 are summarised in Table&nbsp;3, and the Kaplan-Meier curves for PFS and OS are shown in Figure&nbsp;1 and Figure&nbsp;2, respectively.</p><p>&nbsp;</p><p>Table&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ASCEND-4 (Study A2301) - Efficacy results in patients with previously untreated ALK‑positive advanced NSCLC</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:92%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ceritinib</p><p>(N=189)</p></td><td style="vertical-align:top"><p>Chemotherapy</p><p>(N=187)</p></td></tr><tr><td style="vertical-align:top"><p>Progression-free survival (based on BIRC)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number of events, n (%)</p></td><td style="vertical-align:top"><p>89 (47.1)</p></td><td style="vertical-align:top"><p>113 (60.4)</p></td></tr><tr><td style="vertical-align:top"><p>Median, months<sup>d</sup> (95% CI)</p></td><td style="vertical-align:top"><p>16.6 (12.6, 27.2)</p></td><td style="vertical-align:top"><p>8.1 (5.8, 11.1)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)<sup>a</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.55 (0.42, 0.73)</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>Overall survival<sup>c</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number of events, n (%)</p></td><td style="vertical-align:top"><p>48 (25.4)</p></td><td style="vertical-align:top"><p>59 (31.6)</p></td></tr><tr><td style="vertical-align:top"><p>Median, months<sup>d</sup> (95% CI)</p></td><td style="vertical-align:top"><p>NE (29.3, NE)</p></td><td style="vertical-align:top"><p>26.2 (22.8, NE)</p></td></tr><tr><td style="vertical-align:top"><p>OS rate at 24 months<sup>d</sup>, % (95% CI)</p></td><td style="vertical-align:top"><p>70.6 (62.2, 77.5)</p></td><td style="vertical-align:top"><p>58.2 (47.6, 67.5)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)<sup>a</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.73 (0.50,1.08)</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.056</p></td></tr><tr><td style="vertical-align:top"><p>Tumour response (based on BIRC)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Overall response rate (95% CI)</p></td><td style="vertical-align:top"><p>72.5% (65.5, 78.7)</p></td><td style="vertical-align:top"><p>26.7% (20.5, 33.7)</p></td></tr><tr><td style="vertical-align:top"><p>Duration of response (based on BIRC)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number of responders</p></td><td style="vertical-align:top"><p>137</p></td><td style="vertical-align:top"><p>50</p></td></tr><tr><td style="vertical-align:top"><p>Median, months<sup>d</sup> (95% CI)</p></td><td style="vertical-align:top"><p>23.9 (16.6, NE)</p></td><td style="vertical-align:top"><p>11.1 (7.8, 16.4)</p></td></tr><tr><td style="vertical-align:top"><p>Event-free rate at 18&nbsp;months<sup>d</sup>, % (95% CI)</p></td><td style="vertical-align:top"><p>59.0 (49.3, 67.4)</p></td><td style="vertical-align:top"><p>30.4 (14.1, 48.6)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>HR=hazard ratio; CI=confidence interval; BIRC=Blinded Independent Review Committee; NE=not estimable</p><p><sup>a </sup>Based on the Cox proportional hazards stratified analysis.</p><p><sup>b</sup> Based on the stratified log-rank test.</p><p><sup>c</sup> OS analysis was not adjusted for the effects of cross‑over.</p><p><sup>d</sup> Estimated using the Kaplan-Meier method.</p></td></tr></tbody></table><p>&nbsp;</p><p>Figure&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ASCEND-4 (Study A2301) - Kaplan-Meier curves of progression-free survival as assessed by BIRC</p><p><!--[if gte vml 1]><v:group
 id="Group_x0020_20" o:spid="_x0000_s1371" style='position:absolute;
 margin-left:5pt;margin-top:6.65pt;width:463.85pt;height:3in;z-index:251657728'
 coordsize="58911,27432" o:gfxdata="UEsDBBQABgAIAAAAIQCxgme2CgEAABMCAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRwU7DMAyG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">
 <v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75"
  o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="Picture_x0020_22" o:spid="_x0000_s1372" type="#_x0000_t75"
  style='position:absolute;left:3575;top:234;width:54278;height:23036;
  visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQAEqzleAAEAAOYBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
  <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
  <v:path arrowok="t"/>
 </v:shape><v:group id="Group_x0020_23" o:spid="_x0000_s1373" style='position:absolute;
  left:4103;top:22273;width:54808;height:2877' coordsize="54811,2876"
  o:gfxdata="UEsDBBQABgAIAAAAIQCi+E9TBAEAAOwBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRy07DMBBF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==
">
  <v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
   <v:stroke joinstyle="miter"/>
   <v:path gradientshapeok="t" o:connecttype="rect"/>
  </v:shapetype><v:shape id="_x0000_s1374" type="#_x0000_t202" style='position:absolute;
   left:14653;width:4286;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1374'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>10<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1375" type="#_x0000_t202" style='position:absolute;
   left:8850;width:4287;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1375'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>6<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1376" type="#_x0000_t202" style='position:absolute;
   left:6037;width:4286;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1376'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>4<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1377" type="#_x0000_t202" style='position:absolute;
   left:3106;width:4286;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1377'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>2<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1378" type="#_x0000_t202" style='position:absolute;
   width:4286;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1378'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>0<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1379" type="#_x0000_t202" style='position:absolute;
   left:32648;width:4286;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1379'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
      DE-CH'>22<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1380" type="#_x0000_t202" style='position:absolute;
   left:29600;width:4286;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1380'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
      DE-CH'>20<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1381" type="#_x0000_t202" style='position:absolute;
   left:26611;width:4286;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1381'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
      DE-CH'>18<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1382" type="#_x0000_t202" style='position:absolute;
   left:23445;width:4287;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1382'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
      DE-CH'>16<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1383" type="#_x0000_t202" style='position:absolute;
   left:20632;width:4286;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1383'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
      DE-CH'>14<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1384" type="#_x0000_t202" style='position:absolute;
   left:17584;width:4286;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1384'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
      DE-CH'>12<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1385" type="#_x0000_t202" style='position:absolute;
   left:47594;width:4287;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1385'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
      DE-CH'>32</span><span style='mso-ansi-language:EN-US;mso-no-proof:yes'><v:shape
       id="Picture_x0020_176" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:18.75pt;
       height:2.25pt;visibility:visible'>
       <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.emz"
        o:title=""/>
      </v:shape></span><span lang=DE-CH style='mso-ansi-language:DE-CH'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1386" type="#_x0000_t202" style='position:absolute;
   left:44488;width:4286;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1386'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
      DE-CH'>30<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1387" type="#_x0000_t202" style='position:absolute;
   left:41499;width:4286;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1387'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
      DE-CH'>28<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1388" type="#_x0000_t202" style='position:absolute;
   left:38509;width:4287;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1388'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
      DE-CH'>26<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1389" type="#_x0000_t202" style='position:absolute;
   left:35578;width:4287;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1389'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
      DE-CH'>24<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1390" type="#_x0000_t202" style='position:absolute;
   left:12015;width:3048;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1390'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
      DE-CH'>8<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1391" type="#_x0000_t202" style='position:absolute;
   left:50525;width:4286;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1391'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
      DE-CH'>34</span><span style='mso-ansi-language:EN-US;mso-no-proof:yes'><v:shape
       id="Picture_x0020_177" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:18.75pt;
       height:2.25pt;visibility:visible'>
       <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.emz"
        o:title=""/>
      </v:shape></span><span lang=DE-CH style='mso-ansi-language:DE-CH'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape></v:group><v:shape id="Text_x0020_Box_x0020_51" o:spid="_x0000_s1392"
  type="#_x0000_t202" style='position:absolute;top:4454;width:2000;height:16447;
  visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top;
   mso-next-textbox:#Text_x0020_Box_x0020_51' inset="0,0,0,0">
   <![if RotText]><![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:0in;margin-right:-2.45pt;margin-bottom:
     0in;margin-left:1.0pt;margin-bottom:.0001pt;line-height:10.8pt;mso-line-height-rule:
     exactly'><span lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
     mso-fareast-font-family:Arial;letter-spacing:.1pt'>P</span><span
     lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
     mso-fareast-font-family:Arial;letter-spacing:-.05pt'>robab</span><span
     lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
     mso-fareast-font-family:Arial;letter-spacing:-.2pt'>ili</span><span
     lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
     mso-fareast-font-family:Arial'>ty</span><span lang=EN-GB style='font-size:
     10.0pt;font-family:"Arial",sans-serif;letter-spacing:.1pt'> </span><span
     lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
     mso-fareast-font-family:Arial;letter-spacing:-.05pt'>(</span><span
     lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
     mso-fareast-font-family:Arial;letter-spacing:.1pt'>%</span><span
     lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
     mso-fareast-font-family:Arial'>)</span><span lang=EN-GB style='font-size:
     10.0pt;font-family:"Arial",sans-serif;letter-spacing:.2pt'> </span><span
     lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
     mso-fareast-font-family:Arial;letter-spacing:-.05pt'>o</span><span
     lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
     mso-fareast-font-family:Arial'>f</span><span lang=EN-GB style='font-size:
     10.0pt;font-family:"Arial",sans-serif;letter-spacing:.5pt'> </span><span
     lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
     mso-fareast-font-family:Arial;letter-spacing:-.05pt'>e</span><span
     lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
     mso-fareast-font-family:Arial;letter-spacing:-.25pt'>v</span><span
     lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
     mso-fareast-font-family:Arial;letter-spacing:-.05pt'>e</span><span
     lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
     mso-fareast-font-family:Arial;letter-spacing:-.3pt'>n</span><span
     lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
     mso-fareast-font-family:Arial'>t<span style='letter-spacing:-.05pt'>-</span><span
     style='letter-spacing:.2pt'>f</span><span style='letter-spacing:-.05pt'>re</span>e<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]><![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1393" type="#_x0000_t202" style='position:absolute;
  left:36456;top:762;width:20988;height:10820;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#_x0000_s1393;mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;font-family:
     "Arial",sans-serif'>Hazard Ratio = 0.55<o:p></o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;font-family:
     "Arial",sans-serif'>95% CI (0.42, 0.73)<o:p></o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;font-family:
     "Arial",sans-serif'>Kaplan-Meier medians (95% CI) (Months)<o:p></o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;font-family:
     "Arial",sans-serif'>ceritinib 750&nbsp;mg: 16.6 (12.6, 27.2)<o:p></o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;font-family:
     "Arial",sans-serif'>Chemotherapy: 8.1 (5.8, 11.1)<o:p></o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;font-family:
     "Arial",sans-serif'>Logrank p-value = &lt;0.001<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Text_x0020_Box_x0020_303" o:spid="_x0000_s1394" type="#_x0000_t202"
  style='position:absolute;left:11544;top:15709;width:16295;height:5868;
  visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#Text_x0020_Box_x0020_303;
   mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;font-family:
     "Arial",sans-serif'>Censoring Times<o:p></o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;font-family:
     "Arial",sans-serif'>ceritinib 750&nbsp;mg (n/N = 89/189)<o:p></o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;font-family:
     "Arial",sans-serif'>Chemotherapy (n/N = 113/187)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:group id="Group_x0020_54" o:spid="_x0000_s1395" style='position:absolute;
  left:644;width:4990;height:23040' coordsize="4989,23040" o:gfxdata="UEsDBBQABgAIAAAAIQCi+E9TBAEAAOwBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRy07DMBBF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=
">
  <v:shape id="_x0000_s1396" type="#_x0000_t202" style='position:absolute;
   left:703;top:16119;width:4286;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1396'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>20<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1397" type="#_x0000_t202" style='position:absolute;
   width:4286;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1397'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>100<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1398" type="#_x0000_t202" style='position:absolute;
   left:644;top:3927;width:4287;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1398'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>80<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1399" type="#_x0000_t202" style='position:absolute;
   left:703;top:7913;width:4286;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1399'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>60<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1400" type="#_x0000_t202" style='position:absolute;
   left:703;top:12074;width:4286;height:2877;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1400'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>40<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="_x0000_s1401" type="#_x0000_t202" style='position:absolute;
   left:1289;top:20163;width:2858;height:2877;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
   <v:textbox style='mso-next-textbox:#_x0000_s1401'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>0<o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape></v:group><v:shape id="_x0000_s1402" type="#_x0000_t202" style='position:absolute;
  left:24911;top:24384;width:12979;height:3048;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#_x0000_s1402'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;font-family:
     "Arial",sans-serif'>Time (Months)<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:group id="Group_x0020_65" o:spid="_x0000_s1403" style='position:absolute;
  left:8792;top:18170;width:425;height:426' coordorigin="3984,2299"
  coordsize="67,67" o:gfxdata="UEsDBBQABgAIAAAAIQCi+E9TBAEAAOwBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRy07DMBBF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=
">
  <v:shape id="Freeform_x0020_66" o:spid="_x0000_s1404" style='position:absolute;
   left:3984;top:2299;width:67;height:67;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="67,67" o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" path="m,33r67,e" filled="f" strokeweight="3.45pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,2332;67,2332"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_63" o:spid="_x0000_s1405"
  style='position:absolute;left:8792;top:19577;width:489;height:489'
  coordorigin="3984,2519" coordsize="77,77" o:gfxdata="UEsDBBQABgAIAAAAIQCi+E9TBAEAAOwBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRy07DMBBF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=
">
  <v:shape id="Freeform_x0020_64" o:spid="_x0000_s1406" style='position:absolute;
   left:3984;top:2519;width:77;height:77;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="77,77" o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" path="m38,l,77r77,l38,xe" filled="f" strokeweight=".24pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="38,2519;0,2596;77,2596;38,2519"
    o:connectangles="0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_71" o:spid="_x0000_s1407"
  style='position:absolute;left:6447;top:18405;width:5296;height:6'
  coordorigin="3610,2337" coordsize="835,2" o:gfxdata="UEsDBBQABgAIAAAAIQCi+E9TBAEAAOwBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRy07DMBBF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==
">
  <v:shape id="Freeform_x0020_72" o:spid="_x0000_s1408" style='position:absolute;
   left:3610;top:2337;width:835;height:2;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="835,2" o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" path="m,l835,e" filled="f" strokeweight=".96pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;835,0"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_69" o:spid="_x0000_s1409"
  style='position:absolute;left:6447;top:19812;width:5296;height:6'
  coordorigin="3610,2558" coordsize="835,2" o:gfxdata="UEsDBBQABgAIAAAAIQCi+E9TBAEAAOwBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRy07DMBBF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=
">
  <v:shape id="Freeform_x0020_70" o:spid="_x0000_s1410" style='position:absolute;
   left:3610;top:2558;width:835;height:2;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="835,2" o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH
74LvEOYqbaoHEWm6B6tHFV0fYEimbdg2CZlYd9/edD8u4goeZ+b/8SOpV9tpFDNFtt4puC4rEOS0
N9b1Cj7WT8UdCE7oDI7ekYIdMayay4t6vQvEIrsdKxhSCvdSsh5oQi59IJcvnY8TpjzGXgbUG+xJ
3lTVrdTeJXKpSEsGNHVLHX6OSTxu8/pAEmlkEA8H4dKlAEMYrcaUSeXszI+W4thQZudew4MNfJUx
QP7asFzOFxx9L/lpojUkXjGmZ5wyhjSRJQ8YKGvKv1MWzIkL33VWU9lGfl98J6hz4cZ/uUjzf7Pb
bHuj+ZQu9z/UfAMAAP//AwBQSwMEFAAGAAgAAAAhADHdX2HSAAAAjwEAAAsAAABfcmVscy8ucmVs
c6SQwWrDMAyG74O9g9G9cdpDGaNOb4VeSwe7CltJTGPLWCZt376mMFhGbzvqF/o+8e/2tzCpmbJ4
jgbWTQuKomXn42Dg63xYfYCSgtHhxJEM3Elg372/7U40YalHMvokqlKiGBhLSZ9aix0poDScKNZN
zzlgqWMedEJ7wYH0pm23Ov9mQLdgqqMzkI9uA+p8T9X8hx28zSzcl8Zy0Nz33r6iasfXeKK5UjAP
VAy4LM8w09zU50C/9q7/6ZURE31X/kL8TKv1x6wXNXYPAAAA//8DAFBLAwQUAAYACAAAACEAMy8F
nkEAAAA5AAAAEAAAAGRycy9zaGFwZXhtbC54bWyysa/IzVEoSy0qzszPs1Uy1DNQUkjNS85PycxL
t1UKDXHTtVBSKC5JzEtJzMnPS7VVqkwtVrK34+UCAAAA//8DAFBLAwQUAAYACAAAACEASeT5MsEA
AADcAAAADwAAAGRycy9kb3ducmV2LnhtbERPTUvDQBC9C/0PyxS8SDupQmtjt6Uognhr9OJtyI7Z
0OxsyE7b6K93BcHbPN7nbHZj6MyZh9RGsbCYF2BY6uhaaSy8vz3P7sEkJXHURWELX5xgt51cbah0
8SIHPlfamBwiqSQLXrUvEVPtOVCax54lc59xCKQZDg26gS45PHR4WxRLDNRKbvDU86Pn+lidgoX1
zeFVF0/SL/eK3yvE1utHZe31dNw/gFEe9V/8535xef7dCn6fyRfg9gcAAP//AwBQSwECLQAUAAYA
CAAAACEA8PeKu/0AAADiAQAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBL
AQItABQABgAIAAAAIQAx3V9h0gAAAI8BAAALAAAAAAAAAAAAAAAAAC4BAABfcmVscy8ucmVsc1BL
AQItABQABgAIAAAAIQAzLwWeQQAAADkAAAAQAAAAAAAAAAAAAAAAACkCAABkcnMvc2hhcGV4bWwu
eG1sUEsBAi0AFAAGAAgAAAAhAEnk+TLBAAAA3AAAAA8AAAAAAAAAAAAAAAAAmAIAAGRycy9kb3du
cmV2LnhtbFBLBQYAAAAABAAEAPUAAACGAwAAAAA=
" path="m,l835,e" filled="f" strokeweight=".96pt">
   <v:stroke dashstyle="dash"/>
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;835,0"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_61" o:spid="_x0000_s1411"
  style='position:absolute;left:6447;top:16646;width:419;height:419'
  coordorigin="3571,2068" coordsize="67,67" o:gfxdata="UEsDBBQABgAIAAAAIQCi+E9TBAEAAOwBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRy07DMBBF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=
">
  <v:shape id="Freeform_x0020_62" o:spid="_x0000_s1412" style='position:absolute;
   left:3571;top:2068;width:67;height:67;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="67,67" o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" path="m,34r67,e" filled="f" strokeweight="3.47pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,2102;67,2102"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_59" o:spid="_x0000_s1413"
  style='position:absolute;left:11019;top:16588;width:489;height:489'
  coordorigin="4406,2068" coordsize="77,77" o:gfxdata="UEsDBBQABgAIAAAAIQCi+E9TBAEAAOwBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRy07DMBBF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">
  <v:shape id="Freeform_x0020_60" o:spid="_x0000_s1414" style='position:absolute;
   left:4406;top:2068;width:77;height:77;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="77,77" o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH
74LvEOYqbaoHEWm6B6tHFV0fYEimbdg2CZlYd9/edD8u4goeZ+b/8SOpV9tpFDNFtt4puC4rEOS0
N9b1Cj7WT8UdCE7oDI7ekYIdMayay4t6vQvEIrsdKxhSCvdSsh5oQi59IJcvnY8TpjzGXgbUG+xJ
3lTVrdTeJXKpSEsGNHVLHX6OSTxu8/pAEmlkEA8H4dKlAEMYrcaUSeXszI+W4thQZudew4MNfJUx
QP7asFzOFxx9L/lpojUkXjGmZ5wyhjSRJQ8YKGvKv1MWzIkL33VWU9lGfl98J6hz4cZ/uUjzf7Pb
bHuj+ZQu9z/UfAMAAP//AwBQSwMEFAAGAAgAAAAhADHdX2HSAAAAjwEAAAsAAABfcmVscy8ucmVs
c6SQwWrDMAyG74O9g9G9cdpDGaNOb4VeSwe7CltJTGPLWCZt376mMFhGbzvqF/o+8e/2tzCpmbJ4
jgbWTQuKomXn42Dg63xYfYCSgtHhxJEM3Elg372/7U40YalHMvokqlKiGBhLSZ9aix0poDScKNZN
zzlgqWMedEJ7wYH0pm23Ov9mQLdgqqMzkI9uA+p8T9X8hx28zSzcl8Zy0Nz33r6iasfXeKK5UjAP
VAy4LM8w09zU50C/9q7/6ZURE31X/kL8TKv1x6wXNXYPAAAA//8DAFBLAwQUAAYACAAAACEAMy8F
nkEAAAA5AAAAEAAAAGRycy9zaGFwZXhtbC54bWyysa/IzVEoSy0qzszPs1Uy1DNQUkjNS85PycxL
t1UKDXHTtVBSKC5JzEtJzMnPS7VVqkwtVrK34+UCAAAA//8DAFBLAwQUAAYACAAAACEA8VVtcMEA
AADcAAAADwAAAGRycy9kb3ducmV2LnhtbERPTYvCMBC9L/gfwgheFk0VEalGEVlBvIjuitehGdti
M6lJtq3/3iwseJvH+5zlujOVaMj50rKC8SgBQZxZXXKu4Od7N5yD8AFZY2WZFDzJw3rV+1hiqm3L
J2rOIRcxhH2KCooQ6lRKnxVk0I9sTRy5m3UGQ4Qul9phG8NNJSdJMpMGS44NBda0LSi7n3+Nguw4
dU7zpWo+/XPTXr8O293podSg320WIAJ14S3+d+91nD8dw98z8QK5egEAAP//AwBQSwECLQAUAAYA
CAAAACEA8PeKu/0AAADiAQAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBL
AQItABQABgAIAAAAIQAx3V9h0gAAAI8BAAALAAAAAAAAAAAAAAAAAC4BAABfcmVscy8ucmVsc1BL
AQItABQABgAIAAAAIQAzLwWeQQAAADkAAAAQAAAAAAAAAAAAAAAAACkCAABkcnMvc2hhcGV4bWwu
eG1sUEsBAi0AFAAGAAgAAAAhAPFVbXDBAAAA3AAAAA8AAAAAAAAAAAAAAAAAmAIAAGRycy9kb3du
cmV2LnhtbFBLBQYAAAAABAAEAPUAAACGAwAAAAA=
" path="m39,l,77r77,l39,xe" filled="f" strokeweight=".24pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="39,2068;0,2145;77,2145;39,2068"
    o:connectangles="0,0,0,0"/>
  </v:shape></v:group></v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="25" height="176" alt="Text Box: Probability (%) of event-free" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.gif" /><img width="622" height="292" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.gif" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group
 id="Group_x0020_2" o:spid="_x0000_s1369" style='position:absolute;
 margin-left:753.6pt;margin-top:64.05pt;width:.1pt;height:4.8pt;z-index:-251659776;
 mso-position-horizontal-relative:page' coordorigin="15072,1281" coordsize="2,96"
 o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:shape id="Freeform_x0020_3" o:spid="_x0000_s1370" style='position:absolute;
  left:15072;top:1281;width:2;height:96;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="2,96" o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" path="m,l,96e" filled="f" strokeweight=".96pt">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,1281;0,1377"
   o:connectangles="0,0"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="2" height="9" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image005.gif" /></p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td><p>&nbsp;</p></td><td colspan="18"><p>No. of patients still at risk</p></td></tr><tr><td><p>Time (Months)</p></td><td><p>0</p></td><td><p>2</p></td><td><p>4</p></td><td><p>6</p></td><td><p>8</p></td><td><p>10</p></td><td><p>12</p></td><td><p>14</p></td><td><p>16</p></td><td><p>18</p></td><td><p>20</p></td><td><p>22</p></td><td><p>24</p></td><td><p>26</p></td><td><p>28</p></td><td><p>30</p></td><td><p>32</p></td><td><p>34</p></td></tr><tr><td><p>ceritinib 750&nbsp;mg</p></td><td><p>189</p></td><td><p>155</p></td><td><p>139</p></td><td><p>125</p></td><td><p>116</p></td><td><p>105</p></td><td><p>98</p></td><td><p>76</p></td><td><p>59</p></td><td><p>43</p></td><td><p>32</p></td><td><p>23</p></td><td><p>16</p></td><td><p>11</p></td><td><p>1</p></td><td><p>1</p></td><td><p>1</p></td><td><p>0</p></td></tr><tr><td><p>Chemotherapy</p></td><td><p>187</p></td><td><p>136</p></td><td><p>114</p></td><td><p>82</p></td><td><p>71</p></td><td><p>60</p></td><td><p>53</p></td><td><p>35</p></td><td><p>24</p></td><td><p>16</p></td><td><p>11</p></td><td><p>5</p></td><td><p>3</p></td><td><p>1</p></td><td><p>1</p></td><td><p>0</p></td><td><p>0</p></td><td><p>0</p></td></tr></tbody></table><p>&nbsp;</p><p>Figure&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ASCEND-4 (Study A2301)- Kaplan-Meier plot of overall survival by treatment arm</p><p><!--[if gte vml 1]><v:group id="Group_x0020_210" o:spid="_x0000_s1415"
 style='position:absolute;left:0;text-align:left;margin-left:10.1pt;
 margin-top:23.8pt;width:43.4pt;height:180.05pt;z-index:251658752' coordsize="5512,22864"
 o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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==
">
 <v:shape id="_x0000_s1416" type="#_x0000_t202" style='position:absolute;
  width:4282;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#_x0000_s1416'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>100<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1417" type="#_x0000_t202" style='position:absolute;
  left:703;top:3927;width:4280;height:2870;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#_x0000_s1417'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>80<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1418" type="#_x0000_t202" style='position:absolute;
  left:703;top:7913;width:4282;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#_x0000_s1418'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>60<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1419" type="#_x0000_t202" style='position:absolute;
  left:644;top:12074;width:4280;height:2870;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#_x0000_s1419'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>40<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1420" type="#_x0000_t202" style='position:absolute;
  left:703;top:16060;width:4280;height:2870;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#_x0000_s1420'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>20<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1421" type="#_x0000_t202" style='position:absolute;
  left:1230;top:19987;width:4282;height:2877;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox style='mso-next-textbox:#_x0000_s1421'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>0<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape></v:group><v:group id="Group_x0020_202" o:spid="_x0000_s1422"
 style='position:absolute;left:0;text-align:left;margin-left:38.25pt;
 margin-top:205.1pt;width:427pt;height:22.65pt;z-index:251659776' coordsize="54226,2876"
 o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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==
">
 <v:shape id="_x0000_s1423" type="#_x0000_t202" style='position:absolute;
  left:14478;width:4279;height:2870;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>10<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1424" type="#_x0000_t202" style='position:absolute;
  left:11898;width:4280;height:2870;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>8<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1425" type="#_x0000_t202" style='position:absolute;
  left:8968;width:4280;height:2870;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH
74LvEOYqbaoHEWm6B6tHFV0fYEimbdg2CZlYd9/edD8u4goeZ+b/8SOpV9tpFDNFtt4puC4rEOS0
N9b1Cj7WT8UdCE7oDI7ekYIdMayay4t6vQvEIrsdKxhSCvdSsh5oQi59IJcvnY8TpjzGXgbUG+xJ
3lTVrdTeJXKpSEsGNHVLHX6OSTxu8/pAEmlkEA8H4dKlAEMYrcaUSeXszI+W4thQZudew4MNfJUx
QP7asFzOFxx9L/lpojUkXjGmZ5wyhjSRJQ8YKGvKv1MWzIkL33VWU9lGfl98J6hz4cZ/uUjzf7Pb
bHuj+ZQu9z/UfAMAAP//AwBQSwMEFAAGAAgAAAAhADHdX2HSAAAAjwEAAAsAAABfcmVscy8ucmVs
c6SQwWrDMAyG74O9g9G9cdpDGaNOb4VeSwe7CltJTGPLWCZt376mMFhGbzvqF/o+8e/2tzCpmbJ4
jgbWTQuKomXn42Dg63xYfYCSgtHhxJEM3Elg372/7U40YalHMvokqlKiGBhLSZ9aix0poDScKNZN
zzlgqWMedEJ7wYH0pm23Ov9mQLdgqqMzkI9uA+p8T9X8hx28zSzcl8Zy0Nz33r6iasfXeKK5UjAP
VAy4LM8w09zU50C/9q7/6ZURE31X/kL8TKv1x6wXNXYPAAAA//8DAFBLAwQUAAYACAAAACEAMy8F
nkEAAAA5AAAAEAAAAGRycy9zaGFwZXhtbC54bWyysa/IzVEoSy0qzszPs1Uy1DNQUkjNS85PycxL
t1UKDXHTtVBSKC5JzEtJzMnPS7VVqkwtVrK34+UCAAAA//8DAFBLAwQUAAYACAAAACEADmqEzsEA
AADcAAAADwAAAGRycy9kb3ducmV2LnhtbERPS4vCMBC+L/gfwgje1kTRVatRRFnw5OITvA3N2Bab
SWmytvvvN8LC3ubje85i1dpSPKn2hWMNg74CQZw6U3Cm4Xz6fJ+C8AHZYOmYNPyQh9Wy87bAxLiG
D/Q8hkzEEPYJashDqBIpfZqTRd93FXHk7q62GCKsM2lqbGK4LeVQqQ9pseDYkGNFm5zSx/Hbarjs
77frSH1lWzuuGtcqyXYmte512/UcRKA2/Iv/3DsT508n8HomXiCXvwAAAP//AwBQSwECLQAUAAYA
CAAAACEA8PeKu/0AAADiAQAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBL
AQItABQABgAIAAAAIQAx3V9h0gAAAI8BAAALAAAAAAAAAAAAAAAAAC4BAABfcmVscy8ucmVsc1BL
AQItABQABgAIAAAAIQAzLwWeQQAAADkAAAAQAAAAAAAAAAAAAAAAACkCAABkcnMvc2hhcGV4bWwu
eG1sUEsBAi0AFAAGAAgAAAAhAA5qhM7BAAAA3AAAAA8AAAAAAAAAAAAAAAAAmAIAAGRycy9kb3du
cmV2LnhtbFBLBQYAAAAABAAEAPUAAACGAwAAAAA=
" filled="f" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>6<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1426" type="#_x0000_t202" style='position:absolute;
  left:5920;width:4280;height:2870;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>4<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1427" type="#_x0000_t202" style='position:absolute;
  left:2930;width:4280;height:2870;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>2<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1428" type="#_x0000_t202" style='position:absolute;
  width:4279;height:2870;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt'>0<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1429" type="#_x0000_t202" style='position:absolute;
  left:32238;width:4280;height:2870;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
     DE-CH'>22<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1430" type="#_x0000_t202" style='position:absolute;
  left:29366;width:4280;height:2870;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
     DE-CH'>20<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1431" type="#_x0000_t202" style='position:absolute;
  left:26318;width:4280;height:2870;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
     DE-CH'>18<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1432" type="#_x0000_t202" style='position:absolute;
  left:23387;width:4280;height:2870;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
     DE-CH'>16<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1433" type="#_x0000_t202" style='position:absolute;
  left:20456;width:4280;height:2870;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
     DE-CH'>14<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1434" type="#_x0000_t202" style='position:absolute;
  left:17467;width:4280;height:2870;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
     DE-CH'>12<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1435" type="#_x0000_t202" style='position:absolute;
  left:46950;width:4280;height:2870;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
     DE-CH'>32</span><span style='font-size:10.0pt;mso-ansi-language:EN-US;
     mso-no-proof:yes'><v:shape id="Picture_x0020_430" o:spid="_x0000_i1027"
      type="#_x0000_t75" style='width:18.75pt;height:2.25pt;visibility:visible'>
      <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.emz"
       o:title=""/>
     </v:shape></span><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
     DE-CH'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1436" type="#_x0000_t202" style='position:absolute;
  left:44137;width:4280;height:2870;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
     DE-CH'>30<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1437" type="#_x0000_t202" style='position:absolute;
  left:41030;width:4280;height:2870;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
     DE-CH'>28<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1438" type="#_x0000_t202" style='position:absolute;
  left:38100;width:4279;height:2870;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
     DE-CH'>26<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1439" type="#_x0000_t202" style='position:absolute;
  left:35286;width:4280;height:2870;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
     DE-CH'>24<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="_x0000_s1440" type="#_x0000_t202" style='position:absolute;
  left:49940;width:4286;height:2876;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
     DE-CH'>34</span><span style='font-size:10.0pt;mso-ansi-language:EN-US;
     mso-no-proof:yes'><v:shape id="Picture_x0020_431" o:spid="_x0000_i1028"
      type="#_x0000_t75" style='width:18.75pt;height:2.25pt;visibility:visible'>
      <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.emz"
       o:title=""/>
     </v:shape></span><span lang=DE-CH style='font-size:10.0pt;mso-ansi-language:
     DE-CH'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape></v:group><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1441"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:215.8pt;margin-top:219pt;width:102.2pt;height:24pt;z-index:251660800;
 visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" filled="f" stroked="f">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-size:10.0pt;font-family:
    "Arial",sans-serif'>Time (Months)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><v:shape id="Picture_x0020_149" o:spid="_x0000_s1442" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:38.25pt;
 margin-top:18.85pt;width:425.55pt;height:182.75pt;z-index:251661824;
 visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQAEqzleAAEAAOYBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF
90jcwfIWJU5ZIISSdEHKEipUDjCyJ4lFMrY8bmhvj9O0G0SRWNoz/78nu1wfxkFMGNg6quQqL6RA
0s5Y6ir5sXvJHqXgCGRgcISVPCLLdX17U+6OHlmkNHEl+xj9k1KsexyBc+eR0qR1YYSYjqFTHvQn
dKjui+JBaUcRKWZx7pB12WAL+yGKzSFdLyYBB5bieVmcWZUE7werISZTNZH5QcnOhDwlTzvcW893
SUOqXwnz5DrgnHtLTxOsQbGFEF9hTBrKBFbe6rgPmLbyv3tm0ZEz17ZWY94E3i7Ji9g1gHFfFHD6
b3uTYu84XdrV6ZfqbwAAAP//AwBQSwMEFAAGAAgAAAAhAAjDGKTUAAAAkwEAAAsAAABfcmVscy8u
cmVsc6SQwWrDMAyG74O+g9F9cdrDGKNOb4NeSwu7GltJzGLLSG7avv1M2WAZve2oX+j7xL/dXeOk
ZmQJlAysmxYUJkc+pMHA6fj+/ApKik3eTpTQwA0Fdt3qaXvAyZZ6JGPIoioliYGxlPymtbgRo5WG
Mqa66YmjLXXkQWfrPu2AetO2L5p/M6BbMNXeG+C934A63nI1/2HH4JiE+tI4ipr6PrhHVO3pkg44
V4rlAYsBz3IPGeemPgf6sXf9T28OrpwZP6phof7Oq/nHrhdVdl8AAAD//wMAUEsDBBQABgAIAAAA
IQAzLwWeQQAAADkAAAASAAAAZHJzL3BpY3R1cmV4bWwueG1ssrGvyM1RKEstKs7Mz7NVMtQzUFJI
zUvOT8nMS7dVCg1x07VQUiguScxLSczJz0u1VapMLVayt+PlAgAAAP//AwBQSwMEFAAGAAgAAAAh
AGMHI4fBAAAA3AAAAA8AAABkcnMvZG93bnJldi54bWxET99rwjAQfh/4P4QT9jZThxtajeKGg76N
doqvR3OmxeZSkqx2++uXwWBv9/H9vM1utJ0YyIfWsYL5LANBXDvdslFw/Hh7WIIIEVlj55gUfFGA
3XZyt8FcuxuXNFTRiBTCIUcFTYx9LmWoG7IYZq4nTtzFeYsxQW+k9nhL4baTj1n2LC22nBoa7Om1
ofpafVoFQWNVv5en0rx8G188Hc5+KFip++m4X4OINMZ/8Z+70Gn+YgW/z6QL5PYHAAD//wMAUEsB
Ai0AFAAGAAgAAAAhAASrOV4AAQAA5gEAABMAAAAAAAAAAAAAAAAAAAAAAFtDb250ZW50X1R5cGVz
XS54bWxQSwECLQAUAAYACAAAACEACMMYpNQAAACTAQAACwAAAAAAAAAAAAAAAAAxAQAAX3JlbHMv
LnJlbHNQSwECLQAUAAYACAAAACEAMy8FnkEAAAA5AAAAEgAAAAAAAAAAAAAAAAAuAgAAZHJzL3Bp
Y3R1cmV4bWwueG1sUEsBAi0AFAAGAAgAAAAhAGMHI4fBAAAA3AAAAA8AAAAAAAAAAAAAAAAAnwIA
AGRycy9kb3ducmV2LnhtbFBLBQYAAAAABAAEAPcAAACNAwAAAAA=
">
 <v:imagedata src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image006.png"
  o:title=""/>
 <v:path arrowok="t"/>
</v:shape><v:shape id="Text_x0020_Box_x0020_38" o:spid="_x0000_s1443" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:10.1pt;
 margin-top:36.2pt;width:11.6pt;height:133.45pt;z-index:251662848;visibility:visible'
 o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
 <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top;
  mso-next-textbox:#Text_x0020_Box_x0020_38' inset="0,0,0,0">
  <![if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:0in;margin-right:-2.45pt;margin-bottom:
    0in;margin-left:1.0pt;margin-bottom:.0001pt;line-height:10.8pt;mso-line-height-rule:
    exactly'><span lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
    mso-fareast-font-family:Arial;letter-spacing:.1pt'>P</span><span
    lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
    mso-fareast-font-family:Arial;letter-spacing:-.05pt'>robab</span><span
    lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
    mso-fareast-font-family:Arial;letter-spacing:-.2pt'>ili</span><span
    lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
    mso-fareast-font-family:Arial'>ty</span><span lang=EN-GB style='font-size:
    10.0pt;font-family:"Arial",sans-serif;letter-spacing:.1pt'> </span><span
    lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
    mso-fareast-font-family:Arial;letter-spacing:-.05pt'>(</span><span
    lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
    mso-fareast-font-family:Arial;letter-spacing:.1pt'>%</span><span
    lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
    mso-fareast-font-family:Arial'>)</span><span lang=EN-GB style='font-size:
    10.0pt;font-family:"Arial",sans-serif;letter-spacing:.2pt'> </span><span
    lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
    mso-fareast-font-family:Arial;letter-spacing:-.05pt'>o</span><span
    lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
    mso-fareast-font-family:Arial'>f</span><span lang=EN-GB style='font-size:
    10.0pt;font-family:"Arial",sans-serif;letter-spacing:.5pt'> </span><span
    lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
    mso-fareast-font-family:Arial;letter-spacing:-.05pt'>e</span><span
    lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
    mso-fareast-font-family:Arial;letter-spacing:-.25pt'>v</span><span
    lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
    mso-fareast-font-family:Arial;letter-spacing:-.05pt'>e</span><span
    lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
    mso-fareast-font-family:Arial;letter-spacing:-.3pt'>n</span><span
    lang=EN-GB style='font-size:10.0pt;font-family:"Arial",sans-serif;
    mso-fareast-font-family:Arial'>t<span style='letter-spacing:-.05pt'>-</span><span
    style='letter-spacing:.2pt'>f</span><span style='letter-spacing:-.05pt'>re</span>e<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]></v:textbox>
</v:shape><v:shape id="_x0000_s1444" type="#_x0000_t202" style='position:absolute;
 left:0;text-align:left;margin-left:52.55pt;margin-top:89.8pt;width:200.75pt;
 height:98.2pt;z-index:251663872;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
 <v:textbox style='mso-next-textbox:#_x0000_s1444;mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;font-family:
    "Arial",sans-serif'>Hazard Ratio = 0.73<o:p></o:p></span></p>
    <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;font-family:
    "Arial",sans-serif'>95% CI (0.50, 1.08)<o:p></o:p></span></p>
    <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;font-family:
    "Arial",sans-serif'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;font-family:
    "Arial",sans-serif'>Kaplan-Meier medians (95% CI) (Months)<o:p></o:p></span></p>
    <p class=MsoNormal><span lang=FR-CH style='font-size:8.0pt;font-family:
    "Arial",sans-serif;mso-ansi-language:FR-CH'>ceritinib 750&nbsp;mg: NE (29.3,
    NE)<o:p></o:p></span></p>
    <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;font-family:
    "Arial",sans-serif'>Chemotherapy: 26.2 (22.8, NE)<o:p></o:p></span></p>
    <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;font-family:
    "Arial",sans-serif'>Logrank p-value = 0.056<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><v:shape id="Text_x0020_Box_x0020_414" o:spid="_x0000_s1445" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:310.7pt;
 margin-top:149.25pt;width:144.9pt;height:46.2pt;z-index:251664896;
 visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" filled="f" stroked="f">
 <v:textbox style='mso-next-textbox:#Text_x0020_Box_x0020_414;
  mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;font-family:
    "Arial",sans-serif'>Censoring Times<o:p></o:p></span></p>
    <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;font-family:
    "Arial",sans-serif'>ceritinib 750&nbsp;mg (n/N = 48/189)<o:p></o:p></span></p>
    <p class=MsoNormal><span lang=EN-GB style='font-size:8.0pt;font-family:
    "Arial",sans-serif'>Chemotherapy (n/N = 59/187)<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><v:group id="Group_x0020_179" o:spid="_x0000_s1446" style='position:absolute;
 left:0;text-align:left;margin-left:263.5pt;margin-top:159.75pt;width:41.75pt;
 height:27.4pt;z-index:251665920' coordsize="5299,3478" o:gfxdata="UEsDBBQABgAIAAAAIQCi+E9TBAEAAOwBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRy07DMBBF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==
">
 <v:group id="Group_x0020_71" o:spid="_x0000_s1447" style='position:absolute;
  top:1875;width:5299;height:13' coordorigin="3610,2337" coordsize="835,2"
  o:gfxdata="UEsDBBQABgAIAAAAIQCi+E9TBAEAAOwBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRy07DMBBF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=
">
  <v:shape id="Freeform_x0020_72" o:spid="_x0000_s1448" style='position:absolute;
   left:3610;top:2337;width:835;height:2;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="835,2" o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH
74LvEOYqbaoHEWm6B6tHFV0fYEimbdg2CZlYd9/edD8u4goeZ+b/8SOpV9tpFDNFtt4puC4rEOS0
N9b1Cj7WT8UdCE7oDI7ekYIdMayay4t6vQvEIrsdKxhSCvdSsh5oQi59IJcvnY8TpjzGXgbUG+xJ
3lTVrdTeJXKpSEsGNHVLHX6OSTxu8/pAEmlkEA8H4dKlAEMYrcaUSeXszI+W4thQZudew4MNfJUx
QP7asFzOFxx9L/lpojUkXjGmZ5wyhjSRJQ8YKGvKv1MWzIkL33VWU9lGfl98J6hz4cZ/uUjzf7Pb
bHuj+ZQu9z/UfAMAAP//AwBQSwMEFAAGAAgAAAAhADHdX2HSAAAAjwEAAAsAAABfcmVscy8ucmVs
c6SQwWrDMAyG74O9g9G9cdpDGaNOb4VeSwe7CltJTGPLWCZt376mMFhGbzvqF/o+8e/2tzCpmbJ4
jgbWTQuKomXn42Dg63xYfYCSgtHhxJEM3Elg372/7U40YalHMvokqlKiGBhLSZ9aix0poDScKNZN
zzlgqWMedEJ7wYH0pm23Ov9mQLdgqqMzkI9uA+p8T9X8hx28zSzcl8Zy0Nz33r6iasfXeKK5UjAP
VAy4LM8w09zU50C/9q7/6ZURE31X/kL8TKv1x6wXNXYPAAAA//8DAFBLAwQUAAYACAAAACEAMy8F
nkEAAAA5AAAAEAAAAGRycy9zaGFwZXhtbC54bWyysa/IzVEoSy0qzszPs1Uy1DNQUkjNS85PycxL
t1UKDXHTtVBSKC5JzEtJzMnPS7VVqkwtVrK34+UCAAAA//8DAFBLAwQUAAYACAAAACEAQJEmqsMA
AADcAAAADwAAAGRycy9kb3ducmV2LnhtbERPS2sCMRC+F/ofwhR6q9kVKbIapa229eoD1Ns0GXcX
N5Mlibr11xuh0Nt8fM8ZTzvbiDP5UDtWkPcyEMTamZpLBZv158sQRIjIBhvHpOCXAkwnjw9jLIy7
8JLOq1iKFMKhQAVVjG0hZdAVWQw91xIn7uC8xZigL6XxeEnhtpH9LHuVFmtODRW29FGRPq5OVsH3
drD/OunddXDN53P9fvBudvxR6vmpexuBiNTFf/Gfe2HS/GEO92fSBXJyAwAA//8DAFBLAQItABQA
BgAIAAAAIQDw94q7/QAAAOIBAAATAAAAAAAAAAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1s
UEsBAi0AFAAGAAgAAAAhADHdX2HSAAAAjwEAAAsAAAAAAAAAAAAAAAAALgEAAF9yZWxzLy5yZWxz
UEsBAi0AFAAGAAgAAAAhADMvBZ5BAAAAOQAAABAAAAAAAAAAAAAAAAAAKQIAAGRycy9zaGFwZXht
bC54bWxQSwECLQAUAAYACAAAACEAQJEmqsMAAADcAAAADwAAAAAAAAAAAAAAAACYAgAAZHJzL2Rv
d25yZXYueG1sUEsFBgAAAAAEAAQA9QAAAIgDAAAAAA==
" path="m,l835,e" filled="f" strokeweight=".96pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;835,0"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_69" o:spid="_x0000_s1449"
  style='position:absolute;top:3341;width:5299;height:12' coordorigin="3610,2558"
  coordsize="835,2" o:gfxdata="UEsDBBQABgAIAAAAIQCi+E9TBAEAAOwBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRy07DMBBF
90j8g+UtShxYIISadEGAHSAoHzCyJ4lFYlseN7R/z7iPDaJIXdpzz5wre7HcTKOYMZL1rpbXZSUF
Ou2NdX0tP1dPxZ0UlMAZGL3DWm6R5LK5vFistgFJMO2olkNK4V4p0gNOQKUP6HjS+ThB4mPsVQD9
BT2qm6q6Vdq7hC4VKe+QzaLFDtZjEo8bvt43iTiSFA/7YHbVEkIYrYbETdXszC9LcTCUTO4yNNhA
V1xDqj8NeXJacOBe+WmiNSjeIKYXmLiGMpFUH/060AABOVj+vyp3najwXWc1lm2k5wx/ZPhY75TG
+G8XcT5X0DL2jvNxu9r9VfMDAAD//wMAUEsDBBQABgAIAAAAIQBsBtX+2AAAAJkBAAALAAAAX3Jl
bHMvLnJlbHOkkMFKAzEQhu+C7xDm7mbbg4g025vQa63gNSSz2eAmE2biat/eWBBc6c3jzM9838/s
9p9pVguyRMoGNl0PCrMjH3Mw8HJ6unsAJdVmb2fKaOCMAvvh9mZ3xNnWdiRTLKIaJYuBqdbyqLW4
CZOVjgrmlozEydY2ctDFujcbUG/7/l7zbwYMK6Y6eAN88FtQp3Np5j/sFB2T0Fg7R0nTOEZ3jao9
feQjLo1iOWA14FkuS8ala+VAX/du/ukNTO/lebIFX5tkZb9E8h01/08HvXro8AUAAP//AwBQSwME
FAAGAAgAAAAhADMvBZ5BAAAAOQAAABUAAABkcnMvZ3JvdXBzaGFwZXhtbC54bWyysa/IzVEoSy0q
zszPs1Uy1DNQUkjNS85PycxLt1UKDXHTtVBSKC5JzEtJzMnPS7VVqkwtVrK34+UCAAAA//8DAFBL
AwQUAAYACAAAACEAuYmi6sIAAADcAAAADwAAAGRycy9kb3ducmV2LnhtbERPTYvCMBC9L/gfwgje
1rSKi1SjiLjiQYRVQbwNzdgWm0lpsm3990YQvM3jfc582ZlSNFS7wrKCeBiBIE6tLjhTcD79fk9B
OI+ssbRMCh7kYLnofc0x0bblP2qOPhMhhF2CCnLvq0RKl+Zk0A1tRRy4m60N+gDrTOoa2xBuSjmK
oh9psODQkGNF65zS+/HfKNi22K7G8abZ32/rx/U0OVz2MSk16HerGQhPnf+I3+6dDvOnI3g9Ey6Q
iycAAAD//wMAUEsBAi0AFAAGAAgAAAAhAKL4T1MEAQAA7AEAABMAAAAAAAAAAAAAAAAAAAAAAFtD
b250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAbAbV/tgAAACZAQAACwAAAAAAAAAAAAAA
AAA1AQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAMy8FnkEAAAA5AAAAFQAAAAAAAAAAAAAA
AAA2AgAAZHJzL2dyb3Vwc2hhcGV4bWwueG1sUEsBAi0AFAAGAAgAAAAhALmJourCAAAA3AAAAA8A
AAAAAAAAAAAAAAAAqgIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAABAAEAPoAAACZAwAAAAA=
">
  <v:shape id="Freeform_x0020_70" o:spid="_x0000_s1450" style='position:absolute;
   left:3610;top:2558;width:835;height:2;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="835,2" o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" path="m,l835,e" filled="f" strokeweight=".96pt">
   <v:stroke dashstyle="dash"/>
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;835,0"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_61" o:spid="_x0000_s1451"
  style='position:absolute;top:117;width:425;height:425' coordorigin="3571,2068"
  coordsize="67,67" o:gfxdata="UEsDBBQABgAIAAAAIQCi+E9TBAEAAOwBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRy07DMBBF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==
">
  <v:shape id="Freeform_x0020_62" o:spid="_x0000_s1452" style='position:absolute;
   left:3571;top:2068;width:67;height:67;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="67,67" o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" path="m,34r67,e" filled="f" strokeweight="3.47pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,2102;67,2102"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_65" o:spid="_x0000_s1453"
  style='position:absolute;left:2403;top:1582;width:425;height:426'
  coordorigin="3984,2299" coordsize="67,67" o:gfxdata="UEsDBBQABgAIAAAAIQCi+E9TBAEAAOwBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRy07DMBBF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">
  <v:shape id="Freeform_x0020_66" o:spid="_x0000_s1454" style='position:absolute;
   left:3984;top:2299;width:67;height:67;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="67,67" o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" path="m,33r67,e" filled="f" strokeweight="3.45pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,2332;67,2332"
    o:connectangles="0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_63" o:spid="_x0000_s1455"
  style='position:absolute;left:2403;top:2989;width:489;height:489'
  coordorigin="3984,2519" coordsize="77,77" o:gfxdata="UEsDBBQABgAIAAAAIQCi+E9TBAEAAOwBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRy07DMBBF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">
  <v:shape id="Freeform_x0020_64" o:spid="_x0000_s1456" style='position:absolute;
   left:3984;top:2519;width:77;height:77;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="77,77" o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" path="m38,l,77r77,l38,xe" filled="f" strokeweight=".24pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="38,2519;0,2596;77,2596;38,2519"
    o:connectangles="0,0,0,0"/>
  </v:shape></v:group><v:group id="Group_x0020_59" o:spid="_x0000_s1457"
  style='position:absolute;left:4572;width:488;height:488' coordorigin="4406,2068"
  coordsize="77,77" o:gfxdata="UEsDBBQABgAIAAAAIQCi+E9TBAEAAOwBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRy07DMBBF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=
">
  <v:shape id="Freeform_x0020_60" o:spid="_x0000_s1458" style='position:absolute;
   left:4406;top:2068;width:77;height:77;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="77,77" o:gfxdata="UEsDBBQABgAIAAAAIQDw94q7/QAAAOIBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRzUrEMBDH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" path="m39,l,77r77,l39,xe" filled="f" strokeweight=".24pt">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="39,2068;0,2145;77,2145;39,2068"
    o:connectangles="0,0,0,0"/>
  </v:shape></v:group></v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="20" height="182" alt="Text Box: Probability (%) of event-free" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image007.gif" /><img width="611" height="301" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image008.gif" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:598px"><tbody><tr><td><p>&nbsp;</p></td><td colspan="19">&nbsp;<p>No. of patients still at risk</p></td></tr><tr><td><p>Time (Months)</p></td><td><p>0</p></td><td><p>2</p></td><td><p>4</p></td><td><p>6</p></td><td><p>8</p></td><td><p>10</p></td><td><p>12</p></td><td><p>14</p></td><td><p>16</p></td><td><p>18</p></td><td><p>20</p></td><td><p>22</p></td><td><p>24</p></td><td><p>26</p></td><td><p>28</p></td><td><p>30</p></td><td><p>32</p></td><td><p>34</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>ceritinib 750&nbsp;mg</p></td><td><p>189</p></td><td><p>180</p></td><td><p>175</p></td><td><p>171</p></td><td><p>165</p></td><td><p>155</p></td><td><p>150</p></td><td><p>138</p></td><td><p>103</p></td><td><p>77</p></td><td><p>56</p></td><td><p>39</p></td><td><p>26</p></td><td><p>18</p></td><td><p>6</p></td><td><p>3</p></td><td><p>2</p></td><td><p>0</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Chemotherapy</p></td><td><p>187</p></td><td><p>172</p></td><td><p>161</p></td><td><p>150</p></td><td><p>146</p></td><td><p>141</p></td><td><p>134</p></td><td><p>124</p></td><td><p>97</p></td><td><p>69</p></td><td><p>49</p></td><td><p>35</p></td><td><p>19</p></td><td><p>10</p></td><td><p>5</p></td><td><p>1</p></td><td><p>0</p></td><td><p>0</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Patient reported outcome questionnaires (Lung cancer symptom scale [LCSS], EORTC-QLQ-C30 [C30], EORTC QLQ-LC13 [LC13] and EQ-5D-5L) were completed by 80% or more of patients in the ceritinib and chemotherapy arms for all questionnaires at most of the time‑points during the course of the study.</p><p>&nbsp;</p><p>Ceritinib significantly prolonged time to deterioration for the pre-specified lung cancer specific symptoms of interest of cough, pain and dyspnoea (composite endpoint LCSS: HR=0.61, 95% CI: 0.41, 0.90, median Time to Deterioration [TTD] NE [95% CI: 20.9, NE] in the ceritinib arm versus 18.4&nbsp;months [13.9, NE] in the chemotherapy arm; LC13: HR=0.48, 95% CI: 0.34, 0.69, median TTD 23.6&nbsp;months [95% CI: 20.7, NE] in the ceritinib arm versus 12.6&nbsp;months [95% CI: 8.9, 14.9] in the chemotherapy arm).</p><p>&nbsp;</p><p>Patients receiving ceritinib showed significant improvements over chemotherapy in general Quality of Life and global Health Status measures (LCSS [p&lt;0.001], QLQ-C30, [p&lt;0.001] and EQ-5D-5L index [p&lt;0.001]).</p><p>&nbsp;</p><p>In Study A2301, 44&nbsp;patients with measurable brain metastasis at baseline and at least one post-baseline brain radiological assessment (22&nbsp;patients in the ceritinib arm and 22&nbsp;patients in the chemotherapy arm) were assessed for intracranial response by BIRC neuro-radiologist per modified RECIST 1.1 (i.e. up to 5&nbsp;lesions in the brain). The overall intracranial response rate (OIRR) was higher with ceritinib (72.7%, 95% CI: 49.8, 89.3) as compared to the chemotherapy arm (27.3%, 95% CI: 10.7, 50.2).</p><p>&nbsp;</p><p>The median PFS by BIRC using RECIST 1.1 was longer in the ceritinib arm compared to the chemotherapy arm in both subgroups of patients with brain metastases and without brain metastases. The median PFS in patients with brain metastases was 10.7&nbsp;months (95% CI: 8.1, 16.4) versus 6.7&nbsp;months (95% CI: 4.1, 10.6) in the ceritinib and chemotherapy arms, respectively, with HR=0.70 (95% CI: 0.44, 1.12). The median PFS in patients without brain metastases was 26.3&nbsp;months (95% CI: 15.4, 27.7) versus 8.3&nbsp;months (95% CI: 6.0, 13.7) in the ceritinib and chemotherapy arms, respectively, with HR=0.48 (95% CI: 0.33, 0.69).</p><p>&nbsp;</p><p><em><u>Previously treated ALK‑positive advanced NSCLC - randomised phase&nbsp;3 Study A2303 (ASCEND-5)</u></em></p><p>The efficacy and safety of Zykadia for the treatment of ALK-positive advanced NSCLC patients who have received previous treatment with crizotinib, was demonstrated in a global multicentre, randomised, open-label phase&nbsp;3 Study A2303.</p><p>&nbsp;</p><p>A total of 231&nbsp;patients with advanced ALK positive NSCLC who have received prior treatment with crizotinib and chemotherapy (one or two regimen including a platinum-based doublet) were included in the analysis. One hundred fifteen (115) patients were randomised to Zykadia and one hundred sixteen (116) were randomised to chemotherapy (either pemetrexed or docetaxel). Seventy-three (73) patients received docetaxel and 40 received pemetrexed. In the ceritinib arm, 115&nbsp;patients were treated with 750&nbsp;mg once daily fasted. The median age was 54.0&nbsp;years (range: 28 to 84&nbsp;years); 77.1% of patients were younger than 65&nbsp;years. A total of 55.8% of patients were female. 64.5% of the study population were Caucasian, 29.4% Asian, 0.4% Black and 2.6% other races. The majority of patients had adenocarcinoma (97.0%) and had either never smoked or were former smokers (96.1%). The ECOG performance status was 0/1/2 in 46.3%/47.6%/6.1% of patients respectively, and 58.0% had brain metastasis at baseline. All patients were treated with prior crizotinib. All except one patient received prior chemotherapy (including a platinum doublet) for advanced disease; 11.3% of the patients in the ceritinib arm and 12.1% of the patients in the chemotherapy arm were treated with two prior chemotherapy regimen for advanced disease.</p><p>&nbsp;</p><p>Patients were allowed to continue the assigned study treatment beyond initial progression in case of continued clinical benefit as per the investigator&#39;s opinion. Patients randomised to the chemotherapy arm could further crossover to receive Zykadia upon RECIST-defined disease progression confirmed by BIRC.</p><p>&nbsp;</p><p>The median duration of follow-up was 16.5&nbsp;months (from randomisation to data cut-off date).</p><p>&nbsp;</p><p>The study met its primary objective demonstrating a statistically significant improvement in PFS by BIRC with an estimated 51% risk reduction in the ceritinib arm compared to chemotherapy arm (see Table&nbsp;4 and Figure&nbsp;3). The PFS benefit of Zykadia was consistent across various subgroups including age, gender, race, smoking class, ECOG performance status, and presence of brain metastases or prior response to crizotinib. The PFS benefit was further supported by local investigator assessment, and analysis of overall response rate (ORR) and disease control rate (DCR).</p><p>&nbsp;</p><p>OS data was immature with 48 (41.7%) events in the ceritinib arm and 50 (43.1%) events in the chemotherapy arm, corresponding to approximately 50% of the required events for the final OS analysis. In addition, 81&nbsp;patients (69.8%) in the chemotherapy arm received subsequent Zykadia as first antineoplastic therapy after study treatment discontinuation.</p><p>&nbsp;</p><p>Efficacy data from Study A2303 are summarised in Table&nbsp;4, and the Kaplan-Meier curves for PFS and OS are shown in Figure&nbsp;3 and 4, respectively.</p><p>&nbsp;</p><p><strong>Table&nbsp;4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ASCEND-5 (Study A2303) &ndash;</strong> <strong>Efficacy results in patients with previously treated ALK-positive metastatic/advanced NSCLC</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:92%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ceritinib<br />(N=115)</p></td><td style="vertical-align:top"><p>Chemotherapy<br />(N=116)</p></td></tr><tr><td style="vertical-align:top"><p>Duration of follow-up</p><p>Median (months) (min &ndash; max)</p></td><td colspan="2" style="vertical-align:top"><p>16.5</p><p>(2.8 &ndash; 30.9)</p></td></tr><tr><td style="vertical-align:top"><p>Progression-free survival (based on BIRC)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number of events, n (%)</p></td><td style="vertical-align:top"><p>83 (72.2%)</p></td><td style="vertical-align:top"><p>89 (76.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Median, months (95% CI)</p></td><td style="vertical-align:top"><p>5.4 (4.1, 6.9)</p></td><td style="vertical-align:top"><p>1.6 (1.4, 2.8)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)<sup>a</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.49 (0.36, 0.67)</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>Overall survival<sup>c</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number of events, n (%)</p></td><td style="vertical-align:top"><p>48 (41.7%)</p></td><td style="vertical-align:top"><p>50 (43.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Median, months (95% CI)</p></td><td style="vertical-align:top"><p>18.1 (13.4, 23.9)</p></td><td style="vertical-align:top"><p>20.1 (11.9, 25.1)</p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)<sup>a</sup></p></td><td colspan="2" style="vertical-align:top"><p>1.00 (0.67,1.49)</p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.496</p></td></tr><tr><td style="vertical-align:top"><p>Tumour responses (based on BIRC)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Objective response rate (95% CI)</p></td><td style="vertical-align:top"><p>39.1% (30.2, 48.7)</p></td><td style="vertical-align:top"><p>6.9% (3.0, 13.1)</p></td></tr><tr><td style="vertical-align:top"><p>Duration of response</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Number of responders</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>8</p></td></tr><tr><td style="vertical-align:top"><p>Median, months<sup>d</sup> (95% CI)</p></td><td style="vertical-align:top"><p>6.9 (5.4, 8.9)</p></td><td style="vertical-align:top"><p>8.3 (3.5, NE)</p></td></tr><tr><td style="vertical-align:top"><p>Event-free probability estimate at 9 months<sup>d</sup> (95% CI)</p></td><td style="vertical-align:top"><p>31.5% (16.7%, 47.3%)</p></td><td style="vertical-align:top"><p>45.7% (6.9%, 79.5%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>HR=hazard ratio; CI=confidence interval; BIRC=Blinded Independent Review Committee; NE=not estimable</p><p><sup>a </sup>Based on the stratified Cox proportional hazards analysis.</p><p><sup>b</sup> Based on the stratified log-rank test.</p><p><sup>c</sup> OS analysis was not adjusted for the potentially confounding effects of cross over.</p><p><sup>d</sup> Estimated using the Kaplan-Meier method.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ASCEND-5 (Study A2303) &ndash;</strong> <strong>Kaplan-Meier plot of progression-free survival as assessed by BIRC</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="_x0000_s1248" style='position:absolute;
 left:0;text-align:left;margin-left:132.2pt;margin-top:2.45pt;width:393.1pt;
 height:228.1pt;z-index:-251662848;mso-position-horizontal-relative:page'
 coordorigin="2644,49" coordsize="7862,4562">
 <v:group id="_x0000_s1249" style='position:absolute;left:2708;top:128;width:7734;
  height:4417' coordorigin="2708,128" coordsize="7734,4417">
  <v:shape id="_x0000_s1250" style='position:absolute;left:2708;top:128;
   width:7734;height:4417' coordorigin="2708,128" coordsize="7734,4417" path="m2708,128r44,l2752,170r84,l2836,212r14,l2850,254r113,l2963,297r14,l2977,381r71,l3048,425r56,l3104,467r42,l3146,509r15,l3161,551r14,l3175,594r13,l3188,721r15,l3203,805r14,l3217,890r15,l3232,961r56,l3288,1003r13,l3301,1087r71,l3372,1130r98,l3470,1172r142,l3612,1214r14,l3626,1257r15,l3641,1314r27,l3668,1356r15,l3683,1398r14,l3697,1525r57,l3754,1567r13,l3767,1610r127,l3894,1652r43,l3937,1694r113,l4050,1751r13,l4063,1793r43,l4106,1836r14,l4120,1920r14,l4134,2005r29,l4163,2147r42,l4205,2189r14,l4219,2287r28,l4247,2329r29,l4276,2372r310,l4586,2471r28,l4614,2513r14,l4628,2569r42,l4670,2669r15,l4685,2711r197,l4882,2767r254,l5136,2922r29,l5165,2978r98,l5263,3036r353,l5616,3092r56,l5672,3149r57,l5729,3205r282,l6011,3275r43,l6054,3332r42,l6096,3402r14,l6110,3529r28,l6138,3656r424,l6562,3713r112,l6674,3783r29,l6703,3854r917,l7620,3953r84,l7704,4051r340,l8044,4178r13,l8057,4305r2103,l10160,4545r282,e"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1251" style='position:absolute;
  left:2708;top:128;width:6252;height:4361' coordorigin="2708,128" coordsize="6252,4361">
  <v:shape id="_x0000_s1252" style='position:absolute;left:2708;top:128;
   width:6252;height:4361' coordorigin="2708,128" coordsize="6252,4361" path="m2708,128r15,l2822,128r,84l2850,212r,42l2864,254r,85l2892,339r,42l2948,381r15,l2963,509r14,l2977,551r,43l3005,594r,84l3019,678r,43l3034,721r,169l3048,890r,42l3076,932r,42l3104,974r,57l3118,1031r,43l3132,1074r,126l3146,1200r,212l3161,1412r,42l3175,1454r,169l3188,1623r,184l3203,1807r,127l3217,1934r,169l3232,2103r,184l3245,2287r,42l3259,2329r,56l3274,2385r,86l3288,2471r,141l3288,2654r28,l3316,2696r42,l3358,2739r70,l3428,2796r57,l3485,2838r43,l3612,2838r,42l3668,2880r,98l3683,2978r,43l3697,3021r,57l3725,3078r,42l3739,3120r15,l3754,3162r13,l3767,3218r29,l3796,3261r42,l3838,3318r14,l3852,3360r71,l3923,3416r183,l4106,3473r57,l4163,3529r,42l4205,3571r,58l4374,3629r,69l4487,3698r,57l4628,3755r,56l4643,3811r,56l4670,3867r,58l4727,3925r,56l4756,3981r27,l5094,3981r,70l5108,4051r395,l5503,4122r99,l5645,4122r422,l6533,4122r,113l6547,4235r,112l6618,4347r268,l6886,4489r1665,l8960,4489e"
   filled="f" strokeweight=".06pt">
   <v:stroke dashstyle="dash"/>
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1253" style='position:absolute;
  left:2681;top:85;width:71;height:71' coordorigin="2681,85" coordsize="71,71">
  <v:shape id="_x0000_s1254" style='position:absolute;left:2681;top:85;width:71;
   height:71' coordorigin="2681,85" coordsize="71,71" path="m2681,120r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1255" style='position:absolute;
  left:3372;top:1087;width:71;height:71' coordorigin="3372,1087" coordsize="71,71">
  <v:shape id="_x0000_s1256" style='position:absolute;left:3372;top:1087;
   width:71;height:71' coordorigin="3372,1087" coordsize="71,71" path="m3372,1122r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1257" style='position:absolute;
  left:3499;top:1130;width:71;height:70' coordorigin="3499,1130" coordsize="71,70">
  <v:shape id="_x0000_s1258" style='position:absolute;left:3499;top:1130;
   width:71;height:70' coordorigin="3499,1130" coordsize="71,70" path="m3499,1165r71,e"
   filled="f" strokeweight="3.58pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1259" style='position:absolute;
  left:3584;top:1214;width:70;height:71' coordorigin="3584,1214" coordsize="70,71">
  <v:shape id="_x0000_s1260" style='position:absolute;left:3584;top:1214;
   width:70;height:71' coordorigin="3584,1214" coordsize="70,71" path="m3584,1250r70,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1261" style='position:absolute;
  left:3668;top:1483;width:71;height:71' coordorigin="3668,1483" coordsize="71,71">
  <v:shape id="_x0000_s1262" style='position:absolute;left:3668;top:1483;
   width:71;height:71' coordorigin="3668,1483" coordsize="71,71" path="m3668,1518r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1263" style='position:absolute;
  left:4120;top:2139;width:85;height:2' coordorigin="4120,2139" coordsize="85,2">
  <v:shape id="_x0000_s1264" style='position:absolute;left:4120;top:2139;
   width:85;height:2' coordorigin="4120,2139" coordsize="85,0" path="m4120,2139r85,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1265" style='position:absolute;
  left:4403;top:2329;width:70;height:71' coordorigin="4403,2329" coordsize="70,71">
  <v:shape id="_x0000_s1266" style='position:absolute;left:4403;top:2329;
   width:70;height:71' coordorigin="4403,2329" coordsize="70,71" path="m4403,2364r69,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1267" style='position:absolute;
  left:4543;top:2429;width:71;height:71' coordorigin="4543,2429" coordsize="71,71">
  <v:shape id="_x0000_s1268" style='position:absolute;left:4543;top:2429;
   width:71;height:71' coordorigin="4543,2429" coordsize="71,71" path="m4543,2464r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1269" style='position:absolute;
  left:4670;top:2704;width:155;height:2' coordorigin="4670,2704" coordsize="155,2">
  <v:shape id="_x0000_s1270" style='position:absolute;left:4670;top:2704;
   width:155;height:2' coordorigin="4670,2704" coordsize="155,0" path="m4670,2704r155,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1271" style='position:absolute;
  left:5009;top:2760;width:142;height:2' coordorigin="5009,2760" coordsize="142,2">
  <v:shape id="_x0000_s1272" style='position:absolute;left:5009;top:2760;
   width:142;height:2' coordorigin="5009,2760" coordsize="142,0" path="m5009,2760r141,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1273" style='position:absolute;
  left:5405;top:2993;width:70;height:71' coordorigin="5405,2993" coordsize="70,71">
  <v:shape id="_x0000_s1274" style='position:absolute;left:5405;top:2993;
   width:70;height:71' coordorigin="5405,2993" coordsize="70,71" path="m5405,3028r69,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1275" style='position:absolute;
  left:5587;top:3049;width:71;height:71' coordorigin="5587,3049" coordsize="71,71">
  <v:shape id="_x0000_s1276" style='position:absolute;left:5587;top:3049;
   width:71;height:71' coordorigin="5587,3049" coordsize="71,71" path="m5587,3084r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1277" style='position:absolute;
  left:5672;top:3105;width:71;height:71' coordorigin="5672,3105" coordsize="71,71">
  <v:shape id="_x0000_s1278" style='position:absolute;left:5672;top:3105;
   width:71;height:71' coordorigin="5672,3105" coordsize="71,71" path="m5672,3141r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1279" style='position:absolute;
  left:5969;top:3233;width:71;height:71' coordorigin="5969,3233" coordsize="71,71">
  <v:shape id="_x0000_s1280" style='position:absolute;left:5969;top:3233;
   width:71;height:71' coordorigin="5969,3233" coordsize="71,71" path="m5969,3268r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1281" style='position:absolute;
  left:6463;top:3614;width:70;height:71' coordorigin="6463,3614" coordsize="70,71">
  <v:shape id="_x0000_s1282" style='position:absolute;left:6463;top:3614;
   width:70;height:71' coordorigin="6463,3614" coordsize="70,71" path="m6463,3650r70,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1283" style='position:absolute;
  left:6618;top:3671;width:71;height:71' coordorigin="6618,3671" coordsize="71,71">
  <v:shape id="_x0000_s1284" style='position:absolute;left:6618;top:3671;
   width:71;height:71' coordorigin="6618,3671" coordsize="71,71" path="m6618,3706r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1285" style='position:absolute;
  left:6716;top:3811;width:71;height:71' coordorigin="6716,3811" coordsize="71,71">
  <v:shape id="_x0000_s1286" style='position:absolute;left:6716;top:3811;
   width:71;height:71' coordorigin="6716,3811" coordsize="71,71" path="m6716,3846r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1287" style='position:absolute;
  left:6886;top:3811;width:71;height:71' coordorigin="6886,3811" coordsize="71,71">
  <v:shape id="_x0000_s1288" style='position:absolute;left:6886;top:3811;
   width:71;height:71' coordorigin="6886,3811" coordsize="71,71" path="m6886,3846r70,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1289" style='position:absolute;
  left:7451;top:3811;width:71;height:71' coordorigin="7451,3811" coordsize="71,71">
  <v:shape id="_x0000_s1290" style='position:absolute;left:7451;top:3811;
   width:71;height:71' coordorigin="7451,3811" coordsize="71,71" path="m7451,3846r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1291" style='position:absolute;
  left:7648;top:3911;width:71;height:71' coordorigin="7648,3911" coordsize="71,71">
  <v:shape id="_x0000_s1292" style='position:absolute;left:7648;top:3911;
   width:71;height:71' coordorigin="7648,3911" coordsize="71,71" path="m7648,3946r70,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1293" style='position:absolute;
  left:7987;top:4009;width:70;height:71' coordorigin="7987,4009" coordsize="70,71">
  <v:shape id="_x0000_s1294" style='position:absolute;left:7987;top:4009;
   width:70;height:71' coordorigin="7987,4009" coordsize="70,71" path="m7987,4044r70,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1295" style='position:absolute;
  left:8720;top:4263;width:71;height:71' coordorigin="8720,4263" coordsize="71,71">
  <v:shape id="_x0000_s1296" style='position:absolute;left:8720;top:4263;
   width:71;height:71' coordorigin="8720,4263" coordsize="71,71" path="m8720,4299r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1297" style='position:absolute;
  left:9186;top:4263;width:71;height:71' coordorigin="9186,4263" coordsize="71,71">
  <v:shape id="_x0000_s1298" style='position:absolute;left:9186;top:4263;
   width:71;height:71' coordorigin="9186,4263" coordsize="71,71" path="m9186,4299r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1299" style='position:absolute;
  left:10400;top:4503;width:70;height:71' coordorigin="10400,4503" coordsize="70,71">
  <v:shape id="_x0000_s1300" style='position:absolute;left:10400;top:4503;
   width:70;height:71' coordorigin="10400,4503" coordsize="70,71" path="m10400,4539r70,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1301" style='position:absolute;
  left:2681;top:85;width:84;height:85' coordorigin="2681,85" coordsize="84,85">
  <v:shape id="_x0000_s1302" style='position:absolute;left:2681;top:85;width:84;
   height:85' coordorigin="2681,85" coordsize="84,85" path="m2723,85r-42,85l2765,170,2723,85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1303" style='position:absolute;
  left:2681;top:85;width:84;height:85' coordorigin="2681,85" coordsize="84,85">
  <v:shape id="_x0000_s1304" style='position:absolute;left:2681;top:85;width:84;
   height:85' coordorigin="2681,85" coordsize="84,85" path="m2723,85r-42,85l2765,170,2723,85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1305" style='position:absolute;
  left:2681;top:85;width:84;height:85' coordorigin="2681,85" coordsize="84,85">
  <v:shape id="_x0000_s1306" style='position:absolute;left:2681;top:85;width:84;
   height:85' coordorigin="2681,85" coordsize="84,85" path="m2723,85r-42,85l2765,170,2723,85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1307" style='position:absolute;
  left:2681;top:85;width:84;height:85' coordorigin="2681,85" coordsize="84,85">
  <v:shape id="_x0000_s1308" style='position:absolute;left:2681;top:85;width:84;
   height:85' coordorigin="2681,85" coordsize="84,85" path="m2723,85r-42,85l2765,170,2723,85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1309" style='position:absolute;
  left:2681;top:85;width:84;height:85' coordorigin="2681,85" coordsize="84,85">
  <v:shape id="_x0000_s1310" style='position:absolute;left:2681;top:85;width:84;
   height:85' coordorigin="2681,85" coordsize="84,85" path="m2723,85r-42,85l2765,170,2723,85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1311" style='position:absolute;
  left:2681;top:85;width:84;height:85' coordorigin="2681,85" coordsize="84,85">
  <v:shape id="_x0000_s1312" style='position:absolute;left:2681;top:85;width:84;
   height:85' coordorigin="2681,85" coordsize="84,85" path="m2723,85r-42,85l2765,170,2723,85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1313" style='position:absolute;
  left:2906;top:339;width:85;height:85' coordorigin="2906,339" coordsize="85,85">
  <v:shape id="_x0000_s1314" style='position:absolute;left:2906;top:339;
   width:85;height:85' coordorigin="2906,339" coordsize="85,85" path="m2948,339r-42,86l2992,425r-44,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1315" style='position:absolute;
  left:3005;top:890;width:85;height:84' coordorigin="3005,890" coordsize="85,84">
  <v:shape id="_x0000_s1316" style='position:absolute;left:3005;top:890;
   width:85;height:84' coordorigin="3005,890" coordsize="85,84" path="m3048,890r-43,84l3090,974r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1317" style='position:absolute;
  left:3161;top:1892;width:84;height:84' coordorigin="3161,1892" coordsize="84,84">
  <v:shape id="_x0000_s1318" style='position:absolute;left:3161;top:1892;
   width:84;height:84' coordorigin="3161,1892" coordsize="84,84" path="m3203,1892r-42,84l3245,1976r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1319" style='position:absolute;
  left:3175;top:2061;width:84;height:85' coordorigin="3175,2061" coordsize="84,85">
  <v:shape id="_x0000_s1320" style='position:absolute;left:3175;top:2061;
   width:84;height:85' coordorigin="3175,2061" coordsize="84,85" path="m3217,2061r-42,86l3259,2147r-42,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1321" style='position:absolute;
  left:3175;top:2061;width:84;height:85' coordorigin="3175,2061" coordsize="84,85">
  <v:shape id="_x0000_s1322" style='position:absolute;left:3175;top:2061;
   width:84;height:85' coordorigin="3175,2061" coordsize="84,85" path="m3217,2061r-42,86l3259,2147r-42,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1323" style='position:absolute;
  left:3485;top:2796;width:85;height:84' coordorigin="3485,2796" coordsize="85,84">
  <v:shape id="_x0000_s1324" style='position:absolute;left:3485;top:2796;
   width:85;height:84' coordorigin="3485,2796" coordsize="85,84" path="m3528,2796r-43,84l3570,2880r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1325" style='position:absolute;
  left:3570;top:2838;width:84;height:84' coordorigin="3570,2838" coordsize="84,84">
  <v:shape id="_x0000_s1326" style='position:absolute;left:3570;top:2838;
   width:84;height:84' coordorigin="3570,2838" coordsize="84,84" path="m3612,2838r-42,84l3654,2922r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1327" style='position:absolute;
  left:3697;top:3078;width:84;height:84' coordorigin="3697,3078" coordsize="84,84">
  <v:shape id="_x0000_s1328" style='position:absolute;left:3697;top:3078;
   width:84;height:84' coordorigin="3697,3078" coordsize="84,84" path="m3739,3078r-42,84l3781,3162r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1329" style='position:absolute;
  left:3796;top:3275;width:85;height:85' coordorigin="3796,3275" coordsize="85,85">
  <v:shape id="_x0000_s1330" style='position:absolute;left:3796;top:3275;
   width:85;height:85' coordorigin="3796,3275" coordsize="85,85" path="m3838,3275r-42,85l3881,3360r-43,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1331" style='position:absolute;
  left:3810;top:3318;width:84;height:84' coordorigin="3810,3318" coordsize="84,84">
  <v:shape id="_x0000_s1332" style='position:absolute;left:3810;top:3318;
   width:84;height:84' coordorigin="3810,3318" coordsize="84,84" path="m3852,3318r-42,84l3894,3402r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1333" style='position:absolute;
  left:4120;top:3529;width:85;height:85' coordorigin="4120,3529" coordsize="85,85">
  <v:shape id="_x0000_s1334" style='position:absolute;left:4120;top:3529;
   width:85;height:85' coordorigin="4120,3529" coordsize="85,85" path="m4163,3529r-43,85l4205,3614r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1335" style='position:absolute;
  left:4120;top:3529;width:85;height:85' coordorigin="4120,3529" coordsize="85,85">
  <v:shape id="_x0000_s1336" style='position:absolute;left:4120;top:3529;
   width:85;height:85' coordorigin="4120,3529" coordsize="85,85" path="m4163,3529r-43,85l4205,3614r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1337" style='position:absolute;
  left:4712;top:3938;width:85;height:85' coordorigin="4712,3938" coordsize="85,85">
  <v:shape id="_x0000_s1338" style='position:absolute;left:4712;top:3938;
   width:85;height:85' coordorigin="4712,3938" coordsize="85,85" path="m4756,3938r-44,85l4798,4023r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1339" style='position:absolute;
  left:4741;top:3938;width:84;height:85' coordorigin="4741,3938" coordsize="84,85">
  <v:shape id="_x0000_s1340" style='position:absolute;left:4741;top:3938;
   width:84;height:85' coordorigin="4741,3938" coordsize="84,85" path="m4783,3938r-42,85l4825,4023r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1341" style='position:absolute;
  left:5065;top:4009;width:85;height:85' coordorigin="5065,4009" coordsize="85,85">
  <v:shape id="_x0000_s1342" style='position:absolute;left:5065;top:4009;
   width:85;height:85' coordorigin="5065,4009" coordsize="85,85" path="m5108,4009r-43,85l5150,4094r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1343" style='position:absolute;
  left:5560;top:4080;width:85;height:84' coordorigin="5560,4080" coordsize="85,84">
  <v:shape id="_x0000_s1344" style='position:absolute;left:5560;top:4080;
   width:85;height:84' coordorigin="5560,4080" coordsize="85,84" path="m5602,4080r-42,84l5645,4164r-43,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1345" style='position:absolute;
  left:5602;top:4080;width:85;height:84' coordorigin="5602,4080" coordsize="85,84">
  <v:shape id="_x0000_s1346" style='position:absolute;left:5602;top:4080;
   width:85;height:84' coordorigin="5602,4080" coordsize="85,84" path="m5645,4080r-43,84l5687,4164r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1347" style='position:absolute;
  left:6025;top:4080;width:85;height:84' coordorigin="6025,4080" coordsize="85,84">
  <v:shape id="_x0000_s1348" style='position:absolute;left:6025;top:4080;
   width:85;height:84' coordorigin="6025,4080" coordsize="85,84" path="m6067,4080r-42,84l6110,4164r-43,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1349" style='position:absolute;
  left:6576;top:4305;width:84;height:85' coordorigin="6576,4305" coordsize="84,85">
  <v:shape id="_x0000_s1350" style='position:absolute;left:6576;top:4305;
   width:84;height:85' coordorigin="6576,4305" coordsize="84,85" path="m6618,4305r-42,86l6660,4391r-42,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1351" style='position:absolute;
  left:8509;top:4447;width:84;height:84' coordorigin="8509,4447" coordsize="84,84">
  <v:shape id="_x0000_s1352" style='position:absolute;left:8509;top:4447;
   width:84;height:84' coordorigin="8509,4447" coordsize="84,84" path="m8551,4447r-42,84l8593,4531r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1353" style='position:absolute;
  left:8918;top:4447;width:84;height:84' coordorigin="8918,4447" coordsize="84,84">
  <v:shape id="_x0000_s1354" style='position:absolute;left:8918;top:4447;
   width:84;height:84' coordorigin="8918,4447" coordsize="84,84" path="m8960,4447r-42,84l9002,4531r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1355" style='position:absolute;
  left:7620;top:721;width:607;height:2' coordorigin="7620,721" coordsize="607,2">
  <v:shape id="_x0000_s1356" style='position:absolute;left:7620;top:721;
   width:607;height:2' coordorigin="7620,721" coordsize="607,0" path="m7620,721r607,e"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1357" style='position:absolute;
  left:7620;top:947;width:607;height:2' coordorigin="7620,947" coordsize="607,2">
  <v:shape id="_x0000_s1358" style='position:absolute;left:7620;top:947;
   width:607;height:2' coordorigin="7620,947" coordsize="607,0" path="m7620,947r607,e"
   filled="f" strokeweight=".06pt">
   <v:stroke dashstyle="dash"/>
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1359" style='position:absolute;
  left:7874;top:678;width:70;height:71' coordorigin="7874,678" coordsize="70,71">
  <v:shape id="_x0000_s1360" style='position:absolute;left:7874;top:678;
   width:70;height:71' coordorigin="7874,678" coordsize="70,71" path="m7874,713r70,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1361" style='position:absolute;
  left:7874;top:903;width:84;height:85' coordorigin="7874,903" coordsize="84,85">
  <v:shape id="_x0000_s1362" style='position:absolute;left:7874;top:903;
   width:84;height:85' coordorigin="7874,903" coordsize="84,85" path="m7916,903r-42,86l7958,989r-42,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1363" style='position:absolute;
  left:7578;top:438;width:70;height:71' coordorigin="7578,438" coordsize="70,71">
  <v:shape id="_x0000_s1364" style='position:absolute;left:7578;top:438;
   width:70;height:71' coordorigin="7578,438" coordsize="70,71" path="m7578,473r70,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1365" style='position:absolute;
  left:8184;top:438;width:85;height:85' coordorigin="8184,438" coordsize="85,85">
  <v:shape id="_x0000_s1366" style='position:absolute;left:8184;top:438;
   width:85;height:85' coordorigin="8184,438" coordsize="85,85" path="m8227,438r-43,85l8269,523r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="525" height="302" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image009.gif" /><!--[if gte vml 1]><v:shape
 id="_x0000_s1367" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:119.95pt;margin-top:-3.5pt;width:447.4pt;height:256.9pt;
 text-indent:0;z-index:-251661824;mso-position-horizontal-relative:page'
 filled="f" stroked="f">
 <v:textbox style='mso-next-textbox:#_x0000_s1367' inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="14" rowspan="7" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>Censoring Times</p><p>Ceritinib 750&nbsp;mg (n/N = 83/115)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chemotherapy (n/N = 89/116)</p><p>&nbsp;</p><p>&nbsp;</p><p>Hazard Ratio = 0.49</p><p>95% CI (0.36;0.67)</p><p>&nbsp;</p><p>Kaplan-Meier medians (95% CI) (Months)</p><p>Ceritinib 750&nbsp;mg: 5.4 (4.1;6.9)</p><p>Chemotherapy: 1.6 (1.4;2.8)</p><p>&nbsp;</p><p>Log rank p-value = &lt;0.001</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p>100</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;</p><p><!--[if gte vml 1]><v:shape id="_x0000_s1368" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:-2.45pt;
 margin-top:4.6pt;width:29.1pt;height:155.95pt;text-indent:0;z-index:251655680'
 stroked="f">
 <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top;
  mso-next-textbox:#_x0000_s1368'>
  <![if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;font-family:
    "Arial",sans-serif;mso-ansi-language:DE-CH'>Probability (%) of event-free<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]></v:textbox>
</v:shape><![endif]--><img width="43" height="212" alt="Text Box: Probability (%) of event-free" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image010.gif" />&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>80</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>60</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>40</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>20</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>0</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; 22</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24</p></td></tr></tbody></table><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_s1247" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:209.95pt;margin-top:11.45pt;width:130.5pt;
 height:19.5pt;text-indent:0;z-index:251652608' stroked="f">
 <v:textbox style='mso-next-textbox:#_x0000_s1247'/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Time (Months)</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="13" style="vertical-align:top"><p>No. of patients s till at risk</p></td></tr><tr><td style="vertical-align:top"><p>Time (Months)</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>24</p></td></tr><tr><td style="vertical-align:top"><p>Ceritinib 750&nbsp;mg</p></td><td style="vertical-align:top"><p>115</p></td><td style="vertical-align:top"><p>87</p></td><td style="vertical-align:top"><p>68</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Chemotherapy</p></td><td style="vertical-align:top"><p>116</p></td><td style="vertical-align:top"><p>45</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure&nbsp;4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ASCEND-5 (Study A2303) &ndash;</strong> <strong>Kaplan-Meier plot of overall survival by treatment arm</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="_x0000_s1026" style='position:absolute;
 left:0;text-align:left;margin-left:133.3pt;margin-top:4.2pt;width:411.4pt;
 height:235.1pt;z-index:-251666944;mso-position-horizontal-relative:page'
 coordorigin="2666,84" coordsize="8228,4702">
 <v:group id="_x0000_s1027" style='position:absolute;left:2708;top:128;width:7818;
  height:3344' coordorigin="2708,128" coordsize="7818,3344">
  <v:shape id="_x0000_s1028" style='position:absolute;left:2708;top:128;
   width:7818;height:3344' coordorigin="2708,128" coordsize="7818,3344" path="m2708,128r29,l2737,170r85,l2822,212r99,l2921,254r14,l2935,283r99,l3034,325r56,l3090,368r98,l3188,452r113,l3301,494r156,l3457,537r42,l3499,621r71,l3570,665r42,l3612,707r98,l3710,749r86,l3796,791r27,l3823,834r269,l4092,876r71,l4163,918r211,l4374,961r71,l4445,1017r113,l4558,1101r254,l4812,1158r13,l4825,1200r15,l4840,1257r141,l4981,1299r99,l5100,1299r21,l5141,1299r20,l5182,1299r20,l5223,1299r20,l5264,1299r20,l5305,1299r20,l5346,1299r20,l5386,1299r21,l5427,1299r21,l5468,1299r21,l5518,1299r,57l5545,1356r,71l5658,1427r,56l5842,1483r,56l5940,1539r,57l6054,1596r,56l6082,1652r,57l6110,1709r,70l6152,1779r,57l6322,1836r,56l6463,1892r,71l6589,1963r,70l6618,2033r,70l6703,2103r,71l7098,2174r,99l7338,2273r,85l7789,2358r,113l7916,2471r,112l8284,2583r,170l9031,2753r,283l9412,3036r,437l10526,3473e"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1029" style='position:absolute;
  left:2708;top:128;width:8185;height:4657' coordorigin="2708,128" coordsize="8185,4657">
  <v:shape id="_x0000_s1030" style='position:absolute;left:2708;top:128;
   width:8185;height:4657' coordorigin="2708,128" coordsize="8185,4657" path="m2708,128r198,l2906,170r71,l2977,212r28,l3005,254r29,l3034,283r84,l3118,325r141,l3259,368r29,l3288,410r42,l3344,410r57,l3401,452r,42l3428,494r,43l3457,537r,42l3470,579r,42l3485,621r14,l3584,621r,44l3612,665r42,l3654,707r29,l3697,707r,42l3781,749r42,l3823,791r29,l3852,834r56,l3923,834r,42l3937,876r,42l3937,961r70,l4021,961r,56l4050,1017r,42l4120,1059r,84l4176,1143r,44l4234,1187r27,l4261,1243r184,l4445,1285r,42l4472,1327r,43l4487,1370r56,l4543,1427r43,l4656,1427r56,l4712,1469r57,l4910,1469r,42l4939,1511r,56l5023,1567r,43l5038,1610r,57l5052,1667r56,l5108,1709r99,l5207,1765r113,l5630,1765r,56l5645,1821r,57l5743,1878r141,l5884,1949r28,l5954,1949r29,l6054,1949r,56l6110,2005r240,l6350,2076r126,l6476,2147r29,l6985,2147r,69l7888,2216r,127l8353,2343r,156l8410,2499r170,l8580,2682r28,l8749,2682r13,l9088,2682r,296l9144,2978r494,l9751,2978r,453l9864,3431r522,l10894,3431r,1354e"
   filled="f" strokeweight=".06pt">
   <v:stroke dashstyle="dash"/>
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1031" style='position:absolute;
  left:3443;top:494;width:71;height:71' coordorigin="3443,494" coordsize="71,71">
  <v:shape id="_x0000_s1032" style='position:absolute;left:3443;top:494;
   width:71;height:71' coordorigin="3443,494" coordsize="71,71" path="m3443,530r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1033" style='position:absolute;
  left:3457;top:615;width:98;height:2' coordorigin="3457,615" coordsize="98,2">
  <v:shape id="_x0000_s1034" style='position:absolute;left:3457;top:615;
   width:98;height:2' coordorigin="3457,615" coordsize="98,0" path="m3457,615r99,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1035" style='position:absolute;
  left:3612;top:721;width:169;height:2' coordorigin="3612,721" coordsize="169,2">
  <v:shape id="_x0000_s1036" style='position:absolute;left:3612;top:721;
   width:169;height:2' coordorigin="3612,721" coordsize="169,0" path="m3612,721r169,e"
   filled="f" strokeweight="5.74pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1037" style='position:absolute;
  left:3838;top:791;width:71;height:71' coordorigin="3838,791" coordsize="71,71">
  <v:shape id="_x0000_s1038" style='position:absolute;left:3838;top:791;
   width:71;height:71' coordorigin="3838,791" coordsize="71,71" path="m3838,826r70,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1039" style='position:absolute;
  left:4036;top:791;width:71;height:71' coordorigin="4036,791" coordsize="71,71">
  <v:shape id="_x0000_s1040" style='position:absolute;left:4036;top:791;
   width:71;height:71' coordorigin="4036,791" coordsize="71,71" path="m4036,826r70,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1041" style='position:absolute;
  left:4078;top:834;width:71;height:70' coordorigin="4078,834" coordsize="71,70">
  <v:shape id="_x0000_s1042" style='position:absolute;left:4078;top:834;
   width:71;height:70' coordorigin="4078,834" coordsize="71,70" path="m4078,869r70,e"
   filled="f" strokeweight="3.58pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1043" style='position:absolute;
  left:4234;top:876;width:70;height:71' coordorigin="4234,876" coordsize="70,71">
  <v:shape id="_x0000_s1044" style='position:absolute;left:4234;top:876;
   width:70;height:71' coordorigin="4234,876" coordsize="70,71" path="m4234,911r69,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1045" style='position:absolute;
  left:4445;top:1010;width:98;height:2' coordorigin="4445,1010" coordsize="98,2">
  <v:shape id="_x0000_s1046" style='position:absolute;left:4445;top:1010;
   width:98;height:2' coordorigin="4445,1010" coordsize="98,0" path="m4445,1010r98,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1047" style='position:absolute;
  left:4614;top:1095;width:98;height:2' coordorigin="4614,1095" coordsize="98,2">
  <v:shape id="_x0000_s1048" style='position:absolute;left:4614;top:1095;
   width:98;height:2' coordorigin="4614,1095" coordsize="98,0" path="m4614,1095r98,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1049" style='position:absolute;
  left:4854;top:1214;width:71;height:71' coordorigin="4854,1214" coordsize="71,71">
  <v:shape id="_x0000_s1050" style='position:absolute;left:4854;top:1214;
   width:71;height:71' coordorigin="4854,1214" coordsize="71,71" path="m4854,1250r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1051" style='position:absolute;
  left:5038;top:1292;width:155;height:2' coordorigin="5038,1292" coordsize="155,2">
  <v:shape id="_x0000_s1052" style='position:absolute;left:5038;top:1292;
   width:155;height:2' coordorigin="5038,1292" coordsize="155,0" path="m5038,1292r154,e"
   filled="f" strokeweight="3.58pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1053" style='position:absolute;
  left:5376;top:1292;width:142;height:2' coordorigin="5376,1292" coordsize="142,2">
  <v:shape id="_x0000_s1054" style='position:absolute;left:5376;top:1292;
   width:142;height:2' coordorigin="5376,1292" coordsize="142,0" path="m5376,1292r142,e"
   filled="f" strokeweight="3.58pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1055" style='position:absolute;
  left:5729;top:1440;width:71;height:71' coordorigin="5729,1440" coordsize="71,71">
  <v:shape id="_x0000_s1056" style='position:absolute;left:5729;top:1440;
   width:71;height:71' coordorigin="5729,1440" coordsize="71,71" path="m5729,1475r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1057" style='position:absolute;
  left:5940;top:1554;width:71;height:70' coordorigin="5940,1554" coordsize="71,70">
  <v:shape id="_x0000_s1058" style='position:absolute;left:5940;top:1554;
   width:71;height:70' coordorigin="5940,1554" coordsize="71,70" path="m5940,1589r71,e"
   filled="f" strokeweight="3.58pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1059" style='position:absolute;
  left:6011;top:1610;width:71;height:70' coordorigin="6011,1610" coordsize="71,70">
  <v:shape id="_x0000_s1060" style='position:absolute;left:6011;top:1610;
   width:71;height:70' coordorigin="6011,1610" coordsize="71,70" path="m6011,1645r71,e"
   filled="f" strokeweight="3.58pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1061" style='position:absolute;
  left:6167;top:1828;width:84;height:2' coordorigin="6167,1828" coordsize="84,2">
  <v:shape id="_x0000_s1062" style='position:absolute;left:6167;top:1828;
   width:84;height:2' coordorigin="6167,1828" coordsize="84,0" path="m6167,1828r84,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1063" style='position:absolute;
  left:6350;top:1850;width:70;height:70' coordorigin="6350,1850" coordsize="70,70">
  <v:shape id="_x0000_s1064" style='position:absolute;left:6350;top:1850;
   width:70;height:70' coordorigin="6350,1850" coordsize="70,70" path="m6350,1885r70,e"
   filled="f" strokeweight="3.58pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1065" style='position:absolute;
  left:6434;top:1955;width:169;height:2' coordorigin="6434,1955" coordsize="169,2">
  <v:shape id="_x0000_s1066" style='position:absolute;left:6434;top:1955;
   width:169;height:2' coordorigin="6434,1955" coordsize="169,0" path="m6434,1955r170,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1067" style='position:absolute;
  left:6576;top:2097;width:113;height:2' coordorigin="6576,2097" coordsize="113,2">
  <v:shape id="_x0000_s1068" style='position:absolute;left:6576;top:2097;
   width:113;height:2' coordorigin="6576,2097" coordsize="113,0" path="m6576,2097r113,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1069" style='position:absolute;
  left:6703;top:2132;width:70;height:71' coordorigin="6703,2132" coordsize="70,71">
  <v:shape id="_x0000_s1070" style='position:absolute;left:6703;top:2132;
   width:70;height:71' coordorigin="6703,2132" coordsize="70,71" path="m6703,2168r70,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1071" style='position:absolute;
  left:6816;top:2132;width:70;height:71' coordorigin="6816,2132" coordsize="70,71">
  <v:shape id="_x0000_s1072" style='position:absolute;left:6816;top:2132;
   width:70;height:71' coordorigin="6816,2132" coordsize="70,71" path="m6816,2168r70,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1073" style='position:absolute;
  left:6914;top:2168;width:113;height:2' coordorigin="6914,2168" coordsize="113,2">
  <v:shape id="_x0000_s1074" style='position:absolute;left:6914;top:2168;
   width:113;height:2' coordorigin="6914,2168" coordsize="113,0" path="m6914,2168r113,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1075" style='position:absolute;
  left:7112;top:2231;width:70;height:71' coordorigin="7112,2231" coordsize="70,71">
  <v:shape id="_x0000_s1076" style='position:absolute;left:7112;top:2231;
   width:70;height:71' coordorigin="7112,2231" coordsize="70,71" path="m7112,2266r70,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1077" style='position:absolute;
  left:7324;top:2351;width:211;height:2' coordorigin="7324,2351" coordsize="211,2">
  <v:shape id="_x0000_s1078" style='position:absolute;left:7324;top:2351;
   width:211;height:2' coordorigin="7324,2351" coordsize="211,0" path="m7324,2351r211,e"
   filled="f" strokeweight="3.58pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1079" style='position:absolute;
  left:7718;top:2351;width:100;height:2' coordorigin="7718,2351" coordsize="100,2">
  <v:shape id="_x0000_s1080" style='position:absolute;left:7718;top:2351;
   width:100;height:2' coordorigin="7718,2351" coordsize="100,0" path="m7718,2351r100,e"
   filled="f" strokeweight="3.58pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1081" style='position:absolute;
  left:7888;top:2577;width:269;height:2' coordorigin="7888,2577" coordsize="269,2">
  <v:shape id="_x0000_s1082" style='position:absolute;left:7888;top:2577;
   width:269;height:2' coordorigin="7888,2577" coordsize="269,0" path="m7888,2577r268,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1083" style='position:absolute;
  left:8269;top:2746;width:98;height:2' coordorigin="8269,2746" coordsize="98,2">
  <v:shape id="_x0000_s1084" style='position:absolute;left:8269;top:2746;
   width:98;height:2' coordorigin="8269,2746" coordsize="98,0" path="m8269,2746r99,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1085" style='position:absolute;
  left:8509;top:2711;width:71;height:71' coordorigin="8509,2711" coordsize="71,71">
  <v:shape id="_x0000_s1086" style='position:absolute;left:8509;top:2711;
   width:71;height:71' coordorigin="8509,2711" coordsize="71,71" path="m8509,2746r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1087" style='position:absolute;
  left:8706;top:2711;width:71;height:71' coordorigin="8706,2711" coordsize="71,71">
  <v:shape id="_x0000_s1088" style='position:absolute;left:8706;top:2711;
   width:71;height:71' coordorigin="8706,2711" coordsize="71,71" path="m8706,2746r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1089" style='position:absolute;
  left:8904;top:2711;width:71;height:71' coordorigin="8904,2711" coordsize="71,71">
  <v:shape id="_x0000_s1090" style='position:absolute;left:8904;top:2711;
   width:71;height:71' coordorigin="8904,2711" coordsize="71,71" path="m8904,2746r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1091" style='position:absolute;
  left:9017;top:2993;width:71;height:71' coordorigin="9017,2993" coordsize="71,71">
  <v:shape id="_x0000_s1092" style='position:absolute;left:9017;top:2993;
   width:71;height:71' coordorigin="9017,2993" coordsize="71,71" path="m9017,3028r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1093" style='position:absolute;
  left:9313;top:2993;width:71;height:71' coordorigin="9313,2993" coordsize="71,71">
  <v:shape id="_x0000_s1094" style='position:absolute;left:9313;top:2993;
   width:71;height:71' coordorigin="9313,2993" coordsize="71,71" path="m9313,3028r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1095" style='position:absolute;
  left:9370;top:3431;width:71;height:71' coordorigin="9370,3431" coordsize="71,71">
  <v:shape id="_x0000_s1096" style='position:absolute;left:9370;top:3431;
   width:71;height:71' coordorigin="9370,3431" coordsize="71,71" path="m9370,3466r70,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1097" style='position:absolute;
  left:10117;top:3431;width:71;height:71' coordorigin="10117,3431" coordsize="71,71">
  <v:shape id="_x0000_s1098" style='position:absolute;left:10117;top:3431;
   width:71;height:71' coordorigin="10117,3431" coordsize="71,71" path="m10117,3466r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1099" style='position:absolute;
  left:10484;top:3431;width:71;height:71' coordorigin="10484,3431" coordsize="71,71">
  <v:shape id="_x0000_s1100" style='position:absolute;left:10484;top:3431;
   width:71;height:71' coordorigin="10484,3431" coordsize="71,71" path="m10484,3466r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1101" style='position:absolute;
  left:2666;top:85;width:85;height:85' coordorigin="2666,85" coordsize="85,85">
  <v:shape id="_x0000_s1102" style='position:absolute;left:2666;top:85;width:85;
   height:85' coordorigin="2666,85" coordsize="85,85" path="m2708,85r-42,85l2752,170,2708,85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1103" style='position:absolute;
  left:3288;top:368;width:84;height:84' coordorigin="3288,368" coordsize="84,84">
  <v:shape id="_x0000_s1104" style='position:absolute;left:3288;top:368;
   width:84;height:84' coordorigin="3288,368" coordsize="84,84" path="m3330,368r-42,84l3372,452r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1105" style='position:absolute;
  left:3301;top:368;width:85;height:84' coordorigin="3301,368" coordsize="85,84">
  <v:shape id="_x0000_s1106" style='position:absolute;left:3301;top:368;
   width:85;height:84' coordorigin="3301,368" coordsize="85,84" path="m3344,368r-43,84l3386,452r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1107" style='position:absolute;
  left:3443;top:579;width:85;height:85' coordorigin="3443,579" coordsize="85,85">
  <v:shape id="_x0000_s1108" style='position:absolute;left:3443;top:579;
   width:85;height:85' coordorigin="3443,579" coordsize="85,85" path="m3485,579r-42,86l3528,665r-43,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1109" style='position:absolute;
  left:3443;top:579;width:85;height:85' coordorigin="3443,579" coordsize="85,85">
  <v:shape id="_x0000_s1110" style='position:absolute;left:3443;top:579;
   width:85;height:85' coordorigin="3443,579" coordsize="85,85" path="m3485,579r-42,86l3528,665r-43,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1111" style='position:absolute;
  left:3457;top:579;width:84;height:85' coordorigin="3457,579" coordsize="84,85">
  <v:shape id="_x0000_s1112" style='position:absolute;left:3457;top:579;
   width:84;height:85' coordorigin="3457,579" coordsize="84,85" path="m3499,579r-42,86l3541,665r-42,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1113" style='position:absolute;
  left:3570;top:621;width:84;height:85' coordorigin="3570,621" coordsize="84,85">
  <v:shape id="_x0000_s1114" style='position:absolute;left:3570;top:621;
   width:84;height:85' coordorigin="3570,621" coordsize="84,85" path="m3612,621r-42,86l3654,707r-42,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1115" style='position:absolute;
  left:3641;top:665;width:84;height:84' coordorigin="3641,665" coordsize="84,84">
  <v:shape id="_x0000_s1116" style='position:absolute;left:3641;top:665;
   width:84;height:84' coordorigin="3641,665" coordsize="84,84" path="m3683,665r-42,84l3725,749r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1117" style='position:absolute;
  left:3739;top:707;width:84;height:84' coordorigin="3739,707" coordsize="84,84">
  <v:shape id="_x0000_s1118" style='position:absolute;left:3739;top:707;
   width:84;height:84' coordorigin="3739,707" coordsize="84,84" path="m3781,707r-42,84l3823,791r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1119" style='position:absolute;
  left:3866;top:791;width:84;height:85' coordorigin="3866,791" coordsize="84,85">
  <v:shape id="_x0000_s1120" style='position:absolute;left:3866;top:791;
   width:84;height:85' coordorigin="3866,791" coordsize="84,85" path="m3908,791r-42,85l3950,876r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1121" style='position:absolute;
  left:3965;top:918;width:85;height:85' coordorigin="3965,918" coordsize="85,85">
  <v:shape id="_x0000_s1122" style='position:absolute;left:3965;top:918;
   width:85;height:85' coordorigin="3965,918" coordsize="85,85" path="m4007,918r-42,85l4050,1003r-43,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1123" style='position:absolute;
  left:4190;top:1143;width:85;height:85' coordorigin="4190,1143" coordsize="85,85">
  <v:shape id="_x0000_s1124" style='position:absolute;left:4190;top:1143;
   width:85;height:85' coordorigin="4190,1143" coordsize="85,85" path="m4234,1143r-44,86l4276,1229r-42,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1125" style='position:absolute;
  left:4445;top:1327;width:84;height:85' coordorigin="4445,1327" coordsize="84,85">
  <v:shape id="_x0000_s1126" style='position:absolute;left:4445;top:1327;
   width:84;height:85' coordorigin="4445,1327" coordsize="84,85" path="m4487,1327r-42,85l4529,1412r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1127" style='position:absolute;
  left:4543;top:1383;width:85;height:85' coordorigin="4543,1383" coordsize="85,85">
  <v:shape id="_x0000_s1128" style='position:absolute;left:4543;top:1383;
   width:85;height:85' coordorigin="4543,1383" coordsize="85,85" path="m4586,1383r-43,86l4628,1469r-42,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1129" style='position:absolute;
  left:4614;top:1383;width:85;height:85' coordorigin="4614,1383" coordsize="85,85">
  <v:shape id="_x0000_s1130" style='position:absolute;left:4614;top:1383;
   width:85;height:85' coordorigin="4614,1383" coordsize="85,85" path="m4656,1383r-42,86l4699,1469r-43,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1131" style='position:absolute;
  left:4614;top:1383;width:85;height:85' coordorigin="4614,1383" coordsize="85,85">
  <v:shape id="_x0000_s1132" style='position:absolute;left:4614;top:1383;
   width:85;height:85' coordorigin="4614,1383" coordsize="85,85" path="m4656,1383r-42,86l4699,1469r-43,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1133" style='position:absolute;
  left:4727;top:1427;width:85;height:84' coordorigin="4727,1427" coordsize="85,84">
  <v:shape id="_x0000_s1134" style='position:absolute;left:4727;top:1427;
   width:85;height:84' coordorigin="4727,1427" coordsize="85,84" path="m4769,1427r-42,84l4812,1511r-43,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1135" style='position:absolute;
  left:5009;top:1623;width:85;height:85' coordorigin="5009,1623" coordsize="85,85">
  <v:shape id="_x0000_s1136" style='position:absolute;left:5009;top:1623;
   width:85;height:85' coordorigin="5009,1623" coordsize="85,85" path="m5052,1623r-43,86l5094,1709r-42,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1137" style='position:absolute;
  left:5065;top:1667;width:85;height:84' coordorigin="5065,1667" coordsize="85,84">
  <v:shape id="_x0000_s1138" style='position:absolute;left:5065;top:1667;
   width:85;height:84' coordorigin="5065,1667" coordsize="85,84" path="m5108,1667r-43,84l5150,1751r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1139" style='position:absolute;
  left:5065;top:1667;width:85;height:84' coordorigin="5065,1667" coordsize="85,84">
  <v:shape id="_x0000_s1140" style='position:absolute;left:5065;top:1667;
   width:85;height:84' coordorigin="5065,1667" coordsize="85,84" path="m5108,1667r-43,84l5150,1751r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1141" style='position:absolute;
  left:5278;top:1723;width:84;height:84' coordorigin="5278,1723" coordsize="84,84">
  <v:shape id="_x0000_s1142" style='position:absolute;left:5278;top:1723;
   width:84;height:84' coordorigin="5278,1723" coordsize="84,84" path="m5320,1723r-42,84l5362,1807r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1143" style='position:absolute;
  left:5278;top:1723;width:84;height:84' coordorigin="5278,1723" coordsize="84,84">
  <v:shape id="_x0000_s1144" style='position:absolute;left:5278;top:1723;
   width:84;height:84' coordorigin="5278,1723" coordsize="84,84" path="m5320,1723r-42,84l5362,1807r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1145" style='position:absolute;
  left:5334;top:1723;width:84;height:84' coordorigin="5334,1723" coordsize="84,84">
  <v:shape id="_x0000_s1146" style='position:absolute;left:5334;top:1723;
   width:84;height:84' coordorigin="5334,1723" coordsize="84,84" path="m5376,1723r-42,84l5418,1807r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1147" style='position:absolute;
  left:5376;top:1723;width:85;height:84' coordorigin="5376,1723" coordsize="85,84">
  <v:shape id="_x0000_s1148" style='position:absolute;left:5376;top:1723;
   width:85;height:84' coordorigin="5376,1723" coordsize="85,84" path="m5418,1723r-42,84l5461,1807r-43,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1149" style='position:absolute;
  left:5432;top:1723;width:85;height:84' coordorigin="5432,1723" coordsize="85,84">
  <v:shape id="_x0000_s1150" style='position:absolute;left:5432;top:1723;
   width:85;height:84' coordorigin="5432,1723" coordsize="85,84" path="m5474,1723r-42,84l5518,1807r-44,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1151" style='position:absolute;
  left:5447;top:1723;width:84;height:84' coordorigin="5447,1723" coordsize="84,84">
  <v:shape id="_x0000_s1152" style='position:absolute;left:5447;top:1723;
   width:84;height:84' coordorigin="5447,1723" coordsize="84,84" path="m5489,1723r-42,84l5531,1807r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1153" style='position:absolute;
  left:5518;top:1723;width:84;height:84' coordorigin="5518,1723" coordsize="84,84">
  <v:shape id="_x0000_s1154" style='position:absolute;left:5518;top:1723;
   width:84;height:84' coordorigin="5518,1723" coordsize="84,84" path="m5560,1723r-42,84l5602,1807r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1155" style='position:absolute;
  left:5560;top:1723;width:85;height:84' coordorigin="5560,1723" coordsize="85,84">
  <v:shape id="_x0000_s1156" style='position:absolute;left:5560;top:1723;
   width:85;height:84' coordorigin="5560,1723" coordsize="85,84" path="m5602,1723r-42,84l5645,1807r-43,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1157" style='position:absolute;
  left:5701;top:1836;width:84;height:84' coordorigin="5701,1836" coordsize="84,84">
  <v:shape id="_x0000_s1158" style='position:absolute;left:5701;top:1836;
   width:84;height:84' coordorigin="5701,1836" coordsize="84,84" path="m5743,1836r-42,84l5785,1920r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1159" style='position:absolute;
  left:5870;top:1907;width:84;height:84' coordorigin="5870,1907" coordsize="84,84">
  <v:shape id="_x0000_s1160" style='position:absolute;left:5870;top:1907;
   width:84;height:84' coordorigin="5870,1907" coordsize="84,84" path="m5912,1907r-42,84l5954,1991r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1161" style='position:absolute;
  left:5912;top:1907;width:85;height:84' coordorigin="5912,1907" coordsize="85,84">
  <v:shape id="_x0000_s1162" style='position:absolute;left:5912;top:1907;
   width:85;height:84' coordorigin="5912,1907" coordsize="85,84" path="m5954,1907r-42,84l5998,1991r-44,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1163" style='position:absolute;
  left:5940;top:1907;width:85;height:84' coordorigin="5940,1907" coordsize="85,84">
  <v:shape id="_x0000_s1164" style='position:absolute;left:5940;top:1907;
   width:85;height:84' coordorigin="5940,1907" coordsize="85,84" path="m5983,1907r-43,84l6025,1991r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1165" style='position:absolute;
  left:6067;top:1963;width:85;height:84' coordorigin="6067,1963" coordsize="85,84">
  <v:shape id="_x0000_s1166" style='position:absolute;left:6067;top:1963;
   width:85;height:84' coordorigin="6067,1963" coordsize="85,84" path="m6110,1963r-43,84l6152,2047r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1167" style='position:absolute;
  left:6463;top:2103;width:84;height:85' coordorigin="6463,2103" coordsize="84,85">
  <v:shape id="_x0000_s1168" style='position:absolute;left:6463;top:2103;
   width:84;height:85' coordorigin="6463,2103" coordsize="84,85" path="m6505,2103r-42,86l6547,2189r-42,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1169" style='position:absolute;
  left:6660;top:2103;width:85;height:85' coordorigin="6660,2103" coordsize="85,85">
  <v:shape id="_x0000_s1170" style='position:absolute;left:6660;top:2103;
   width:85;height:85' coordorigin="6660,2103" coordsize="85,85" path="m6703,2103r-43,86l6745,2189r-42,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1171" style='position:absolute;
  left:6731;top:2103;width:85;height:85' coordorigin="6731,2103" coordsize="85,85">
  <v:shape id="_x0000_s1172" style='position:absolute;left:6731;top:2103;
   width:85;height:85' coordorigin="6731,2103" coordsize="85,85" path="m6773,2103r-42,86l6816,2189r-43,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1173" style='position:absolute;
  left:6787;top:2103;width:85;height:85' coordorigin="6787,2103" coordsize="85,85">
  <v:shape id="_x0000_s1174" style='position:absolute;left:6787;top:2103;
   width:85;height:85' coordorigin="6787,2103" coordsize="85,85" path="m6829,2103r-42,86l6872,2189r-43,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1175" style='position:absolute;
  left:6816;top:2103;width:84;height:85' coordorigin="6816,2103" coordsize="84,85">
  <v:shape id="_x0000_s1176" style='position:absolute;left:6816;top:2103;
   width:84;height:85' coordorigin="6816,2103" coordsize="84,85" path="m6858,2103r-42,86l6900,2189r-42,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1177" style='position:absolute;
  left:6900;top:2103;width:85;height:85' coordorigin="6900,2103" coordsize="85,85">
  <v:shape id="_x0000_s1178" style='position:absolute;left:6900;top:2103;
   width:85;height:85' coordorigin="6900,2103" coordsize="85,85" path="m6942,2103r-42,86l6985,2189r-43,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1179" style='position:absolute;
  left:6914;top:2103;width:84;height:85' coordorigin="6914,2103" coordsize="84,85">
  <v:shape id="_x0000_s1180" style='position:absolute;left:6914;top:2103;
   width:84;height:85' coordorigin="6914,2103" coordsize="84,85" path="m6956,2103r-42,86l6998,2189r-42,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1181" style='position:absolute;
  left:6985;top:2174;width:84;height:85' coordorigin="6985,2174" coordsize="84,85">
  <v:shape id="_x0000_s1182" style='position:absolute;left:6985;top:2174;
   width:84;height:85' coordorigin="6985,2174" coordsize="84,85" path="m7027,2174r-42,85l7069,2259r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1183" style='position:absolute;
  left:6998;top:2174;width:85;height:85' coordorigin="6998,2174" coordsize="85,85">
  <v:shape id="_x0000_s1184" style='position:absolute;left:6998;top:2174;
   width:85;height:85' coordorigin="6998,2174" coordsize="85,85" path="m7042,2174r-44,85l7084,2259r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1185" style='position:absolute;
  left:7126;top:2174;width:85;height:85' coordorigin="7126,2174" coordsize="85,85">
  <v:shape id="_x0000_s1186" style='position:absolute;left:7126;top:2174;
   width:85;height:85' coordorigin="7126,2174" coordsize="85,85" path="m7169,2174r-43,85l7211,2259r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1187" style='position:absolute;
  left:7238;top:2174;width:85;height:85' coordorigin="7238,2174" coordsize="85,85">
  <v:shape id="_x0000_s1188" style='position:absolute;left:7238;top:2174;
   width:85;height:85' coordorigin="7238,2174" coordsize="85,85" path="m7282,2174r-44,85l7324,2259r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1189" style='position:absolute;
  left:7295;top:2174;width:85;height:85' coordorigin="7295,2174" coordsize="85,85">
  <v:shape id="_x0000_s1190" style='position:absolute;left:7295;top:2174;
   width:85;height:85' coordorigin="7295,2174" coordsize="85,85" path="m7338,2174r-43,85l7380,2259r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1191" style='position:absolute;
  left:7351;top:2174;width:85;height:85' coordorigin="7351,2174" coordsize="85,85">
  <v:shape id="_x0000_s1192" style='position:absolute;left:7351;top:2174;
   width:85;height:85' coordorigin="7351,2174" coordsize="85,85" path="m7394,2174r-43,85l7436,2259r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1193" style='position:absolute;
  left:7366;top:2174;width:85;height:85' coordorigin="7366,2174" coordsize="85,85">
  <v:shape id="_x0000_s1194" style='position:absolute;left:7366;top:2174;
   width:85;height:85' coordorigin="7366,2174" coordsize="85,85" path="m7408,2174r-42,85l7451,2259r-43,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1195" style='position:absolute;
  left:7380;top:2174;width:85;height:85' coordorigin="7380,2174" coordsize="85,85">
  <v:shape id="_x0000_s1196" style='position:absolute;left:7380;top:2174;
   width:85;height:85' coordorigin="7380,2174" coordsize="85,85" path="m7422,2174r-42,85l7465,2259r-43,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1197" style='position:absolute;
  left:7465;top:2174;width:84;height:85' coordorigin="7465,2174" coordsize="84,85">
  <v:shape id="_x0000_s1198" style='position:absolute;left:7465;top:2174;
   width:84;height:85' coordorigin="7465,2174" coordsize="84,85" path="m7507,2174r-42,85l7549,2259r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1199" style='position:absolute;
  left:7662;top:2174;width:85;height:85' coordorigin="7662,2174" coordsize="85,85">
  <v:shape id="_x0000_s1200" style='position:absolute;left:7662;top:2174;
   width:85;height:85' coordorigin="7662,2174" coordsize="85,85" path="m7704,2174r-42,85l7747,2259r-43,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1201" style='position:absolute;
  left:7760;top:2174;width:85;height:85' coordorigin="7760,2174" coordsize="85,85">
  <v:shape id="_x0000_s1202" style='position:absolute;left:7760;top:2174;
   width:85;height:85' coordorigin="7760,2174" coordsize="85,85" path="m7804,2174r-44,85l7846,2259r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1203" style='position:absolute;
  left:7874;top:2301;width:84;height:84' coordorigin="7874,2301" coordsize="84,84">
  <v:shape id="_x0000_s1204" style='position:absolute;left:7874;top:2301;
   width:84;height:84' coordorigin="7874,2301" coordsize="84,84" path="m7916,2301r-42,84l7958,2385r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1205" style='position:absolute;
  left:7902;top:2301;width:85;height:84' coordorigin="7902,2301" coordsize="85,84">
  <v:shape id="_x0000_s1206" style='position:absolute;left:7902;top:2301;
   width:85;height:84' coordorigin="7902,2301" coordsize="85,84" path="m7944,2301r-42,84l7987,2385r-43,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1207" style='position:absolute;
  left:8227;top:2301;width:84;height:84' coordorigin="8227,2301" coordsize="84,84">
  <v:shape id="_x0000_s1208" style='position:absolute;left:8227;top:2301;
   width:84;height:84' coordorigin="8227,2301" coordsize="84,84" path="m8269,2301r-42,84l8311,2385r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1209" style='position:absolute;
  left:8269;top:2301;width:84;height:84' coordorigin="8269,2301" coordsize="84,84">
  <v:shape id="_x0000_s1210" style='position:absolute;left:8269;top:2301;
   width:84;height:84' coordorigin="8269,2301" coordsize="84,84" path="m8311,2301r-42,84l8353,2385r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1211" style='position:absolute;
  left:8284;top:2301;width:84;height:84' coordorigin="8284,2301" coordsize="84,84">
  <v:shape id="_x0000_s1212" style='position:absolute;left:8284;top:2301;
   width:84;height:84' coordorigin="8284,2301" coordsize="84,84" path="m8326,2301r-42,84l8368,2385r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1213" style='position:absolute;
  left:8368;top:2456;width:85;height:85' coordorigin="8368,2456" coordsize="85,85">
  <v:shape id="_x0000_s1214" style='position:absolute;left:8368;top:2456;
   width:85;height:85' coordorigin="8368,2456" coordsize="85,85" path="m8410,2456r-42,85l8453,2541r-43,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1215" style='position:absolute;
  left:8566;top:2640;width:84;height:85' coordorigin="8566,2640" coordsize="84,85">
  <v:shape id="_x0000_s1216" style='position:absolute;left:8566;top:2640;
   width:84;height:85' coordorigin="8566,2640" coordsize="84,85" path="m8608,2640r-42,85l8650,2725r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1217" style='position:absolute;
  left:8566;top:2640;width:84;height:85' coordorigin="8566,2640" coordsize="84,85">
  <v:shape id="_x0000_s1218" style='position:absolute;left:8566;top:2640;
   width:84;height:85' coordorigin="8566,2640" coordsize="84,85" path="m8608,2640r-42,85l8650,2725r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1219" style='position:absolute;
  left:8566;top:2640;width:84;height:85' coordorigin="8566,2640" coordsize="84,85">
  <v:shape id="_x0000_s1220" style='position:absolute;left:8566;top:2640;
   width:84;height:85' coordorigin="8566,2640" coordsize="84,85" path="m8608,2640r-42,85l8650,2725r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1221" style='position:absolute;
  left:8706;top:2640;width:85;height:85' coordorigin="8706,2640" coordsize="85,85">
  <v:shape id="_x0000_s1222" style='position:absolute;left:8706;top:2640;
   width:85;height:85' coordorigin="8706,2640" coordsize="85,85" path="m8749,2640r-43,85l8791,2725r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1223" style='position:absolute;
  left:8720;top:2640;width:85;height:85' coordorigin="8720,2640" coordsize="85,85">
  <v:shape id="_x0000_s1224" style='position:absolute;left:8720;top:2640;
   width:85;height:85' coordorigin="8720,2640" coordsize="85,85" path="m8762,2640r-42,85l8806,2725r-44,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1225" style='position:absolute;
  left:9102;top:2936;width:84;height:85' coordorigin="9102,2936" coordsize="84,85">
  <v:shape id="_x0000_s1226" style='position:absolute;left:9102;top:2936;
   width:84;height:85' coordorigin="9102,2936" coordsize="84,85" path="m9144,2936r-42,85l9186,3021r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1227" style='position:absolute;
  left:9595;top:2936;width:85;height:85' coordorigin="9595,2936" coordsize="85,85">
  <v:shape id="_x0000_s1228" style='position:absolute;left:9595;top:2936;
   width:85;height:85' coordorigin="9595,2936" coordsize="85,85" path="m9638,2936r-43,85l9680,3021r-42,-85xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1229" style='position:absolute;
  left:9821;top:3389;width:85;height:84' coordorigin="9821,3389" coordsize="85,84">
  <v:shape id="_x0000_s1230" style='position:absolute;left:9821;top:3389;
   width:85;height:84' coordorigin="9821,3389" coordsize="85,84" path="m9864,3389r-43,84l9906,3473r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1231" style='position:absolute;
  left:10344;top:3389;width:84;height:84' coordorigin="10344,3389" coordsize="84,84">
  <v:shape id="_x0000_s1232" style='position:absolute;left:10344;top:3389;
   width:84;height:84' coordorigin="10344,3389" coordsize="84,84" path="m10386,3389r-42,84l10428,3473r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1233" style='position:absolute;
  left:2794;top:2343;width:607;height:2' coordorigin="2794,2343" coordsize="607,2">
  <v:shape id="_x0000_s1234" style='position:absolute;left:2794;top:2343;
   width:607;height:2' coordorigin="2794,2343" coordsize="607,0" path="m2794,2343r607,e"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1235" style='position:absolute;
  left:2794;top:2583;width:607;height:2' coordorigin="2794,2583" coordsize="607,2">
  <v:shape id="_x0000_s1236" style='position:absolute;left:2794;top:2583;
   width:607;height:2' coordorigin="2794,2583" coordsize="607,0" path="m2794,2583r607,e"
   filled="f" strokeweight=".06pt">
   <v:stroke dashstyle="dash"/>
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1237" style='position:absolute;
  left:3061;top:2301;width:71;height:71' coordorigin="3061,2301" coordsize="71,71">
  <v:shape id="_x0000_s1238" style='position:absolute;left:3061;top:2301;
   width:71;height:71' coordorigin="3061,2301" coordsize="71,71" path="m3061,2337r71,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1239" style='position:absolute;
  left:3061;top:2541;width:85;height:84' coordorigin="3061,2541" coordsize="85,84">
  <v:shape id="_x0000_s1240" style='position:absolute;left:3061;top:2541;
   width:85;height:84' coordorigin="3061,2541" coordsize="85,84" path="m3104,2541r-43,84l3146,2625r-42,-84xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1241" style='position:absolute;
  left:2752;top:2061;width:71;height:71' coordorigin="2752,2061" coordsize="71,71">
  <v:shape id="_x0000_s1242" style='position:absolute;left:2752;top:2061;
   width:71;height:71' coordorigin="2752,2061" coordsize="71,71" path="m2752,2097r70,e"
   filled="f" strokeweight="3.64pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><v:group id="_x0000_s1243" style='position:absolute;
  left:3358;top:2061;width:85;height:85' coordorigin="3358,2061" coordsize="85,85">
  <v:shape id="_x0000_s1244" style='position:absolute;left:3358;top:2061;
   width:85;height:85' coordorigin="3358,2061" coordsize="85,85" path="m3401,2061r-43,86l3443,2147r-42,-86xe"
   filled="f" strokeweight=".06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="551" height="317" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image011.gif" /><!--[if gte vml 1]><v:shape id="_x0000_s1245"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:119.95pt;margin-top:-3.5pt;width:447.4pt;height:256.9pt;
 text-indent:0;z-index:-251665920;mso-position-horizontal-relative:page'
 filled="f" stroked="f">
 <v:textbox style='mso-next-textbox:#_x0000_s1245' inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="17" rowspan="7" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Censoring Times</p><p>Ceritinib 750&nbsp;mg (n/N = 48/115)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Chemotherapy (n/N = 50/116)</p><p>&nbsp;</p><p>Hazard Ratio = 1.00</p><p>95% CI (0.67;1.49)</p><p>&nbsp;</p><p>Kaplan-Meier medians (95% CI) (Months)</p><p>Ceritinib 750&nbsp;mg: 18.1 (13.4;23.9)</p><p>Chemotherapy: 20.1 (11.9;25.1)</p><p>&nbsp;</p><p>Log rank p-value = 0.496</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p>100</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape
 id="_x0000_s1246" type="#_x0000_t202" style='position:absolute;margin-left:8.05pt;
 margin-top:6.05pt;width:29.1pt;height:155.95pt;text-indent:0;z-index:251651584'
 stroked="f">
 <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top;
  mso-next-textbox:#_x0000_s1246'>
  <![if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal><span lang=DE-CH style='font-size:10.0pt;font-family:
    "Arial",sans-serif;mso-ansi-language:DE-CH'>Probability (%) of event-free<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]></v:textbox>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="43" height="212" alt="Text Box: Probability (%) of event-free" src="file:///C:/Users/omarkma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image012.gif" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>80</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>60</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>40</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>20</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:679px"><tbody><tr><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>8</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>10</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>12</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>18</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>20</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>22</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>24</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>26</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>28</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>30</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>No. of patients s till at risk</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Time (Months)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Time (Months)</p></td><td style="vertical-align:top"><p>0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>12</p></td><td style="vertical-align:top"><p>14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>24</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>30</p></td></tr><tr><td style="vertical-align:top"><p>Ceritinib 750&nbsp;mg</p></td><td style="vertical-align:top"><p>115&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 107&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 92&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 83</p></td><td style="vertical-align:top"><p>71</p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 28</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Chemotherapy</p></td><td style="vertical-align:top"><p>116&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 109&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 91&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 78</p></td><td style="vertical-align:top"><p>66</p></td><td style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>43</p></td><td style="vertical-align:top"><p>39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 29</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p>&nbsp;</p><p>Patient reported outcome questionnaires were collected using the EORTC QLQ C30/LC13, LCSS and EQ-5D-5L. 75% or more of patients in the ceritinib and chemotherapy arms completed the LCSS questionnaires at most of the time points during the course of the study. Significant improvements were reported for the majority of lung cancer specific symptoms for Zykadia compared to chemotherapy (four out of six LCSS and 10 out of 12 QLQ-LC13 symptom scores). Ceritinib significantly prolonged time to deterioration for the lung cancer specific symptoms of interest of cough, pain and dyspnoea (composite endpoint LCSS: HR=0.40; 95% CI: 0.25, 0.65, median Time to Deterioration [TTD] 18.0&nbsp;months [95% CI: 13.4, NE] in the ceritinib arm versus 4.4&nbsp;months [95% CI: 1.6, 8.6] in the chemotherapy arm; LC13: HR=0.34; 95% CI: 0.22, 0. 52, median TTD 11.1&nbsp;months [95% CI: 7.1, 14.2] in the ceritinib arm versus 2.1&nbsp;months [95% CI: 1.0, 5.6] in the chemotherapy arm). The EQ-5D questionnaire showed a significant overall health status improvement for Zykadia in comparison to the chemotherapy.</p><p>&nbsp;</p><p>In Study A2303, 133&nbsp;patients with baseline brain metastasis (66&nbsp;patients in the Zykadia arm and 67&nbsp;patients in the chemotherapy arm) were assessed for intracranial response by BIRC neuro-radiologist (per modified RECIST 1.1 (i.e. up to 5&nbsp;lesions in the brain). The OIRR in patients with measurable disease in the brain at baseline and at least one post-baseline assessment was higher in the ceritinib arm (35.3%, 95% CI: 14.2, 61.7) compared to the chemotherapy arm (5.0%, 95% CI: 0.1, 24.9). The median PFS by BIRC using RECIST 1.1 was longer in the ceritinib arm compared to the chemotherapy arm in both subgroups of patients with brain metastases and without brain metastases. The median PFS in patients with brain metastases was 4.4&nbsp;months (95% CI: 3.4, 6.2) versus 1.5&nbsp;months (95% CI: 1.3, 1.8) in the ceritinib and chemotherapy arms, respectively with HR=0.54 (95% CI: 0.36, 0.80). The median PFS in patients without brain metastases was 8.3&nbsp;months (95% CI: 4.1, 14.0) versus 2.8&nbsp;months (95% CI: 1.4, 4.1) in the ceritinib and chemotherapy arms, respectively with HR=0.41 (95% CI: 0.24, 0.69).</p><p>&nbsp;</p><p><em><u>Dose optimisation Study A2112 (ASCEND-8)</u></em></p><p>The efficacy of Zykadia 450&nbsp;mg with food was evaluated in a multicentre, open-label dose optimisation study A2112 (ASCEND-8). A total of 147 previously untreated patients with ALK‑positive locally advanced or metastatic NSCLC were randomised to receive Zykadia 450&nbsp;mg once daily with food (N=73) or Zykadia 750&nbsp;mg once daily under fasted conditions (N=74). A key secondary efficacy endpoint was ORR according to RECIST 1.1 as evaluated by BIRC.</p><p>&nbsp;</p><p>The population characteristics of the previously untreated patients with ALK‑positive locally advanced or metastatic NSCLC across the two arms, 450&nbsp;mg with food (N=73) and 750&nbsp;mg fasted (N=74), were: mean age 54.3 and 51.3&nbsp;years, age less than 65 (78.1% and 83.8%), female (56.2% and 47.3%), Caucasian (49.3% and 54.1%), Asian (39.7% and 35.1%), never or former smoker (90.4% and 95.9%), WHO PS 0 or 1 (91.7% and 91.9%), adenocarcinoma histology (98.6% and 93.2%), and metastases to the brain (32.9% and 28.4%), respectively.</p><p>&nbsp;</p><p>Efficacy results from ASCEND-8 are summarised in Table&nbsp;5 below.</p><p>&nbsp;</p><p><strong>Table&nbsp;5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ASCEND-8 (Study&nbsp;A2112) - Efficacy results in patients with previously untreated ALK-positive locally advanced or metastatic NSCLC by BIRC</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p>Efficacy Parameter</p></td><td style="vertical-align:top"><p>Ceritinib 450&nbsp;mg with food (N=73)</p></td><td style="vertical-align:top"><p>Ceritinib 750&nbsp;mg fasted (N=74)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Overall Response Rate (ORR: CR+PR), n (%) (95% CI)<sup>a</sup></p></td><td style="vertical-align:top"><p>57 (78.1)</p><p>(66.9, 86.9)</p></td><td style="vertical-align:top"><p>56 (75.7)</p><p>(64.3, 84.9)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>CI: Confidence Interval</p><p>Complete Response (CR), Partial Response (PR) confirmed by repeat assessments performed not less than 4&nbsp;weeks after response criteria were first met</p><p>Overall response rate determined based on BIRC assessment per RECIST 1.1</p><p><sup>a</sup>Exact binomial 95% confidence interval</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Single arm studies X2101 and A2201</u></em></p><p>The use of Zykadia in the treatment of ALK‑positive NSCLC patients previously treated with an ALK inhibitor was investigated in two global, multicentre, open‑label, single‑arm phase&nbsp;1/2 studies (Study&nbsp;X2101 and Study&nbsp;A2201).</p><p>&nbsp;</p><p>In study&nbsp;X2101 a total of 246&nbsp;ALK‑positive NSCLC patients were treated at a Zykadia dose of 750&nbsp;mg once daily fasted: 163 who had received prior treatment with an ALK inhibitor and 83 who were ALK inhibitor na&iuml;ve. Of the 163&nbsp;ALK‑positive NSCLC patients who had received prior treatment with an ALK inhibitor, the median age was 52&nbsp;years (range:&nbsp;24‑80&nbsp;years); 86.5% were younger than 65&nbsp;years and 54% were female. The majority of patients were Caucasian (66.3%) or Asian (28.8%). 93.3% had adenocarcinoma and 96.9% had either never been or were former smokers. All of the patients were treated with at least one regimen prior to enrolment into the study and 84.0% with two or more regimens.</p><p>&nbsp;</p><p>Study&nbsp;A2201 involved 140&nbsp;patients who had been previously treated with 1‑3&nbsp;lines of cytotoxic chemotherapy followed by treatment with crizotinib, and who had then progressed on crizotinib. The median age was 51&nbsp;years (range:&nbsp;29‑80&nbsp;years); 87.1% of patients were younger than 65&nbsp;years and 50.0% were female. The majority of patients were Caucasian (60.0%) or Asian (37.9%). 92.1% of patients had adenocarcinoma.</p><p>&nbsp;</p><p>The main efficacy data for both studies are summarised in Table&nbsp;6. Final overall survival (OS) data are presented for Study&nbsp;A2201. For Study&nbsp;X2101, OS data were not yet mature at the time of the analysis.</p><p>&nbsp;</p><p><strong>Table&nbsp;6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ALK-positive advanced NSCLC ‑ overview of efficacy results from Studies&nbsp;X2101 and A2201</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:92%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Study&nbsp;X2101<br />ceritinib 750&nbsp;mg</p></td><td style="vertical-align:top"><p>Study&nbsp;A2201<br />ceritinib 750&nbsp;mg</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=163</p></td><td style="vertical-align:top"><p>N=140</p></td></tr><tr><td style="vertical-align:top"><p>Duration of follow-up</p><p>Median (months) (min &ndash; max)</p></td><td style="vertical-align:top"><p>10.2<br />(0.1 &ndash; 24.1)</p></td><td style="vertical-align:top"><p>14.1<br />(0.1 &ndash; 35.5)</p></td></tr><tr><td style="vertical-align:top"><p>Overall response rate</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigator (95% CI)</p></td><td style="vertical-align:top"><p>56.4% (48.5, 64.2)</p></td><td style="vertical-align:top"><p>40.7% (32.5, 49.3)</p></td></tr><tr><td style="vertical-align:top"><p>BIRC (95% CI)</p></td><td style="vertical-align:top"><p>46.0% (38.2, 54.0)</p></td><td style="vertical-align:top"><p>35.7% (27.8, 44.2)</p></td></tr><tr><td style="vertical-align:top"><p>Duration of response*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigator (months, 95% CI)</p></td><td style="vertical-align:top"><p>8.3 (6.8, 9.7)</p></td><td style="vertical-align:top"><p>10.6 (7.4, 14.7)</p></td></tr><tr><td style="vertical-align:top"><p>BIRC (months, 95% CI)</p></td><td style="vertical-align:top"><p>8.8 (6.0, 13.1)</p></td><td style="vertical-align:top"><p>12.9 (9.3, 18.4)</p></td></tr><tr><td style="vertical-align:top"><p>Progression-free survival</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigator (months, 95% CI)</p></td><td style="vertical-align:top"><p>6.9 (5.6, 8.7)</p></td><td style="vertical-align:top"><p>5.8 (5.4, 7.6)</p></td></tr><tr><td style="vertical-align:top"><p>BIRC (months, 95% CI)</p></td><td style="vertical-align:top"><p>7.0 (5.7, 8.7)</p></td><td style="vertical-align:top"><p>7.4 (5.6, 10.9)</p></td></tr><tr><td style="vertical-align:top"><p>Overall survival (months, 95% CI)</p></td><td style="vertical-align:top"><p>16.7 (14.8, NE)</p></td><td style="vertical-align:top"><p>15.6 (13.6, 24.2)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>NE = not estimable</p><p>Study&nbsp;X2101: Responses assessed using RECIST 1.0</p><p>Study&nbsp;A2201: Responses assessed using RECIST 1.1</p><p>*Includes only patients with confirmed CR, PR</p></td></tr></tbody></table><p>&nbsp;</p><p>In Studies&nbsp;X2101 and A2201, brain metastases were seen in 60.1% and 71.4% of patients, respectively. The ORR, DOR and PFS (by BIRC assessment) for patients with brain metastases at baseline were in line with those reported for the overall population of these studies.</p><p>&nbsp;</p><p><u>Non‑adenocarcinoma histology</u></p><p>&nbsp;</p><p>Limited information is available in ALK‑positive NSCLC patients with non‑adenocarcinoma histology.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>&nbsp;</p><p>Limited efficacy data are available in elderly patients. No efficacy data are available in patients over 85&nbsp;years of age.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Zykadia in all subsets of the paediatric population in lung carcinoma (small cell and non‑small cell carcinoma) (see section&nbsp;4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p>Peak plasma levels (C<sub>max</sub>) of ceritinib are achieved approximately 4 to 6&nbsp;hours after a single oral administration in patients. Oral absorption was estimated to be &ge;25% based on metabolite percentages in the faeces. The absolute bioavailability of ceritinib has not been determined.</p><p>&nbsp;</p><p>Systemic exposure of ceritinib was increased when administered with food. Ceritinib AUC<sub>inf</sub> values were approximately 58% and 73% higher (C<sub>max</sub> approximately 43% and 41% higher) in healthy subjects when a single 500&nbsp;mg ceritinib dose was administered with a low fat meal (containing approximately 330&nbsp;kcalories and 9&nbsp;grams of fat) and a high fat meal (containing approximately 1000&nbsp;kcalories and 58&nbsp;grams of fat), respectively, as compared with the fasted state.</p><p>&nbsp;</p><p>In a dose optimisation study A2112 (ASCEND-8) in patients comparing Zykadia 450&nbsp;mg or 600&nbsp;mg daily with food (approximately 100 to 500&nbsp;kcalories and 1.5 to 15&nbsp;grams of fat) to 750&nbsp;mg daily under fasted conditions (dose and food condition of administration initially authorised), there was no clinically meaningful difference in the systemic steady-state exposure of ceritinib for the 450&nbsp;mg with food arm (N=36) compared to the 750&nbsp;mg fasted arm (N=31), with only small increases in steady-state AUC (90% CI) by 4% (‑13%, 24%) and C<sub>max</sub> (90% CI) by 3% (‑14%, 22%). In contrast, the steady‑state AUC (90% CI) and C<sub>max</sub> (90% CI) for the 600&nbsp;mg with food arm (N=30) increased by 24% (3%, 49%) and 25% (4%, 49%), respectively, compared to the 750&nbsp;mg fasted arm. The maximum recommended dose of Zykadia is 450&nbsp;mg taken orally once daily with food (see section&nbsp;4.2).</p><p>&nbsp;</p><p>After single oral administration of ceritinib in patients, plasma exposure to ceritinib, as represented by C<sub>max</sub> and AUC<sub>last</sub>, increased dose‑proportionally over the 50 to 750&nbsp;mg dose range under fasted conditions. In contrast with single‑dose data, pre‑dose concentration (C<sub>min</sub>) after repeated daily dosing appeared to increase in a greater than dose‑proportional manner.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>Binding of ceritinib to human plasma proteins <em>in vitro</em> is approximately 97% in a concentration independent manner, from 50&nbsp;ng/ml to 10,000&nbsp;ng/ml. Ceritinib also has a slight preferential distribution to red blood cells, relative to plasma, with a mean <em>in vitro</em> blood‑to‑plasma ratio of 1.35. <em>In vitro</em> studies suggest that ceritinib is a substrate for P‑glycoprotein (P‑gp), but not of breast cancer resistance protein (BCRP) or multi‑resistance protein&nbsp;2 (MRP2). The <em>in vitro</em> apparent passive permeability of ceritinib was determined to be low.</p><p>&nbsp;</p><p>In rats, ceritinib crosses the intact blood brain barrier with a brain‑to‑blood exposure (AUC<sub>inf</sub>) ratio of about 15%. There are no data related to brain‑to‑blood exposure ratio in humans.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p><em>In vitro</em> studies demonstrated that CYP3A was the major enzyme involved in the metabolic clearance of ceritinib.</p><p>&nbsp;</p><p>Following a single oral administration of radioactive ceritinib dose at 750&nbsp;mg fasted, ceritinib was the main circulating component in human plasma. A total of 11&nbsp;metabolites were found circulating in plasma at low levels with mean contribution to the radioactivity AUC of &le;2.3% for each metabolite. Main biotransformation pathways identified in healthy subjects included mono‑oxygenation, O‑dealkylation, and N‑formylation. Secondary biotransformation pathways involving the primary biotransformation products included glucuronidation and dehydrogenation. Addition of a thiol group to O‑dealkylated ceritinib was also observed.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Following single oral doses of ceritinib under fasted conditions, the geometric mean apparent plasma terminal half‑life (T<sub>&frac12;</sub>) of ceritinib ranged from 31 to 41&nbsp;hours in patients over the 400 to 750&nbsp;mg dose range. Daily oral dosing of ceritinib results in achievement of steady‑state by approximately 15&nbsp;days and remains stable afterwards, with a geometric mean accumulation ratio of 6.2 after 3&nbsp;weeks of daily dosing. The geometric mean apparent clearance (CL/F) of ceritinib was lower at steady‑state (33.2&nbsp;litres/hour) after 750&nbsp;mg daily oral dosing than after a single 750&nbsp;mg oral dose (88.5&nbsp;litres/hour), suggesting that ceritinib demonstrates non‑linear pharmacokinetics over time.</p><p>&nbsp;</p><p>The primary route of excretion of ceritinib and its metabolites is in the faeces. Recovery of unchanged ceritinib in the faeces accounts for a mean 68% of an oral dose. Only 1.3% of the administered oral dose is recovered in the urine.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>The effect of hepatic impairment on the single‑dose pharmacokinetics of ceritinib (750&nbsp;mg under fasted conditions) was evaluated in subjects with mild (Child-Pugh class A; N=8), moderate (Child-Pugh class B; N=7), or severe (Child-Pugh class C; N=7) hepatic impairment and in 8 healthy subjects with normal hepatic function. The geometric mean AUCinf (unbound AUCinf) of ceritinib was increased by 18% (35%) and 2% (22%) in subjects with mild and moderate hepatic impairment, respectively, compared to subjects with normal hepatic function.</p><p>&nbsp;</p><p>The geometric mean AUCinf (unbound AUCinf) of ceritinib was increased by 66% (108%) in subjects with severe hepatic impairment compared to subjects with normal hepatic function (see section&nbsp;4.2). A dedicated pharmacokinetic study under steady-state in patients with hepatic impairment has not been conducted.</p><p><em>Renal impairment</em></p><p>A dedicated pharmacokinetic study in patients with renal impairment has not been conducted. Based on available data, ceritinib elimination via the kidney is negligible (1.3% of a single oral administered dose).</p><p>&nbsp;</p><p>Based on a population pharmacokinetic analysis of 345&nbsp;patients with mild renal impairment (CLcr 60 to &lt;90&nbsp;ml/min), 82&nbsp;patients with moderate renal impairment (CLcr 30 to &lt;60&nbsp;ml/min) and 546&nbsp;patients with normal renal function (&ge;90&nbsp;ml/min), ceritinib exposures were similar in patients with mild and moderate renal impairment and normal renal function, suggesting that no dose adjustment is necessary in patients with mild to moderate renal impairment. Patients with severe renal impairment (CLcr &lt;30&nbsp;ml/min) were not included in the clinical studies of Zykadia (see section&nbsp;4.2).</p><p>&nbsp;</p><p><em>Effects of age, gender, and race</em></p><p>Population pharmacokinetic analyses showed that age, gender and race had no clinically meaningful influence on ceritinib exposure.</p><p>&nbsp;</p><p><em>Cardiac electrophysiology</em></p><p>The potential for QT interval prolongation of ceritinib was assessed in seven clinical studies with Zykadia. Serial ECGs were collected following a single dose and at steady‑state to evaluate the effect of ceritinib on the QT interval in 925&nbsp;patients treated with Zykadia 750&nbsp;mg once daily fasted. A categorical outlier analysis of ECG data demonstrated new QTc &gt;500&nbsp;msec in 12&nbsp;patients (1.3%). There were 58&nbsp;patients (6.3%) with a QTc increase from baseline &gt;60&nbsp;msec. A central tendency analysis of the QTc data at average steady-state concentration from Study&nbsp;A2301 demonstrated that the upper bound of the 2‑sided 90% CI for QTc increase from baseline was 15.3&nbsp;msec at Zykadia 750&nbsp;mg fasted. A pharmacokinetic analysis suggested that ceritinib causes concentration‑dependent increases in QTc (see section&nbsp;4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Safety pharmacology studies indicate that ceritinib is unlikely to interfere with vital functions of the respiratory and central nervous systems. <em>In vitro</em> data show that the IC50 for the inhibitory effect of ceritinib on the hERG potassium channel was 0.4&nbsp;micromolar. An <em>in vivo</em> telemetry study in monkeys showed a modest QT prolongation in 1 of 4&nbsp;animals after receiving the highest dose of ceritinib. ECG studies in monkeys after 4‑ or 13‑weeks of dosing with ceritinib have not shown QT prolongation or abnormal ECGs.</p><p>&nbsp;</p><p>The micronucleus test in TK6 cells was positive. No signs of mutagenicity or clastogenicity were observed in other <em>in vitro</em> and <em>in vivo</em> genotoxicity studies with ceritinib. Therefore, genotoxic risk is not expected in humans.</p><p>&nbsp;</p><p>Carcinogenicity studies have not been performed with ceritinib.</p><p>&nbsp;</p><p>Reproductive toxicology studies (i.e. embryo‑foetal development studies) in pregnant rats and rabbits indicated no foetotoxicity or teratogenicity after dosing with ceritinib during organogenesis; however, maternal plasma exposure was less than that observed at the recommended human dose. Formal non‑clinical studies on the potential effects of ceritinib on fertility have not been conducted.</p><p>&nbsp;</p><p>The principal toxicity related to ceritinib administration in rats and monkeys was inflammation of the extra‑hepatic bile ducts accompanied by increased neutrophil counts in the peripheral blood. Mixed cell/neutrophilic inflammation of the extra‑hepatic ducts extended to the pancreas and/or duodenum at higher doses. Gastrointestinal toxicity was observed in both species characterised by body weight loss, decreased food consumption, emesis (monkey), diarrhoea and, at high doses, by histopathological lesions including erosion, mucosal inflammation and foamy macrophages in the duodenal crypts and submucosa. The liver was also affected in both species, at exposures that approximate clinical exposures at the recommended human dose, and included minimal increases in liver transaminases in a few animals and vacuolation of the intra‑hepatic bile duct epithelium. Alveolar foamy macrophages (confirmed phospholipidosis) were seen in the lungs of rats, but not in monkeys, and the lymph nodes of rats and monkeys had macrophage aggregates. Target organ effects showed partial to complete recovery.</p><p>&nbsp;</p><p>Effects on the thyroid were observed in both rat (mild increases in thyroid stimulating hormone and triiodothyronine/thyroxine T3/T4 concentrations with no microscopic correlate) and monkey (depletion of colloid in males in 4‑week study, and one monkey at high dose with diffuse follicular cell hyperplasia and increased thyroid stimulating hormone in 13‑week study). As these non‑clinical effects were mild, variable and inconsistent, the relationship between ceritinib and thyroid gland changes in animals is unclear.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule content</u></p><p>&nbsp;</p><p>Cellulose, microcrystalline</p><p>Hydroxypropylcellulose, low-substituted</p><p>Sodium starch glycolate (type A)</p><p>Magnesium stearate</p><p>Silica, colloidal anhydrous</p><p>&nbsp;</p><p><u>Capsule shell</u></p><p>&nbsp;</p><p>Gelatin</p><p>Indigotine (E132)</p><p>Titanium dioxide (E171)</p><p>&nbsp;</p><p><u>Printing ink</u></p><p>&nbsp;</p><p>Shellac (bleached, de‑waxed) glaze 45%</p><p>Iron oxide black (E172)</p><p>Propylene glycol</p><p>Ammonium hydroxide 28%</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PCTFE (polyvinylchloride/polychlorotrifluoroethylene) and PVC/PE/PVDC (Polyvinyl chloride/ polyethylene/ polyvinylidene chloride) &ndash; Aluminium blisters</p><p>containing 10&nbsp;hard capsules.</p><p>&nbsp;</p><p>Packs containing 150&nbsp;(3&nbsp;packs of 50)&nbsp;hard capsules.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special precautions for handling and disposal</strong></p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p><em>Handling:</em></p><p><em>&nbsp;</em></p><p><em>Zykadia is an anti-cancer medical product. In healthcare settings, use designated area for medication storage and restrict access to only authorized personal.</em></p><p><em>&nbsp;</em></p><p><em>Disposal:</em></p><p><em>&nbsp;</em></p><p><em>Any unused medicinal product or waste material should be disposed in accordance with local requirements. Wash hands thoroughly with water after disposal of any unused medicinal product or waste material. For further instructions on handling and disposal of this medicine, please refer to local guidelines and US NIOSH documents.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Approved by EMA in April 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>